Therapeutic genetic variation revealed in diverse Hsp104 homologs

Zachary M. March^{1,2}, Katelyn Sweeney^{3,4#}, Hanna Kim^{6#}, Xiaohui Yan^{6#}, Laura M. Castellano^{1,5}, Meredith E. Jackrel^{1,9}, Edward Chuang^{1,5}, Edward Gomes¹, Karolina Michalska^{7,8}, Robert Jedrzejczak⁷, Andrzej Joachimiak^{7,8}, Kim A. Caldwell⁶, Guy A. Caldwell⁶, Ophir Shalem^{3,4}, and James Shorter^{1,2,4,5*}.

¹Department of Biochemistry and Biophysics, ²Biochemistry and Molecular Biophysics Graduate Group, ³Department of Genetics, ⁴Cell and Molecular Biology Graduate Group, ⁵Pharmacology Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, U.S.A.

⁶Department of Biological Sciences, The University of Alabama, Tuscaloosa, AL 35487, U.S.A.

⁷Structural Biology Center, X-ray Science Division, Argonne National Laboratory, Argonne, IL 60439, U.S.A.

⁸Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL 60637 U.S.A.

⁹Current Affiliation: Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63105, U.S.A.

#These authors contributed equally

*Correspondence: jshorter@pennmedicine.upenn.edu

ABSTRACT

The AAA+ protein disaggregase, Hsp104, increases fitness under stress by reversing stress-induced protein aggregation. We have engineered potentiated Hsp104 variants to antagonize proteotoxic misfolding linked to human neurodegenerative diseases. However, these Hsp104 variants can exhibit off-target toxicity, which may limit their therapeutic utility. Hsp104 is conserved among all nonmetazoan eukaryotes, which raises the possibility that natural variants might exist with enhanced, selective activity against neurodegenerative disease substrates. To assess this possibility, we screened a cross-kingdom collection of Hsp104 homologs in several yeast proteotoxicity models. We uncovered therapeutic genetic variation among several Hsp104 homologs that specifically antagonize TDP-43 or α -synuclein condensate formation and toxicity in yeast, human cells, and *C. elegans*. Surprisingly, this variation manifested as increased passive chaperone activity, distinct from disaggregase activity, which neutralizes proteotoxicity of specific substrates. Thus, by exploring natural tuning of passive chaperone activity we elucidated enhanced, substrate-specific agents to counter proteotoxicity underlying neurodegenerative disease.

INTRODUCTION

Alternative protein folding underpins fatal neurodegenerative diseases [1]. Diseases such as Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) have distinct clinical manifestations but are united by the prominent pathological accumulation of misfolded protein conformers [2]. The proteins implicated in each disease can adopt a range of misfolded conformations [3]. Thus, in PD, alpha-synuclein (α Syn) accumulates in toxic soluble oligomers and amyloid fibers that are the major component of cytoplasmic Lewy bodies in degenerating dopaminergic neurons [4-8]. Likewise, in ALS, the normally nuclear RNA-binding proteins, TDP-43 and FUS, accumulate in toxic oligomeric structures and cytoplasmic inclusions [9-13].

Protein disaggregation represents an innovative and appealing therapeutic strategy for the treatment of protein-misfolding disorders in that it simultaneously reverses: (a) loss-of-function phenotypes associated with sequestration of functional soluble protein into misfolded oligomers and insoluble aggregates; and (b) any toxic gain-of-function phenotypes associated with the misfolded conformers themselves [14-16]. The AAA+ (ATPases Associated with diverse Activities) protein Hsp104 from *Saccharomyces cerevisiae* (ScHsp104) rapidly disassembles a diverse range of misfolded protein conformers, including amorphous aggregates, preamyloid oligomers, and amyloid fibers [17-23]. Hsp104 assembles into asymmetric ring-shaped hexamers that undergo conformational changes upon ATP binding and hydrolysis, which drive substrate translocation across the central channel to power protein disaggregation [17, 22-27]. Each protomer is comprised of an N-terminal domain (NTD), nucleotide-binding domain 1 (NBD1), a middle domain (MD), NBD2, and a short C-terminal domain [22, 23]. Hsp104 can disassemble preamyloid oligomer and amyloid conformers of several proteins associated with neurodegenerative disease, including α Syn, polyglutamine, amyloid-beta, and tau [17, 21]. Moreover, these protein-remodeling events result in neuroprotection. For example, Hsp104 suppresses protein misfolding-induced neurodegeneration in rat and *D. melanogaster* models of polyglutamine-expansion disorders [28, 29], and a rat

model Parkinson's disease [21]. Hsp104 is the only factor known to eliminate α Syn fibers and oligomers *in vitro*, and prevent α Syn-mediated dopaminergic neurodegeneration in rats [21]. However, these activities have limits and typically high concentrations of Hsp104 are required for modest protein remodeling [17, 21, 30].

Previously, we circumvented limitations on Hsp104 disaggregase activity by developing a suite of potentiated Hsp104 variants, differing from wild-type Hsp104 by one or more missense mutations in the autoregulatory middle domain [31]. These potentiated Hsp104 variants antagonize proteotoxic misfolding of several disease-linked proteins, including TDP-43, FUS, TAF15, FUS-CHOP, EWS-FLI and α Syn [30, 32-36]. However, in some circumstances, these Hsp104 variants can also exhibit off-target toxicity [30, 32, 33]. Thus, uncovering other therapeutic Hsp104s with diminished propensity for off-target effects is a key objective [37].

Hsp104 is conserved among all non-metazoan eukaryotes [38], yet natural Hsp104 sequence space remains largely unexplored. This lack of exploration raises the possibility that natural Hsp104 sequences may exist with divergent enhanced and selective activity against neurodegenerative disease substrates. Indeed, we reported that an Hsp104 homolog from the thermophilic fungus *Calcarisporiella thermophila* antagonizes toxicity of TDP-43, α Syn, and polyglutamine in yeast without apparent toxic off-target effects [27]. These findings support our hypothesis that natural Hsp104 homologs may have therapeutically beneficial properties.

Here, we survey a cross-kingdom collection of Hsp104 homologs from diverse lineages for their ability to suppress proteotoxicity from several proteins implicated in human neurodegenerative disease. We discovered several homologs that are capable of selectively suppressing TDP-43 or α Syn toxicity. Mechanistic studies and mutational analysis suggest that these activities are due to genetic variation that impacts passive chaperone activity of Hsp104 homologs for select substrates. Thus, we establish that manipulating passive chaperone

activity of Hsp104 represents a novel route to enhanced, substrate-specific agents to counter protein misfolding that causes neurodegenerative disease.

RESULTS

Diverse Hsp104 homologs selectively suppress TDP-43 toxicity and aggregation in yeast

In yeast, galactose-inducible expression of several proteins associated with neurodegenerative diseases, including α Syn [39], TDP-43 [40], and FUS [13] is toxic. However, coexpression of potentiated Hsp104 variants or the natural homolog *Calcarisporiella thermophila* Hsp104 (CtHsp104), but not ScHsp104, reduces this toxicity [27, 30, 33, 37]. For a deeper exploration of natural Hsp104 sequence space, we screened a collection of 15 additional Hsp104 homologs from diverse eukaryotes spanning ~2 billion years of evolution and encompassing fungi (*Thielavia terrestris*, *Thermomyces lanuginosus*, *Dictyostelium discoideum*, *Chaetomium thermophilum*, *Lachancea thermotolerans*, *Myceliophthora thermophila*, *Scytalidium thermophilum*, and *Thermoascus aurantiacus*), plants (*Arabidopsis thaliana* and *Populus euphratica*), protozoa (*Monosiga brevicollis*, *Salpingoeca rosetta*, and *Plasmodium falciparum*), and chromista (*Chlamydomonas reinhardtii* and *Galdieria sulphuraria*) (**Figure 1A**; see **Table S1** for homolog sequences, **Figures S1** for an alignment of all homologs). All Hsp104 homologs, except the homolog from *Plasmodium falciparum* (Pf), were non-toxic to yeast at 30 °C or 37 °C (**Figure S2**). PfHsp104 was even more toxic than the potentiated Hsp104 variant, Hsp104^{A503V}, at 37°C (**Figure S2**). This toxicity might reflect the very different role played by PfHsp104 in its host where it is not simply a soluble protein disaggregase [41-43]. Rather, PfHsp104 is a key component of a membrane-embedded translocon, which transports malarial proteins across a parasite-encasing vacuolar membrane into erythrocytes [41-43].

We screened the Hsp104 homologs for suppression of TDP-43, FUS, and α Syn proteotoxicity (**Figures 1B-C, 2A-B, and S3**). The toxic Hsp104 homolog, PfHsp104, was unable to reduce TDP-43, FUS, and α Syn proteotoxicity (**Figure**

S3C). By contrast, in addition to CtHsp104, which suppresses TDP-43 and α Syn (**Figures 1B and 2A**), five of these new homologs (from protozoa: *Monosiga brevicollis* (*Mb*) and *Salpingoeca rosetta* (*Sr*), from chromista: *Chlamydomonas reinhardtii* (*Cr*) and *Galdieria sulphuraria* (*Gs*), and the plant *Populus euphratica* (*Pe*)), suppress TDP-43 toxicity (**Figure 1C**; see **Figure S4** for an alignment comparing TDP-43-rescuing homologs to ScHsp104). Interestingly, the Hsp104 homologs that suppress TDP-43 toxicity do not suppress α Syn toxicity, nor do they suppress toxicity of FUS (**Figure S3A**). Thus, we describe the first natural or engineered Hsp104 variants that diminish TDP-43 toxicity in a substrate-specific manner.

Hsp104 homologs were consistently expressed, and had minimal effect on TDP-43 levels (**Figure 1D**), indicating that suppression of toxicity was not due to reduced TDP-43 expression. Moreover, levels of the small heat-shock protein, Hsp26, were similar in all strains and lower than in control strains that had been pretreated at 37 °C to mount a heat shock response (HSR) [44]. Thus, expression of heterologous Hsp104s does not indirectly suppress TDP-43 toxicity by inducing a yeast HSR (**Figure 1D**).

Next, we examined how these Hsp104 homologs affect TDP-43 localization in our yeast model. In human cells, TDP-43 normally shuttles between the nucleus and cytoplasm, but in ALS TDP-43 becomes mislocalized to cytoplasmic inclusions [45]. Expression of GFP-tagged TDP-43 (TDP43-GFP) in yeast recapitulates this phenotype (**Figure 1E-F**) [10, 40]. Consistent with previous observations, expression of ScHsp104 does not affect TDP43-GFP cytoplasmic localization (**Figure 1F**) but slightly exacerbates formation of TDP43-GFP foci (**Figure 1G**). By contrast, the potentiated variant, Hsp104^{A503S}, restores nuclear TDP-43 localization in ~40% of cells [30, 32] (**Figure 1F**) and suppresses TDP-43 foci formation (**Figure 1F-G**). Cells expressing Hsp104 homologs that suppress TDP-43 toxicity (e.g. *Ct*, *Gs*, *Mb*, *Cr*, *Pe*, and *Sr*), show at most a modest increase in nuclear TDP43-GFP compared to control strains lacking Hsp104 ($\Delta hsp104$) or expressing ScHsp104 (**Figure 1F**). However, formation of cytoplasmic TDP43-GFP foci is suppressed by all homologs (**Figure 1G**). Thus,

TDP-43 toxicity can be mitigated in yeast by limiting TDP-43 focus formation without restoring nuclear localization. Indeed, PeHsp104 and SrHsp104 reduced TDP-43 toxicity as effectively as Hsp104^{A503S}, but without restoring TDP-43 to the nucleus (**Figure 1C, F**).

Distinct Hsp104 homologs selectively suppress α Syn toxicity and inclusion formation in yeast

In addition to the five Hsp104 homologs that suppress TDP-43 toxicity, we discovered two new Hsp104 homologs (from *Thielavia terrestris* (*Tt*) and *Thermomyces lanuginosus* (*Tl*)) that suppress α Syn toxicity (**Figure 2B**; see **Figure S5** for an alignment comparing α Syn-rescuing homologs to ScHsp104 and **Figure S6** for an alignment comparing TDP-43-rescuing homologs to α Syn-rescuing homologs). Similar to the Hsp104s that suppress TDP-43 toxicity, these new Hsp104 homologs were selective and suppressed α Syn toxicity but not TDP-43 or FUS toxicity (**Figure S3B**). Eight of the fifteen Hsp104 homologs tested do not suppress TDP-43, α Syn, or FUS toxicity (**Figure S3C**). TtHsp104 and TlHsp104 suppressed α Syn toxicity without affecting α Syn expression and without inducing an HSR as indicated by Hsp26 levels (**Figure 2C**).

We also examined how Hsp104 homologs that suppress α Syn toxicity affect α Syn localization in yeast. α Syn is a lipid-binding protein that mislocalizes to cytoplasmic Lewy bodies in Parkinson's disease [46]. Overexpression of α Syn in yeast recapitulates some aspects of this phenotype [39]. Indeed, α Syn forms toxic cytoplasmic foci that are detergent-insoluble and react with the amyloid-diagnostic dye, Thioflavin-S, and cluster cytoplasmic vesicles akin to Lewy pathology observed in PD patients [32, 39, 47-50]. We observed that all Hsp104 homologs that suppress α Syn toxicity also restore α Syn localization to the plasma membrane in ~75% of cells (**Figure 2D-E**). Cells with membrane-localized α Syn showed no cytoplasmic foci (**Figure 2D-E**). Taken together, our results demonstrate that Hsp104 homologs that suppress TDP-43 or α Syn toxicity also suppress the formation of TDP-43 or α Syn inclusions.

Sequence characteristics of Hsp104 homologs

We next sought to examine sequence relatedness among Hsp104 homologs in an effort to understand what sets Hsp104 homologs with particular toxicity-suppression characteristics apart. Hsp104 homologs with particular suppression characteristics clustered together phylogenetically (**Figure 1A**) although there are exceptions. Thus, while *A. thaliana* and *P. euphratica* are closely related species, AtHsp104 does not suppress TDP-43 while PeHsp104 does. We wondered whether Hsp104 homologs had particular sequence signatures that would predict their toxicity-suppression capacities. Multiple sequence alignments did not reveal any clear patterns to differentiate, for instance, TDP-43-suppressing Hsp104s from ScHsp104 (**Figure S4**) or from α Syn-suppressing ones (**Figure S6A**). We next calculated pairwise sequence identities between each possible pair of Hsp104 homologs (**Table S3**), and compared the average percent identity of pairs with similar and dissimilar toxicity suppression profiles (**Figure S6B**). The mean pairwise identity between TtHsp104 and TIHsp104, which both suppress α Syn toxicity, was 76%, which was unsurprising given that these homologs are from two closely related species. The ten pairwise identities comparing Hsp104 homologs that both rescue TDP-43 had a mean of 56% (with range of 51-71%), while the ten pairwise identities comparing one Hsp104 homolog that suppresses TDP-43 to another that suppresses α Syn had a mean of 44% (with range of 25-49%). Thus, homologs that suppress TDP-43 or α Syn seem to be more similar to one another than between groups.

ClpG_{GI} from *Pseudomonas aeruginosa* reduces α Syn toxicity

In addition to the eukaryotic Hsp104 homologs discussed above, we also studied two prokaryotic Hsp104 homologs: ClpB from *Escherichia coli* and ClpG_{GI} from the pathogenic bacteria *Pseudomonas aeruginosa*. Wild-type ClpB does not suppress TDP-43, FUS, or α Syn toxicity (**Figure S7A**). We wondered whether ClpB activity could be enhanced via missense mutations in the middle domain, in analogy with Hsp104, so we also selected two previously-described hyperactive

ClpB variants, ClpB^{K476D} and ClpB^{Y503D} [51-53], to test for suppression of TDP-43, FUS, and α Syn toxicity. Neither ClpB^{K476D} nor ClpB^{Y503D} suppressed TDP-43, FUS, or α Syn toxicity (**Figure S7A**). Thus, despite being able to exert forces of more than 50 pN and translocate polypeptides at speeds of more than 500 residues per second [54], neither ClpB nor hyperactive ClpB variants are capable of suppressing TDP-43, FUS or α Syn proteotoxicity.

Next, we tested ClpG_{GI}, which bears significant homology to Hsp104 but is distinguished from other ClpB/Hsp104 proteins by an extended N-terminal domain and a shorter middle domain roughly corresponding to loss of middle domain Motif 2 [55] (**Figure S1**). ClpG_{GI} has been reported to be a more effective disaggregase than ClpB from *E. coli* [56]. Furthermore, we previously established that deleting Motif 2 from ScHsp104 yields a potentiated disaggregase [33]. Thus, we wondered whether ClpG_{GI} may suppress TDP-43, FUS, or α Syn toxicity. Indeed, we found ClpG_{GI} potently suppresses α Syn toxicity and slightly suppresses TDP-43 and FUS toxicity (**Figure S7B**). ClpB, ClpB variants, and ClpG_{GI} all express robustly in yeast and do not affect TDP-43, FUS, or α Syn levels (**Figure S7C**). ClpB and ClpG_{GI} are also not toxic to yeast when expressed at 37 °C (**Figure S7D**). Thus, ClpG_{GI} is a prokaryotic disaggregase with therapeutic properties and may represent a natural example of Hsp104 potentiation via loss of Motif 2 from the middle domain [33].

Hsp104 homologs prevent TDP-43 aggregation in human cells

We next examined whether Hsp104 homologs that suppress TDP-43 toxicity in yeast would have a beneficial effect in higher model systems. Thus, we transfected human HEK293T cells with an inducible plasmid encoding fluorescently-tagged TDP-43 lacking a functional nuclear-localization sequence (mClover3-TDP43 Δ NLS) to enhance cytoplasmic accumulation and aggregation [57]. We co-transfected these cells with an empty vector or inducible plasmids encoding ScHsp104^{WT}, the potentiated variant ScHsp104^{A503S}, PeHsp104, SrHsp104, or a catalytically-inactive variant ScHsp104^{DPLA:DWB} deficient in both peptide translocation (due to Y257A and Y662A mutations in NBD1 and NBD2

substrate-binding pore loops) and ATP hydrolysis (due to E285Q and E687Q mutations in NBD1 and NBD2 Walker B motifs) [17]. PeHsp104 and SrHsp104 display the most potent and selective suppression of TDP-43 toxicity in yeast (**Figure 1B**). We monitored TDP-43 expression and aggregation by pulse-shape analysis of flow cytometry data (see methods) [58] over time and quantified the percentage of cells bearing aggregates upon coexpression of each Hsp104 (**Figure 3A**). Expression of Hsp104 variants in HEK293T cells was confirmed by Western blotting (**Figure 3B**). We also monitored mClover3-TDP-43 Δ NLS levels by Western blot, and did not observe a strong Hsp104-dependent effect on TDP-43 expression (**Figure 3B**), suggesting that Hsp104 variants are not merely affecting accumulation of TDP-43 foci by reducing TDP-43 levels. At 24 h post-transfection, all catalytically active Hsp104 variants significantly decreased the proportion of cells with TDP-43 aggregates compared to cells expressing no Hsp104 or cells expressing the catalytically-inactive ScHsp104^{DPLA:DWB} [17] (**Figure 3C**, *left panel*, Day 1). We were surprised that ScHsp104^{WT} reduced the proportion of cells with TDP-43 aggregates at this time point, given that it does not reduce TDP-43 aggregation in yeast (**Figure 1B-C**). However, at 48 h post-transfection, we observed that cells expressing the catalytically-inactive variant ScHsp104^{DPLA:DWB} or ScHsp104^{WT} both had a significantly increased proportion of cells with TDP-43 aggregates compared to cells expressing no Hsp104, while cells expressing the potentiated variant ScHsp104^{A503S} or the TDP-43 specific variant PeHsp104 continued to show a significantly lower number of cells with TDP-43 aggregates (**Figure 3C**, *right panel*, Day 2). The TDP-43-specific variant SrHsp104, meanwhile, reduced TDP-43 aggregate burden at day 1 but not day 2, suggesting an intermediate effect (**Figure 3C**). Thus, while ScHsp104 and SrHsp104 show a short-lived suppression of TDP-43 foci formation, we show two Hsp104 variants, one engineered (A503S) and one natural (PeHsp104) that show an enduring reduction of TDP-43 foci in human cells.

α Syn-selective Hsp104 homologs prevent dopaminergic neurodegeneration in *C. elegans*

To test whether CtHsp104, TtHsp104, and TlHsp104, which suppress α Syn toxicity in yeast, would likewise suppress α Syn toxicity in animals, we turned to a *C. elegans* model of Parkinson's disease in which the dopamine transporter (*dat-1*) promoter is used to direct expression of α Syn to dopaminergic (DA) neurons [59]. We generated transgenic worms expressing α Syn either alone or in combination with different Hsp104 variants in DA neurons, and confirmed α Syn and Hsp104 expression by qRT-PCR (**Figure 4A**). Only ~20% of worms expressing α Syn alone have a full complement of DA neurons at day 7 post-hatching (**Figure 4B-C**). Wild-type Hsp104 from *S. cerevisiae* does not protect *C. elegans* DA neurons in this context [30]. Surprisingly, CtHsp104 also does not affect *C. elegans* DA neuron survival (**Figure 4B-C**), despite robust suppression of α Syn-mediated toxicity and inclusion formation in yeast (**Figure 2**) [27]. This lack of neuroprotection by CtHsp104 may be due to the fact that it is promiscuous. Indeed, coexpression of TtHsp104 or TlHsp104, which both selectively mitigate α Syn toxicity in yeast, both result in significant protection of DA neurons in *C. elegans* (~40% worms with normal DA neurons in each case) after 7 days post-hatching (**Figure 4B-C**). This level of DA neuron protection is comparable to that conferred by the potentiated Hsp104 variants, Hsp104^{A503S} and Hsp104^{DPLF:A503V} [30]. Thus, our results demonstrate that natural, substrate-specific Hsp104 homologs can function in a wide variety of contexts, including in an intact animal nervous system.

Differential suppression of proteotoxicity by Hsp104 homologs is not due to changes in disaggregase activity

Next, we sought to understand why some Hsp104 homologs suppress TDP-43 or α Syn toxicity while others do not. One possible explanation is that Hsp104 homologs differ in disaggregase activity, as has been the case with potentiated Hsp104 variants [30, 32-34, 37, 60]. Potentiated disaggregases typically display elevated ATPase and disaggregase activities. This elevated

activity can sometimes manifest as a temperature-dependent toxicity phenotype [30, 33]. However, the Hsp104 homologs we assess here (except for PfHsp104) are non-toxic under conditions where some potentiated Hsp104 variants, such as Hsp104^{A503V}, are toxic (**Figure S2**). This finding hints that these natural homologs are not potentiated in the same way as engineered variants. To explore this issue further, we directly assessed whether the toxicity-suppression behavior of Hsp104 homologs could be rationalized by differences in disaggregase activity.

First, we tested how well our Hsp104 homologs conferred thermotolerance to yeast. Hsp104 is an essential factor for induced thermotolerance in yeast [61], and Hsp104 homologs in bacteria and plants have similar functions in their respective hosts [62, 63]. The ability of Hsp104 to confer thermotolerance depends on its disaggregase activity, which solubilizes proteins trapped in heat-induced protein assemblies [18, 64-67]. Thus, thermotolerance is a convenient *in vivo* proxy for disaggregase activity among different Hsp104 homologs. Indeed, ~75% of wild-type yeast survive a 20-min heat shock at 50°C whereas ~1% of $\Delta hsp104$ mutants survive the same shock (**Figure 5A-B**). Expressing FLAG-tagged ScHsp104 from a plasmid effectively complements the thermotolerance defect of $\Delta hsp104$ yeast (**Figure 5A-B**). We generated transgenic yeast strains in which Hsp104 homologs are expressed under the control of the native *S. cerevisiae* HSP104 promoter, and assessed the thermotolerance phenotypes of these strains. We observed a range of phenotypes. Specifically, 15 of 17 Hsp104s tested conferred some degree of thermotolerance above $\Delta hsp104$ alone (**Figure 5A-B**). The two exceptions were ClpB from *Escherichia coli* and Hsp104 from *Populus euphratica* (**Figure 5A-B**). Some homologs, such as those from *Thielavia terrestris*, *Galdieria sulphuraria*, and *Dictyostelium discoideum* strongly complement thermotolerance while others were quite weak (**Figure 5A-B**). These differences are not due to differences in expression, as all homologs were consistently expressed, as confirmed by Western blot (**Figure 5C**). Thermotolerance phenotypes are not explained by the evolutionary divergence time of a particular species from *S. cerevisiae* (**Figure 5D**). Likewise, thermotolerance was not noticeably different between Hsp104 homologs that

reduced TDP-43 or α Syn toxicity compared to those that did not (**Figure 5E**). Interestingly, ClpG_{GI} confers a strong thermotolerance phenotype to $\Delta hsp104$ yeast (**Figure S7E**) while ClpB does not, although both are from prokaryotes. This difference may be due to the fact that ClpG_{GI} is a stand-alone disaggregase and does not depend on Hsp70 and Hsp40 for disaggregation [55, 56] while ClpB is incompatible with yeast Hsp70 and Hsp40 [68]. Nevertheless, our results cumulatively demonstrate that evolutionarily diverse Hsp104s confer thermotolerance to $\Delta hsp104$ yeast, but differences in thermotolerance activity do not explain differences in suppression of TDP-43 or α Syn toxicity.

We next expressed and purified several Hsp104 homologs (MbHsp104, CrHsp104, TtHsp104, TlHsp104, ScHsp104, and CtHsp104) to define their biochemical properties. All Hsp104 homologs are active ATPases, and display increased ATPase activity with increasing temperature (**Figure 5F**). These findings are consistent with the fact that Hsp104 is a disaggregase induced by thermal stress. We also investigated the disaggregase activity of Hsp104 homologs by assessing their ability to disaggregate disordered luciferase aggregates *in vitro* [17, 18]. Each Hsp104 homolog was able to disassemble and reactivate aggregated luciferase (**Figure 5G-H**). Luciferase disaggregation required the presence of Hsp70 and Hsp40 chaperones, which could be from yeast (Ssa1, Sis1, and Ydj1 **Figure 5H**) or human (Hsc70, Hdj1, and Hdj2 **Figure 5G**). We did not observe differences between luciferase disaggregation activity of Hsp104 homologs that suppress TDP-43 toxicity versus those that suppress α Syn (**Figure 5G-H**).

Next, we tested the activity of several Hsp104 homologs (ScHsp104, CtHsp104, TtHsp104, AtHsp104, and MtHsp104) against an ordered amyloid substrate, semen-derived enhancer of viral infection (SEVI) [69]. As previously reported [27, 53], all Hsp104 homologs tested rapidly remodeled SEVI fibrils (**Figure S8A**). Electron microscopy revealed that Hsp104 homologs remodeled SEVI fibrils into small, amorphous structures (**Figure S8B**). Thus, eukaryotic Hsp104 homologs are generally able to remodel amyloid fibrils. However, there was not an obvious difference in amyloid-remodeling activity between homologs

that also suppress α Syn toxicity (CtHsp104 and TtHsp104) and those that do not (ScHsp104, AtHsp104, and MtHsp104). Taken together, these findings suggest that differences in proteotoxicity suppression by Hsp104 homologs is not simply due to differences in general disaggregase activity of Hsp104 homologs.

Hsp104 homologs inhibit protein aggregation in an ATP-independent manner

Since differences in general disaggregase activity do not explain differences in proteotoxicity suppression among Hsp104 homologs, we wondered whether Hsp104 homologs may act instead to inhibit protein aggregation. To test this possibility, we reconstituted TDP-43 aggregation *in vitro* to test how Hsp104 homologs affect TDP-43 aggregation. We performed reactions in the presence (**Figure 5I**) or absence (**Figure 5J**) of ATP. Hsp104 from *Monosiga brevicollis* and *Chlamydomonas reinhardtii*, which selectively suppress TDP-43 toxicity and foci formation in yeast, inhibit TDP-43 aggregation *in vitro*, whereas Hsp104 from *Saccharomyces cerevisiae* has no effect (**Figure 5I-J**). Hsp104-mediated inhibition of TDP-43 aggregation occurred in the presence or absence of ATP (**Figure 5I-J**). Hsp104 homologs did not inhibit TDP-43 aggregation merely by inhibiting cleavage of the MBP tag by TEV protease (**Figure S9**). Thus, unexpectedly, specific Hsp104 homologs appear to suppress TDP-43 toxicity by inhibiting its aggregation in an ATP-independent manner.

ATPase-independent passive chaperone activity underlies suppression of TDP-43 and α Syn toxicity by Hsp104 homologs

Since we determined that Hsp104 homologs engage in passive chaperone activity to inhibit TDP-43 aggregation *in vitro*, we next tested whether or not this reflected the predominant mechanism by which Hsp104 homologs suppress TDP-43 or α Syn toxicity in yeast. Thus, we generated a series of mutants for each Hsp104 homolog intended to disrupt their disaggregase activity. Hsp104 disaggregase activity is driven by: (1) ATP binding and hydrolysis, which are mediated by Walker A and Walker B motifs, respectively, and which drive

conformational changes within the hexamer to support substrate translocation [17, 25, 66], and (2) substrate translocation through the central pore of the hexamer, which is mediated by tyrosine-bearing pore loops [17, 24, 70, 71]. These motifs are highly conserved among all Hsp104 homologs (**Figures 6A and S1**). We mutated: (1) conserved lysine residues in the Walker A motifs to either alanine or threonine (Hsp104^{DWA(KA)} and Hsp104^{DWA(KT)}) in NBD1 and NBD2 to impair ATP binding, (2) conserved glutamate residues in the Walker B motifs to either alanine or glutamine (e.g. Hsp104^{DWB(EA)} or Hsp104^{DWB(EQ)}) in NBD1 and NBD2 to impair ATP hydrolysis, and (3) conserved tyrosines in the pore loops to alanine (e.g. Hsp104^{DPLA}) in NBD1 and NBD2 to impair substrate threading through the central hexamer pore [17]. We also generated mutants lacking the NTD, which also plays a role in substrate binding and processing [35, 72]. We monitored expression of Hsp104 mutant proteins by Western blotting, and found all mutants were expressed similarly to wild-type protein, from either the galactose or native *HSP104* promoter (**Figure S10A-H**). Strains expressing Walker A, Walker B, or pore-loop mutant proteins are all severely impaired in thermotolerance compared to wild-type controls, while Δ N mutants are only mildly impaired in thermotolerance compared to wild-type proteins (**Figure S10I**). The only exception is PeHsp104, where the wild-type protein confers no thermotolerance benefit over Δ *hsp104* cells, which precludes any conclusions being drawn about the impact of mutations on this protein (**Figure 5B, S10I**). These findings are similar to thermotolerance phenotypes of ScHsp104 mutants that have been previously reported [17, 66, 72]. Thus, we confirm that these mutations have a conserved effect on Hsp104 disaggregase activity.

Next, we examined how these mutations affect the ability of different Hsp104 homologs to reduce TDP-43 or α Syn toxicity in yeast. TDP-43 or α Syn expression levels were unaffected by Hsp104 mutants, as assessed by Western blot (**Figure S10A-H**). All of the aforementioned mutations strongly impair the ability of a potentiated Hsp104 variant, ScHsp104^{A503S}, to suppress TDP-43 and α Syn toxicity [60, 72] (**Figure 6B**). Thus, ScHsp104^{A503S} suppresses TDP-43 toxicity by a disaggregase-mediated mechanism that necessitates ATP binding

and hydrolysis and substrate-engagement by conserved pore-loop tyrosines [60]. Remarkably, however, Hsp104 homolog-mediated suppression of TDP-43 or α Syn toxicity was largely unaffected by these mutations (**Figure 6C-J**). For example, mutation of conserved pore-loop tyrosines to alanine had no effect on suppression of TDP-43 or α Syn toxicity (**Figure 6C-J**). Thus, canonical substrate translocation is not required to mitigate TDP-43 or α Syn toxicity. Likewise, in most cases, mutation of Walker A or Walker B motifs did not affect suppression of TDP-43 or α Syn toxicity (**Figure 6C-J**). There were, however, some exceptions: CrHsp104 which was inhibited by mutations in the Walker B motifs (**Figure 6E**), and PeHsp104, which was modestly inhibited by K to A but not K to T substitutions in the Walker A motif and E to A but not E to Q substitutions in the Walker B motifs (**Figure 6F**). Thus, CrHsp104 and PeHsp104 likely require ATPase activity for optimal suppression of toxicity, but this requirement was not coupled to substrate translocation by conserved pore-loop tyrosines. Nevertheless, the remaining Hsp104 homologs tested here (GsHsp104, MbHsp104, SrHsp104, CtHsp104, TtHsp104, and TIHsp104) suppressed TDP-43 or α Syn toxicity by a mechanism that does not require ATPase activity or conserved pore-loop tyrosines that engage substrate in the Hsp104 channel. Mechanistically, these findings suggest that toxicity suppression by the Hsp104 homologs is primarily due to ATPase-independent chaperoning of specific substrates, such as TDP-43 or α Syn, and not due to disaggregation or ATPase-dependent chaperone activity.

Suppression of TDP-43 toxicity by MbHsp104 and CrHsp104, and suppression of α Syn toxicity by TtHsp104 is mediated by the NTD

Next, we sought to identify the requisite architecture of Hsp104 homologs that enables TDP-43 or α Syn proteotoxicity suppression. The engineered ScHsp104 variant, Hsp104^{A503S}, requires the NTD to mitigate TDP-43 and α Syn toxicity (**Figure 6B**) [72]. TDP-43 or α Syn proteotoxicity suppression by several Hsp104 homologs (GsHsp104, PeHsp104, SrHsp104, CtHsp104, and TIHsp104)

is unaffected by NTD deletion (**Figure 6C, F, G, H, J**). Interestingly, MbHsp104^{ΔN} and CrHsp104^{ΔN} are unable to suppress TDP-43 toxicity (**Figure 6D-E**), and TtHsp104^{ΔN} is unable to suppress αSyn toxicity (**Figure 6I**). Thus, proteotoxicity suppression by these Hsp104 homologs appears to be mediated by their NTDs.

We wondered whether the NTDs might drive the toxicity suppression phenotypes for MbHsp104, CrHsp104, and TtHsp104. To test this possibility, we made a series of chimeras in which we systematically replaced domains of ScHsp104 with the homologous domains from other Hsp104 homologs (see **Figure 7A** for illustration of domain boundaries and chimeras). First, we found that replacing the NTD of ScHsp104 with the NTD of either MbHsp104 or CrHsp104 did not enable suppression of TDP-43 toxicity by the resulting chimeras (**Figures 7B-C**). Similarly, replacing the ScHsp104 NTD with the NTD from TtHsp104 did not enable suppression of αSyn toxicity by the resulting chimera (**Figure 7D**). Thus, proteotoxicity suppression by MbHsp104, CrHsp104, and TtHsp104 is not simply transmitted through or encoded by the NTD. Rather, the NTD must work together with neighboring domains of the same Hsp104 homolog to enable toxicity suppression.

Suppression of TDP-43 toxicity is enabled by NBD1 and MD residues in Hsp104 homologs

Based on our observation that suppression of TDP-43 and αSyn toxicity by MbHsp104, CrHsp104, and TtHsp104 is not conferred solely by the NTD (**Figure 7B-D**), and the observation that ΔN mutants of other homologs (GsHsp104, PeHsp104, SrHsp104, CtHsp104, and TlHsp104) retained their ability to reduce either TDP-43 or αSyn toxicity (**Figure 6C, F, G, H, J**), we reasoned that residues in other domains must also contribute to substrate selectivity. Within the ScHsp104 hexamer, the NTD interacts with NBD1 and the MD [35]. Thus, we made a series of additional chimeras by progressively replacing the NTD, NBD1 or MD of ScHsp104 for the homologous domain from another Hsp104 homolog (see **Figure 7A** for illustration). Generally, the chimeras expressed well in yeast (**Figure S11**). We observed that chimeras

consisting of the NTD, NBD1, and MD from a TDP-43-selective homolog appended to the NBD2 and CTD from SchSp104 phenocopied the TDP-43 suppression phenotype associated with the homolog itself (**Figure 7B, C, E, F, G**). These same chimeras do not reduce α Syn toxicity (**Figure S12A-E**). Thus, these chimeras encompass the sequence determinants that are crucial for passive chaperoning of TDP-43. Chimeras where cognate NTD:NBD1:MD networks were disrupted do not reduce TDP-43 toxicity (**Figure 7B, C, E, F, G**). We conclude that genetic variation in NBD1 and the MD of Hsp104 homologs also contributes to mitigation of TDP-43 proteotoxicity.

Non-cognate NTD:NBD1 units can yield toxic chimeras at 37°C

We next assessed the fitness effects intrinsic to the chimeras. We expressed all chimeras in *Δhsp104* yeast at 37 °C in the absence of any toxic substrate protein to observe any intrinsic toxicity associated with the chimeras themselves. We observed that NTD replacement alone does not cause toxicity (**Figure S13A-H**, third row in all panels). By contrast, replacing both the NTD and NBD1 resulted in toxicity in several cases (e.g. for GsHsp104, CrHsp104, PeHsp104, SrHsp104, and CtHsp104; **Figure S13A, C-F, boxed**), although TtHsp104 and TIHsp104 (α Syn-specific variants) were exceptions **Figure S13G, H**). Interestingly, no toxicity was observed in chimeras where the NTD, NBD1, and MD were replaced together (**Figure S13A-H**, fifth row), nor in chimeras where the MD was replaced alone (**Figure S13A-H**, sixth row) or in combination with the NTD (**Figure S13A-H**, seventh row). These findings suggest that altered non-cognate interactions between the NTD:NBD1 unit and the MD can elicit off-target toxicity [35].

Hsp104 chimeras display reduced thermotolerance

We then characterized the thermotolerance activity of all chimeras (**Figure S14**) to understand how perturbing cognate interdomain interactions affects the disaggregase activity of each chimera. We found that, while swapping the NTD alone generally has a minimal effect on thermotolerance activity (the exception

was $\text{Sr}^{\text{NTD}}\text{Sc}^{\text{NBD1:MD:NBD2:CTD}}$ which displayed minimal thermotolerance) swaps of subsequent domains, either alone or in combination, severely impair thermotolerance function (**Figure S14**). Some of the weak thermotolerance phenotypes may be attributable to low expression levels of certain chimeras from *pHSP104*; for instance, several chimeras between MbHsp104 and ScHsp104 are poorly expressed from *pHSP104* (**Figure S11C**). But, expression levels of chimeras alone are insufficient to explain their thermotolerance phenotypes: even specific chimeras that reduce TDP-43 toxicity and express well from *pHSP104* (e.g. $\text{Cr}^{\text{NTD:NBD2:MD}}\text{Sc}^{\text{NBD2:CTD}}$) fail to confer thermotolerance. We conclude that this observation provides further evidence that the mechanism that enables Hsp104 homologs to suppress TDP-43 toxicity is distinct from Hsp104 disaggregase activity.

Select chimeras mimic potentiated ScHsp104 variants to suppress α Syn toxicity

Interestingly, two chimeras consisting of cognate NTD:NBD1 pairs fused to MD:NBD2:CTD from ScHsp104 unexpectedly suppressed α Syn toxicity. First, a chimera consisting of the CtHsp104 NTD and NBD1 fused to the ScHsp104 MD, NBD2, and CTD suppressed α Syn toxicity even more strongly than CtHsp104^{WT} (**Figure 7H**). Similarly, a chimera consisting of the PeHsp104 NTD and NBD1 fused to the ScHsp104 MD, NBD2, and CTD reduced α Syn toxicity (**Figure S12D**). This finding was particularly unexpected because full-length PeHsp104 is specific to TDP-43, and this same chimera is inactive against TDP-43 (**Figure 7F**). Both of these chimeras were toxic to yeast when expressed alone at 37°C (**Figure S13D, F**, boxed). Thus, in these cases, disruption of interaction between the NTD:NBD1 unit and the MD appears to mimic potentiated ScHsp104 variants and enables suppression of α Syn toxicity.

The NBD2:CTD unit of TtHsp104 and TlHsp104 contribute to suppression of α Syn toxicity

For the α Syn-specific Hsp104 homologs, TtHsp104 and TlHsp104, chimeras consisting of NTD:NBD1:MD from TtHsp104 or TlHsp104 fused to NBD2:CTD from ScHsp104 were unable to reduce α Syn toxicity (**Figure 7D, I**). To test whether suppression of α Syn toxicity is encoded by residues within NBD2:CTD, we tested chimeras in which NTD:NBD1:MD were from ScHsp104 and NBD2:CTD was from either TtHsp104 or TlHsp104. However, these chimeras were also incapable of suppressing α Syn toxicity (**Figure 7J, K**; see **Figure S11J, K** for accompanying Western blots). Thus, these results suggest that additional residues or contacts in the NBD2:CTD unit are necessary but not sufficient for TtHsp104 and TlHsp104 to suppress α Syn toxicity.

Homolog-mediated suppression of TDP-43 toxicity requires the NBD2:CTD unit

Finally, we tested whether NBD2 was required for suppression of TDP-43 toxicity by Hsp104 homologs, or whether expressing Hsp104 fragments encompassing the NTD, NBD1, and MD (which contain sequence determinants that reduce TDP-43 toxicity) would recapitulate the suppression of toxicity seen with the full-length homolog. We therefore co-expressed PeHsp104¹⁻⁵⁴¹ and SrHsp104¹⁻⁵⁵¹ with TDP-43 in yeast. Neither of these fragments reduce TDP-43 toxicity (**Figure 7L**; see **Figure S11L** for accompanying Western blot). Two additional fragments, PeHsp104⁷⁶⁷⁻⁹¹⁴ and SrHsp104⁷⁸¹⁻⁸⁹², which correspond to the small domain of NBD2 and the CTD also did not reduce TDP-43 toxicity (**Figure 7L**). Since these Hsp104 fragments are likely monomeric [73, 74], we thus conclude that proteotoxicity suppression is an emergent property of hexameric Hsp104 homologs or chimeras.

DISCUSSION

Here, we used yeast toxicity models to identify naturally occurring Hsp104 homologs, from diverse eukaryotic hosts, capable of buffering proteotoxicity of

several proteins implicated in human neurodegenerative diseases, including TDP-43 and α Syn (**Figures 1 and 2**). Excitingly, Hsp104 homologs that suppress TDP-43 toxicity in yeast also suppress TDP-43 aggregation in human cells (**Figure 3**), and Hsp104 homologs that suppress α Syn toxicity in yeast also suppress α Syn toxicity-induced neurodegeneration in *C. elegans* (**Figure 4**). Thus, we suggest that, like previously-defined potentiated Hsp104 variants, these naturally-occurring Hsp104 variants may be able to mitigate proteotoxicity in a wide variety of circumstances, including in metazoan systems.

Several features of the Hsp104 homologs presented here contrast with potentiated Hsp104 variants. Hsp104 homologs are substrate-specific and typically only suppress either TDP-43 or α Syn toxicity (the exception is CtHsp104). Indeed, we did not isolate any Hsp104 homologs capable of suppressing FUS toxicity. In contrast, potentiated Hsp104 variants typically are able to suppress toxicity of multiple toxic substrates (**Figures 1, 2, and S3**) [30, 32-34, 37]. Natural Hsp104 homologs also displayed no intrinsic toxicity, even when expressed at elevated temperatures (**Figure S2**). Thus, extant Hsp104 homologs have likely been filtered through natural selection to avoid deleterious and destabilizing sequences. In contrast, potentiated Hsp104 variants have predominantly been engineered by destabilizing the NBD1:MD interface [30, 33-35, 37]. This difference is further reflected in fundamental mechanistic differences between how the Hsp104 homologs described here and potentiated Hsp104 variants operate to antagonize proteotoxic misfolding. Engineered Hsp104 variants are generally enhanced disaggregases [30, 32-34]. We hypothesize that these enhanced disaggregase and unfoldase activities may come at the cost of substrate specificity (e.g. by mistargeting natively-folded complexes for disassembly), analogous to trade-offs between speed and fidelity observed in other NTPase molecular machines, such as RNA polymerases [75]. However, the Hsp104 homologs presented here are not similarly enhanced disaggregases, and in fact do not require disaggregase activity to antagonize proteotoxic misfolding of TDP-43 or α Syn. Rather, they appear to act as ATP-

independent chaperones to suppress toxicity of specific substrates (**Figures 5 and 6**).

The dual role of Hsp104 as a molecular chaperone capable of preventing substrate misfolding in addition to a disaggregase capable of reversing protein aggregation has been long-appreciated [19, 20]. Both of these activities require ATPase activity for maximum effect, although disaggregase activity is much more sensitive to reduced ATPase activity than chaperone activity [19, 20]. Here, we find that diverse Hsp104 homologs are able to suppress toxicity of select substrates in a manner that requires neither active ATPase domains nor substrate engagement by the canonical pore loops (**Figure 6**). Rather, we have uncovered genetic variation outside of these core AAA+ features that enables molecular recognition of specific substrates. Thus, in future work it will be important to tune this genetic variation to create designer disaggregases with highly specific molecular recognition. Indeed, we envision making modular disaggregases by combining potentiating mutations with molecular recognition motifs to generate Hsp104 variants with enhanced specificity *and* disaggregase activity.

What sequence determinants of Hsp104 homologs enable their toxicity suppression phenotypes? Hsp104 homologs that suppress TDP-43 or suppress α Syn are more similar to each other than between groups (average sequence identities of 56%, 76%, and 44%, respectively; **Table S3** and **Figure S6B**). To further address this question, we first tested the effect of deleting the NTD on the toxicity suppression phenotypes associated with Hsp104 homologs (**Figure 6**). We observed that suppression of TDP-43 toxicity by MbHsp104 and CrHsp104, and suppression of α Syn toxicity by TtHsp104, depends on the presence of the NTD of these homologs (**Figure 6**). The ScHsp104 NTD enables many aspects of ScHsp104 function, including hexamer cooperativity, substrate binding, amyloid dissolution, and proteotoxicity suppression by potentiated Hsp104 variants [35, 72]. We suggest that the NTD-dependent rescue phenotypes we observed may reflect a role of NTD-substrate binding in suppressing proteotoxicity.

While the NTD is necessary for proteotoxicity suppression under some circumstances, it is not universally required. Three out of five TDP-43-specific homologs did not require the NTD to suppress TDP-43 toxicity, and TIHsp104 did not require the NTD to mitigate α Syn toxicity (**Figure 6**). Furthermore, simply replacing the ScHsp104 NTD with the NTD from MbHsp104 or CrHsp104 does not enable suppression of TDP-43 toxicity, nor does replacing the ScHsp104 NTD with the NTD from TtHsp104 impart suppression of α Syn toxicity (**Figure 7**). Thus, we reasoned that additional domains must be required. Indeed, for TDP-43, we found that replacing the NTD:NBD1:MD unit of the ScHsp104 hexamer with the homologous domains from any TDP-43-rescuing homolog enables suppression of TDP-43 toxicity by the resulting chimera (**Figure 7**). The NBD2 and CTD domains were required to facilitate suppression of toxicity, as fragments of PeHsp104 and SrHsp104 encompassing NTD:NBD1:MD but lacking NBD2 and the CTD failed to suppress toxicity. However, NBD2:CTD could be from ScHsp104. In contrast, NBD2:CTD could not be from ScHsp104 for suppression of α Syn toxicity by TtHsp104 and TIHsp104 (**Figure 7**). We propose two explanations for these divergent observations. The first is that, particularly for the homologs where NTD deletion does not diminish suppression of toxicity (e.g. GsHsp104, PeHsp104, and SrHsp104 for TDP-43 and TIHsp104 for α Syn), there are important sequence determinants throughout the protein that enable each homolog to produce a protective phenotype. The second possible explanation is that these other domains contribute to suppression of toxicity indirectly by stabilizing overall protein architecture of the chimeras. There are no obvious trends in the primary sequence of the homologs, however, that would clarify these two competing possibilities. Indeed, further work is needed to gain a complete understanding of how homologous Hsp104 sequences confer variable substrate-specific proteotoxicity suppression.

That nearly half of the Hsp104 homologs we tested (8/17) were able to antagonize toxicity of either TDP-43 or α Syn (or both, in the case of CtHsp104) was unanticipated. There are no clear TDP-43 or α Syn homologs in the host species from which we selected Hsp104 homologs to test. Our observation that,

for a given Hsp104, there was not a predictable relationship between TDP-43 or α Syn toxicity suppression and thermotolerance function, which may more closely reflect the primary *in vivo* function of these Hsp104 homologs, suggests one interpretation involving cryptic genetic variation [76]. Variation that is neutral or nearly neutral with respect to thermotolerance function, but which enables suppression of TDP-43 or α Syn, may have accumulated in these lineages in the absence of selective pressure and was only revealed by our synthetic experimental paradigm. Alternatively, it is possible that the Hsp104 homologs we tested are adapted to host proteomes that have higher-than-average content of TDP-43-like or α Syn-like motifs, which is reflected in their ability to selectively antagonize misfolding of similar motifs in TDP-43 or α Syn. Nevertheless, the fact that Hsp104 homologs that are active against at least one of TDP-43 or α Syn were so widespread amongst diverse eukaryotic lineages, and the fact that we have now identified ~100 potentiating mutations in Hsp104 that enable similar toxicity suppression phenotypes (albeit by different mechanisms) suggests that Hsp104, and possibly other AAA+ proteins, are uniquely poised to buffer deleterious protein misfolding and aggregation [15].

ACKNOWLEDGEMENTS

We thank Ryan Cupo, JiaBei Lin, and Charlotte Fare for comments on the manuscript. We thank Susan Lindquist, Aaron Gitler, Simon Alberti, and Adrian Tsang for generous provision of reagents. This work was supported by a Muscular Dystrophy Association Research Award (J.S.), an ALS Association Award (J.S.), the Life Extension Foundation (J.S.), a Linda Montague Pechenik Research Award (J.S.), the Packard Center for ALS Research at Johns Hopkins University (J.S.), Target ALS (M.E.J. and J.S.), NSF Graduate Research Fellowship DGE-0822 (L.M.C.), a Blavatnik Family Fellowship (E.C.), NIH grants T32GM071399, F31NS101807 (to Z.M.M.), T32GM008076 (E.C.), and R01GM099836 (J.S.).

AUTHOR CONTRIBUTIONS

ZMM conceived, designed, and performed experiments and analyzed data. KS designed and performed experiments in human cells. HK and ZY designed and performed experiments with *C. elegans*. LMC designed and performed SEVI remodeling experiments. MEJ designed and performed experiments with ClpB variants. EC, EG, KM, RJ, and AJ contributed reagents. KAC, GAC, OS, and JS conceived and designed experiments, analyzed data, and supported research. ZMM and JS wrote the paper with feedback from all authors.

Methods

Bioinformatic analyses

Multiple sequence alignments of Hsp104 homologs were generated with Clustal Omega [77]. Multiple sequence alignments were visualized in JalView [78]. The phylogenetic tree in **Figure 1** was generated using EMBL-EBI Simple Phylogeny tool [79]. Pairwise sequence identities in **Table S3** and **Figure S6B** were calculated using UniProt Align tool. Divergence times shown in **Figure 5** were from TimeTree [80].

Yeast strains and media

All yeast were WT W303a (*MATa*, *can1-100*, *his3-11,15*, *leu2-3,112*, *trp1-1*, *ura3-1*, *ade2-1*) or the isogenic strain W303a Δ *hsp104* [81]. Yeast were grown in rich medium (YPD) or in the appropriate synthetic selection media. Media was supplemented with 2% glucose, raffinose, or galactose.

Plasmids

Yeast expression vectors encoding TDP-43 (pAG303GAL-TDP-43), FUS (pAG303GAL-FUS), and α Syn-GFP (pAG303GAL- α Syn-GFP and pAG304GAL- α Syn-GFP) were from Aaron Gitler [13, 40, 47]. pRS313HSE-ScHsp104^{WT}-FLAG, pAG416GAL-ScHsp104^{WT}-FLAG, pAG416GAL-ScHsp104^{A503S}-FLAG, and pAG416GAL-CtHsp104-FLAG have been described previously [27]. cDNAs encoding some Hsp104 homologs were kind gifts from Adrian Tsang (Concordia

University; TtHsp104, TlHsp104, ChtHsp104, LtHsp104, MtHsp104, StHsp104, and TaHsp104), Susan Lindquist (Whitehead Institute; AtHsp104), and Simon Alberti (MPI-CBG; DdHsp104), while yeast codon-optimized cDNAs encoding other Hsp104s were synthesized by Invitrogen (MbHsp104 and PfHsp104) or Genscript (GsHsp104, CrHsp104, SrHsp104, and PeHsp104). Hsp104 cDNAs codon-optimized for expression in mammalian cells were used for experiments shown in **Figure 4**. Amino acid sequences of all Hsp104 homologs are included in **Table S1**. Gateway BP reactions were used to shuttle Hsp104 genes into a Gateway entry vector, pDONR221-ccdB. The entry clones were then used to shuttle Hsp104 ORFs into suitable yeast (pAG416GAL-ccdB or pAG413GAL-ccdB or pRS313HSE-ccdB), *C. elegans* (pDAT-ccdB), or mammalian (pInducer20-ccdB) expression vectors via LR reactions. MbHsp104 and CrHsp104 were cloned into pNOTAG for bacterial expression through NdeI and SacI sites. Hsp104 mutants were obtained by Quikchange mutagenesis. Hsp104 chimeras were cloned by overlap-extension PCR. Sequences of all Hsp104 chimeras are included in **Table S2**.

Doxycycline-inducible TDP-43 Δ NLS mammalian expression vector [57] was modified as follows. Human wild-type TDP-43 was amplified in two separate PCR reactions excluding the NLS and reassembled using Gibson cloning (NEB) into a Doxycycline-inducible expression vector containing an N-terminal mClover3 tag. PCR primers used to generate TRE-mClover3-linker-TDP-43 Δ NLS: 5'-GGATCCGGAAGTGGCTCAAGCGGAATGTCTGAATATATTCGGGT-3'; 5'-TGCTGCTGCCACTGCCACTGCTGATGAAGCATCTGTCTCATCCATTGCTGCTGCGTTAT CTTTGGATAGTTGACA-3'; 5'-ATCAGCAGTGGCAGTGGCAGCAGCAGTCCAGAAAACATCCGA-3'; 5'-AAGTTTGTTGCGCCGGATCC CATTCCCCAGCCAGAAGACT-3'.

Yeast transformation and spotting assays

Yeast were transformed according to standard protocols using polyethylene glycol and lithium acetate [82]. For spotting assays, yeast were grown to saturation overnight in synthetic raffinose dropout media at 30 °C. Cultures were

normalized and serially diluted 5-fold and spotted in duplicate onto synthetic dropout media containing glucose or galactose. Plates were analyzed after growth for 2-3 days at 30 °C.

Assessing toxicity of Hsp104 homologs and chimeras

W303a Δ *hsp104* yeast were transformed with the indicated Hsp104 plasmid. Transformants were grown to saturation overnight in synthetic raffinose media. Cultures were normalized, spotted onto synthetic dropout media containing glucose or galactose, and incubated at 30 °C or 37 °C for 2-3 d before growth was documented.

Western blotting

Yeast were grown in galactose-containing media to induce protein expression for 5h (for strains expressing Hsp104s alone or with TDP-43) or 8h (for strains expressing α Syn). Cultures were normalized to OD₆₀₀=0.6, and 6 mL of cells were harvested. For heat shock controls, samples were incubated at 37 °C for 30 minutes prior to processing. Yeast lysates were extracted by incubation with 0.1M NaOH at room temperature for 5 min. Lysates were mixed with SDS sample buffer, boiled for 5 min, and subjected to Tris-HCl SDS-PAGE (4-20% gradient, Bio-Rad) followed by transfer to a PVDF membrane (Millipore). Membranes were blocked in Odyssey blocking buffer (LI-COR) for 1h at room temperature or overnight at 4 °C. Primary antibody incubations were performed at 4 °C overnight or at room temperature for 2h. After washing with PBST, membranes were incubated with fluorescently labeled secondary antibodies at room temperature for 1h, followed by washing with PBST. Proteins were detected using an Odyssey Fc Dual-Mode Imaging system. Primary antibodies used: mouse monoclonal anti-FLAG M2 (Sigma-Aldrich), rabbit polyclonal anti-TDP-43 (Proteintech), rabbit polyclonal anti-GFP (Sigma-Aldrich), mouse monoclonal 3-phosphoglycerate kinase (Novex), rabbit polyclonal anti-Hsp26 (Johannes Buchner, TU-Munich), fluorescently labeled anti-mouse and anti-rabbit secondary antibodies (Li-Cor).

Fluorescence microscopy

To visualize changes in TDP-43 and α Syn localization in response to coexpression of various Hsp104s, yeast strains expressing fluorescently-tagged TDP-43 and α Syn were previously generated and described [30]. For microscopy, these strains were grown for 5 h (TDP-43) or 8 h (α Syn) in galactose-containing media at 30 °C. For TDP-43 microscopy, cells were harvested and fixed with ice-cold 70% ethanol, washed 3 times with ice-cold PBS, and stained with 4',6-diamidino-2-phenylindole (DAPI) in Vectashield mounting medium (Vector Laboratories) to visualize nuclei. For α Syn, imaging was performed with live cells. Images were collected at 100x magnification using a Leica-DMIRBE microscope and processed using ImageJ software (NIH).

HEK-293T cell culture and transfections

HEK-293T cells were maintained in Dulbecco's modified Eagle's medium, high glucose (Gibco) containing 10% fetal bovine serum (Life Sciences), 1% non-essential amino acids (Gibco), and 1% anti-anti (Gibco). Cells were plated in gelatin-coated 6-well plates at a density of 3×10^6 cells/plate 24hr before transfection. Cells were transfected with 2 μ g total DNA and 7.35 μ l polyethylenimine HCl MAX transfection reagent (Polysciences, Inc). Wells co-transfected with mClover3-TDP Δ NLS and HSP104 variants received 1 μ g of each plasmid. Media was changed 6hrs post-transfection to media containing 1 μ g/ml of doxycycline hyclate (Sigma-Aldrich) in order to induce transgene expression. Transfected cells were lifted every 24 h over 2 days, at which point cells were analyzed by FACS (FACSAria Fusion BD). Cells were gated to have a narrow range of FCS and SSC values and to be fluorescence positive. TDP-43 aggregation was quantified by comparing the height (FITC-H) to the width (FIRC-W) of the fluorescence channel using 488nm laser and FITC filters.

Generation of transgenic *C. elegans* and neurodegeneration analysis

Nematodes were maintained through well-established methods [83]. Constructs were injected into animals to create transgenic line using previously described methods [84]. Strains UA381 (*baln11* [$P_{dat-1}::\alpha\text{-syn}$, $P_{dat-1}::\text{GFP}$]; *baEx210* [$P_{dat-1}::\text{CtHsp104}$, *rol-6*], UA382 (*baln11* [$P_{dat-1}::\alpha\text{-syn}$, $P_{dat-1}::\text{GFP}$]; *baEx211* [$P_{dat-1}::\text{TtHsp104}$, *rol-6*], UA383 (*baln11* [$P_{dat-1}::\alpha\text{-syn}$, $P_{dat-1}::\text{GFP}$]; *baEx212* [$P_{dat-1}::\text{THsp104}$, *rol-6*] were generated by injecting 50 ng/ μl of corresponding plasmid construct into UA44 (*baln11* [$P_{dat-1}::\alpha\text{Syn}$, $P_{dat-1}::\text{GFP}$]) with phenotypic marker (*rol-6*, 50 ng/ μl , for roller expression). Three independent stable lines were created for each group. For dopaminergic neurodegeneration analyses, the transgenic animals were scored as described previously [85]. Briefly, on the day of analysis, the six anterior dopaminergic neurons [four CEP (cephalic) and two ADE (anterior deirid)] were examined in 30 animals randomly selected for each trial worms that express the roller marker in the body wall muscle cells. Neurons were analyzed for any degenerative phenotypes, such as a missing dendritic process, cell body loss, or a blebbing neuronal process. Each animal was scored as having normal or wild-type neurons when none of the degenerative phenotypes were present in any anterior dopaminergic neurons. Three independent transgenic worm lines were analyzed per genetic background and an average of total percentage of worms with normal neurons was reported in the study. One-way ANOVA, followed by a Dunnett's multiple comparisons *post hoc* test, was performed for statistical analysis using GraphPad Prism Software.

Quantitative real-time PCR

RNA isolation and RT-qPCR was performed on worms using previously published methods [86]. Briefly, total RNA was isolated from 100 young adult (day 4 post hatching) nematodes from corresponding transgenic lines using TRI reagent (Molecular Research Center). The genomic DNA contamination was removed with 1 μl of DNaseI (Promega) treatment for 60 minutes at 37°C, then with DNase Stop solution for 10 minutes at 65°C. 1 μg of RNA was used for cDNA synthesis using the iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad) following the manufacturer's protocol. RT-qPCR was performed using IQ-

SYBR Green Supermix (Bio-Rad) with the Bio-Rad CFX96 Real-Time System. Each reaction contained 7.5 µl of the IQ SYBR Green Supermix, 200 nM of forward and reverse primers and 5 ng of cDNA, to a final volume of 15 µl. The cycling conditions were as follows: polymerase activation and DNA denaturation at 95°C for 3 min, followed by 35 cycles of 10 s at 95°C, 30 s at 60°C. After the final cycle, a melting curve analysis was performed using the default setting of CFX96 Real-Time System. A single melt peak for each targeted gene was observed and no non-specific amplification was detected in each reaction mixture by agarose gel electrophoresis. PCR efficiency was calculated from standard curves that were generated using serial dilution ($E_{\alpha\text{-syn}}=98.8\%$, $E_{TtHsp104}=101.0\%$, $E_{TlHsp104}=97.4\%$, $E_{tba-1}=98.8\%$, $E_{cdc-42}=98.4\%$, $E_{snb-1}=95.3\%$). The expression levels of α -syn and Hsp104 variants were normalized to three reference genes (*snb-1*, *cdc-42*, and *tba-1*). No amplification was detected in NTC and NRT controls. The reference target stability was analyzed by GeNorm and passed for all reference genes listed above. All target genes were measured in triplicates for three independent transgenic lines for each sample in this study. The data analysis was performed by the Gene Expression Module of CFX Manager software.

The following primers were used for the assays;

CtHsp104 Forward: GACGAAGCGTGTGCCAATAC

CtHsp104 Reverse: CACTTCCTGGAGCCGCTG

TtHsp104 Forward: CAACTACTTCCTGCCCGAG

TtHsp104 Reverse: ATCTGGACGTTGCGGTCGT

TlHsp104 Forward: AACCGTCTCACCAAGCGTG

TlHsp104 Reverse: GCCTCTCCGAGATAGTCCT

α -syn Forward: ATGTAGGCTCCAAAACCAAGG

α -syn Reverse: ACTGCTCCTCCAACATTTGTC

snb-1 Forward: CCGGATAAGACCATCTTGACG

snb-1 Reverse: GACGACTTCATCAACCTGAGC

cdc-42 Forward: CCGAGAAAAATGGGTGCCTG

cdc-42 Reverse: TTCTCGAGCATTCCTGGATCAT

tba-1 Forward: ATCTCTGCTGACAAGGCTTAC

tba-1 Reverse: GTACAAGAGGCAAACAGCCAT

Thermotolerance

W303a Δ *hsp104* yeast were transformed with plasmids bearing either Hsp104 from *S. cerevisiae*, the indicated Hsp104 homolog, or Hsp104 mutant under the native *HSP104* promoter (except for TtHsp104 and derivative mutants, which were expressed from pGAL), or an empty vector control. Transformants were selected, grown to saturation in yeast minimal media (SD-His), and then diluted to OD₆₀₀=0.2 in fresh SD-His. Yeast were allowed to double at 30 °C, after which cultures were normalized. Cells were then heat shocked at 50 °C for the indicated time and cooled for 2 min on ice. Cultures were then diluted 1000-fold, plated on SD-His, and plates were incubated at 30 °C for 2-3 days to observe viable colonies.

Protein expression and purification

Untagged ScHsp104 was expressed from the pNOTAG-ScHsp104 vector [73] and purified as previously described [60, 87]. Briefly, pNOTAG-ScHsp104 was used to transform BL21(DE3)RIL *E. coli*. Transformed cells were grown in 2xYT broth supplemented with 25 µg/ml chloramphenicol and 100 µg/ml ampicillin at 37 °C until an OD₆₀₀ of 0.4-0.6 was reached, at which point cells were cooled to 15 °C. Expression was induced by addition of 1 mM isopropyl 1-thio-β-D-galactopyranoside for 15-18 h. Cells were harvested by centrifugation (4,000×g, 4°C, 25 min), resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 2.5% glycerol, 2 mM β-mercaptoethanol, 5 µM pepstatin, complete EDTA-free protease inhibitors (Roche)). Cells were treated on ice with 20 mg lysozyme per 1L culture and lysed by sonication. Cell debris was removed by centrifugation at 16,000×g at 4°C for 20 min, and the supernatant was applied to Affi-Gel Blue resin (Bio-Rad). Resin was incubated with the lysates for 4 h at 4 °C with slow rotation. Resin was then washed 4 times with wash buffer (50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 100 mM KCl, 2.5% glycerol, 2 mM β-mercaptoethanol).

ScHsp104 was eluted with wash buffer supplemented with 1 M KCl. The protein was then exchanged into running buffer Q (20 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 5 mM MgCl₂, 50 mM NaCl), further purified by ResourceQ anion exchange chromatography, and eluted with a linear salt gradient (50 mM-1 M NaCl). Eluted protein was then exchanged into storage buffer (40 mM HEPES-KOH pH 7.4, 150 mM KCl, 20 mM MgCl₂, 10% glycerol, 1 mM DTT), snap-frozen, and stored at -80 °C until use.

MbHsp104 and CrHsp104 were expressed as untagged proteins by subcloning the MbHsp104 and CrHsp104 ORFs into pNOTAG through NdeI and SacI sites. Protein expression and lysis were carried out as for ScHsp104. However, MbHsp104 and CrHsp104 bound poorly to Affi-Blue resin, even after extended incubation times (data not shown). Instead, MbHsp104 and CrHsp104 were precipitated from clarified bacterial lysates by addition of solid ammonium sulfate to 40% of saturation. Precipitates were collected by centrifugation (16,000×g at 4 °C, 20 min) and resuspended in buffer containing 50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 100 mM KCl, 2.5% glycerol, 2 mM β-mercaptoethanol. To resolubilize precipitates, ammonium sulfate was removed by dialysis against this buffer, with 3 buffer changes. The dialyzate was filtered and applied to a 5 mL HiTrapQ column and purified with running buffer Q (20 mM Tris pH 8.0, 0.5 mM EDTA, 5 mM MgCl₂, 50 mM NaCl) and eluted with a linear gradient of buffer Q+ (20 mM Tris pH 8.0, 0.5 mM EDTA, 5mM MgCl₂, 1 M NaCl) over 40 column volumes. Peak fractions were collected, pooled, and exchanged into size exclusion buffer (40 mM HEPES-KOH pH 7.4, 150 mM KCl, 10 mM MgCl₂ 1 mM DTT) and further purified by size exclusion chromatography on a pre-equilibrated Superdex 200 column (GE healthcare). Protein in size exclusion buffer was concentrated to ~10 mg/mL, supplemented with 10% glycerol, snap-frozen and stored at -80 °C until use.

CtHsp104, TtHsp104, and TlHsp104 were expressed from pMCSG68 vector as TEV protease-cleavable His₆-tagged fusion proteins. Protein expression and lysis were carried out as for other Hsp104s, except in this case lysis buffer consisted of 40 mM HEPES-KOH pH 7.4, 500 mM KCl, 20 mM

MgCl₂, 2.5% glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol supplemented with 5 μM pepstatin A and complete protease inhibitor tablets. Clarified lysate was loaded onto Ni-NTA resin. The resin was washed with 10 volumes of wash buffer (same formulation as lysis buffer except without protease inhibitors) and eluted in wash buffer supplemented with 350 mM imidazole. TEV protease was added to the eluted protein, and the sample was dialyzed against wash buffer containing no imidazole for 4 h at room temperature followed by ~16h at 4 °C. After dialysis and cleavage, the protein was loaded onto a second Ni-NTA column to remove the His₆ tag and uncleaved protein. Eluted protein was pooled, concentrated, and exchanged into high salt storage buffer (40 mM HEPES-KOH pH 7.4, 500 mM KCl, 20 mM MgCl₂, 10% glycerol, and 1 mM DTT), snap-frozen in liquid nitrogen, and stored at -80 °C until further use.

Ssa1, Hsc70, Sis1, Ydj1, Hdj1, and Hdj2 (in pESUMO (Life Sensors)) were expressed as N-terminally His₆-SUMO-tagged proteins in BL21(DE3)RIL cells. Transformed cells were grown at 37 °C in Luria broth supplemented with 25 μg/ml chloramphenicol and 100 μg/ml ampicillin to an OD₆₀₀ ~0.5. Cultures were cooled to 15 °C, and expression was induced with 1 mM IPTG for 16 h. Cells were harvested, resuspended in lysis buffer (50 mM HEPES pH 7.5, 750 mM KCl, 5 mM MgCl₂, 10% glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol, 5 μM pepstatin A, and cOmplete protease inhibitor (Roche)), and lysed by treatment with lysozyme and sonication. Lysates were clarified by centrifugation (16,000×g, 20 min, 4°C), and incubated with Ni-NTA resin for 90 min at 4°C. Resin was washed with 10 column volumes of wash buffer (50 mM HEPES pH 7.5, 750 mM KCl, 10 mM MgCl₂, 10% glycerol, 20 mM imidazole, 1 mM ATP, 2 mM β-mercaptoethanol) and eluted with 2 column volumes of elution buffer (wash buffer+300 mM imidazole). To cleave the His₆-SUMO tag, Ulp1 was added at a 1:100 molar ratio, and imidazole was removed by dialysis against wash buffer. After dialysis, protein was loaded onto a 5 mL HisTrap column (GE Healthcare) and eluted with a linear imidazole gradient (20-350 mM) over 40 column volumes. Fractions containing cleaved protein were pooled,

concentrated, and purified further by Resource Q (Ssa1, Hsc70, Ydj1, and Hdj2) or Resource S (Sis1 and Hdj1) ion exchange chromatography.

TDP-43 was expressed with an N-terminal, TEV-cleavable maltose binding protein (MBP) tag in BL21(DE3)RIL cells. Transformed cells were grown at 37 °C in Luria broth supplemented with 25 µg/ml chloramphenicol and 100 µg/ml ampicillin to an OD₆₀₀ ~0.8. Cultures were cooled to 15 °C, and expression was induced with 1 mM IPTG for 16 h. Cells were harvested, resuspended in lysis buffer (50 mM HEPES-KOH pH 7.5, 500 mM NaCl, 10% glycerol, 2 mM EDTA, 2 mM DTT, and c0mplete protease inhibitor (Roche)), and lysed by treatment with lysozyme and sonication. Lysates were clarified by centrifugation (16,000×g, 20 min, 4 °C). Cleared lysate was added to a 50% slurry of amylose resin (New England Biolabs) in lysis buffer and incubated at 4 °C for 30 min to bind MBP-TDP-43. The resin was washed with lysis buffer, and eluted MBP-TEV with elution buffer (50 mM HEPES-KOH pH 7.5, 500 mM NaCl, 10% glycerol, 2 mM EDTA, 2 mM DTT, 10 mM maltose). Purified fractions were pooled, snap-frozen, and stored at -80 °C until use.

ATPase activity

Hsp104 (0.25 µM monomer) was incubated with ATP (1 mM) for 5 min at the indicated temperatures in buffer (25 mM HEPES-KOH pH 7.4, 150 mM potassium acetate, 10 mM magnesium acetate, 10 mM DTT). ATPase activity was determined by inorganic phosphate release using a malachite green phosphate detection kit (Innova). Background hydrolysis was determined at time zero and subtracted.

Luciferase reactivation

Aggregated luciferase (50 nM) was incubated with Hsp104 (0.167 µM hexamer) with ATP (5 mM) and an ATP regeneration system (ARS; 1 mM creatine phosphate, 0.25 µM creatine kinase) plus or minus 0.167 µM Hsp70 (Ssa1 or Hsc70) and 0.167 µM Hsp40 (Sis1, Ydj1, Hdj1, or Hdj2, as indicated). Luciferase activity was assessed by luminescence on a TECAN Safire II plate reader.

Semen-Derived Enhancer of Virus Infection (SEVI) remodeling

SEVI remodeling was performed as previously described [53]. SEVI fibrils (20 μ M monomer) were incubated with Hsp104 homologs (3 μ M hexamer) in LRB buffer in the presence of ATP (5 mM) and an ATP regeneration system (0.1 mM ATP, 0.02 mg/mL creatine kinase, 10 mM creatine phosphate). Samples were incubated at 37 °C for the duration of the experiments. At various time points, aliquots were removed, added to a 96-well plate containing a solution of 25 μ M ThT in LRB buffer. ThT fluorescence characteristics were measured on a Tecan Safire² microplate reader with excitation and emission filters set to 440 nm and 482 nm, respectively. To assess fibril morphology by negative stain EM, reaction aliquots were spotted on Formvar carbon-coated grids (EM Sciences) and stained with 2% uranyl acetate. Samples were visualized using a JEOL-1010 electron microscope.

TDP-43 aggregation experiments

TDP-43 aggregation was initiated by incubating 3 μ M MBP-TEV-TDP-43 with TEV protease in assembly buffer (40 mM HEPES-KOH pH 7.5, 150 mM NaCl, 10 mM MgCl₂, 1 mM DTT) without agitation. Aggregation was monitored by turbidity ($A_{395\text{ nm}}$) in a TECAN Infinite M1000 plate reader. In some reactions, either ScHsp104, MbHsp104, or CrHsp104 were added (6 μ M) with or without ATP (5 μ M) and regeneration system (1 mM creatine phosphate and 0.25 μ M creatine kinase). We verified that Hsp104s nor ATP affected cleavage of the MBP tag by Western blotting (see **Figure S2**).

References

1. Chuang E, Hori AM, Hesketh CD, Shorter J. Amyloid assembly and disassembly. *J Cell Sci.* 2018;131(8). Epub 2018/04/15. doi: 10.1242/jcs.189928. PubMed PMID: 29654159; PubMed Central PMCID: PMC5963839.
2. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. *Nat Med.* 2004;10(10):1055-63. doi: 10.1038/nm1113. PubMed PMID: 15459709.

3. Shorter J. Designer protein disaggregases to counter neurodegenerative disease. *Curr Opin Genet Dev.* 2017;44:1-8. Epub 2017/02/17. doi: 10.1016/j.gde.2017.01.008. PubMed PMID: 28208059; PubMed Central PMCID: PMC5447488.
4. Gallegos S, Pacheco C, Peters C, Opazo CM, Aguayo LG. Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. *Front Neurosci.* 2015;9:59. Epub 2015/03/26. doi: 10.3389/fnins.2015.00059. PubMed PMID: 25805964; PubMed Central PMCID: PMC4353246.
5. Gitler AD, Shorter J. Prime time for alpha-synuclein. *J Neurosci.* 2007;27(10):2433-4. doi: 10.1523/JNEUROSCI.0094-07.2007. PubMed PMID: 17344380.
6. Kim WS, Kagedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. *Alzheimers Res Ther.* 2014;6(5):73. doi: 10.1186/s13195-014-0073-2. PubMed PMID: 25580161; PubMed Central PMCID: PMC4288216.
7. Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson's diseases. *Front Neuroanat.* 2014;8.
8. Snead D, Eliezer D. Alpha-synuclein function and dysfunction on cellular membranes. *Exp Neurobiol.* 2014;23(4):292-313. doi: 10.5607/en.2014.23.4.292. PubMed PMID: 25548530; PubMed Central PMCID: PMC4276801.
9. Gitler AD, Shorter J. RNA-binding proteins with prion-like domains in ALS and FTL-D. *Prion.* 2011;5(3):179-87. doi: 10.4161/pri.5.3.17230. PubMed PMID: 21847013; PubMed Central PMCID: PMC3226045.
10. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. *J Biol Chem.* 2009;284(30):20329-39. doi: 10.1074/jbc.M109.010264. PubMed PMID: 19465477; PubMed Central PMCID: PMC2740458.
11. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. *Neuron.* 2013;79(3):416-38. doi: 10.1016/j.neuron.2013.07.033. PubMed PMID: 23931993; PubMed Central PMCID: PMC4411085.
12. March ZM, King OD, Shorter J. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. *Brain Res.* 2016;1647:9-18. doi: 10.1016/j.brainres.2016.02.037. PubMed PMID: 26996412; PubMed Central PMCID: PMC45003744.

13. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. *PLoS Biol.* 2011;9(4):e1000614. doi: 10.1371/journal.pbio.1000614. PubMed PMID: 21541367; PubMed Central PMCID: PMC3082519.
14. Shorter J. Hsp104: a weapon to combat diverse neurodegenerative disorders. *Neurosignals.* 2008;16(1):63-74. doi: 10.1159/000109760. PubMed PMID: 18097161.
15. March ZM, Mack KL, Shorter J. AAA+ Protein-Based Technologies to Counter Neurodegenerative Disease. *Biophys J.* 2019;116(8):1380-5. Epub 2019/04/07. doi: 10.1016/j.bpj.2019.03.007. PubMed PMID: 30952364; PubMed Central PMCID: PMC6486517.
16. Vashist S, Cushman M, Shorter J. Applying Hsp104 to protein-misfolding disorders. *Biochem Cell Biol.* 2010;88(1):1-13. Epub 2010/02/05. doi: 10.1139/o09-121. PubMed PMID: 20130674; PubMed Central PMCID: PMC3082519.
17. DeSantis ME, Leung EH, Sweeny EA, Jackrel ME, Cushman-Nick M, Neuhaus-Follini A, et al. Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. *Cell.* 2012;151(4):778-93. doi: 10.1016/j.cell.2012.09.038. PubMed PMID: 23141537; PubMed Central PMCID: PMC3496281.
18. Glover JR, Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. *Cell.* 1998;94(1):73-82. Epub 1998/07/23. PubMed PMID: 9674429.
19. Shorter J, Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. *Science.* 2004;304(5678):1793-7. doi: 10.1126/science.1098007. PubMed PMID: 15155912.
20. Shorter J, Lindquist S. Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. *Mol Cell.* 2006;23(3):425-38. Epub 2006/08/04. doi: 10.1016/j.molcel.2006.05.042. PubMed PMID: 16885031; PubMed Central PMCID: PMC1540446.
21. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, Lindquist S, et al. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. *J Clin Invest.* 2008;118(9):3087-97. Epub 2008/08/16. doi: 10.1172/jci35781. PubMed PMID: 18704197; PubMed Central PMCID: PMC2515383.
22. Sweeny EA, Shorter J. Mechanistic and Structural Insights into the Prion-Disaggregase Activity of Hsp104. *J Mol Biol.* 2016;428(9 Pt B):1870-85. Epub

2015/11/27. doi: 10.1016/j.jmb.2015.11.016. PubMed PMID: 26608812; PubMed Central PMCID: PMC4860052.

23. Shorter J, Southworth DR. Spiraling in Control: Structures and Mechanisms of the Hsp104 Disaggregase. *Cold Spring Harb Perspect Biol.* 2019;11(8). Epub 2019/02/13. doi: 10.1101/cshperspect.a034033. PubMed PMID: 30745294; PubMed Central PMCID: PMC6671941.
24. Gates SN, Yokom AL, Lin J, Jackrel ME, Rizo AN, Kendzersky NM, et al. Ratchet-like polypeptide translocation mechanism of the AAA+ disaggregase Hsp104. *Science.* 2017;357(6348):273-9. Epub 2017/06/18. doi: 10.1126/science.aan1052. PubMed PMID: 28619716; PubMed Central PMCID: PMC5770238.
25. Ye X, Lin J, Mayne L, Shorter J, Englander SW. Hydrogen exchange reveals Hsp104 architecture, structural dynamics, and energetics in physiological solution. *Proc Natl Acad Sci U S A.* 2019;116(15):7333-42. Epub 2019/03/29. doi: 10.1073/pnas.1816184116. PubMed PMID: 30918129; PubMed Central PMCID: PMC6462101.
26. Yokom AL, Gates SN, Jackrel ME, Mack KL, Su M, Shorter J, et al. Spiral architecture of the Hsp104 disaggregase reveals the basis for polypeptide translocation. *Nat Struct Mol Biol.* 2016;23(9):830-7. Epub 2016/08/02. doi: 10.1038/nsmb.3277. PubMed PMID: 27478928; PubMed Central PMCID: PMC5509435.
27. Michalska K, Zhang K, March ZM, Hatzos-Skintges C, Pintilie G, Bigelow L, et al. Structure of *Calcarisporiella thermophila* Hsp104 Disaggregase that Antagonizes Diverse Proteotoxic Misfolding Events. *Structure.* 2019;27(3):449-63. Epub 2019/03/05. doi: 10.1016/j.str.2018.11.001. PubMed PMID: 30595457.
28. Vacher C, Garcia-Oroz L, Rubinsztein DC. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. *Hum Mol Genet.* 2005;14(22):3425-33. doi: 10.1093/hmg/ddi372. PubMed PMID: 16204350.
29. Cushman-Nick M, Bonini NM, Shorter J. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model. *PLoS Genet.* 2013;9(9):e1003781. doi: 10.1371/journal.pgen.1003781. PubMed PMID: 24039611; PubMed Central PMCID: PMC3764203.
30. Jackrel ME, DeSantis ME, Martinez BA, Castellano LM, Stewart RM, Caldwell KA, et al. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. *Cell.* 2014;156(1-2):170-82. doi: 10.1016/j.cell.2013.11.047. PubMed PMID: 24439375; PubMed Central PMCID: PMC3909490.
31. Jackrel ME, Shorter J. Engineering enhanced protein disaggregases for neurodegenerative disease. *Prion.* 2015;9(2):90-109. Epub 2015/03/05. doi:

10.1080/19336896.2015.1020277. PubMed PMID: 25738979; PubMed Central PMCID: PMC4601286.

32. Jackrel ME, Shorter J. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. *Dis Model Mech*. 2014;7(10):1175-84. doi: 10.1242/dmm.016113. PubMed PMID: 25062688; PubMed Central PMCID: PMC4174528.

33. Jackrel ME, Yee K, Tariq A, Chen AI, Shorter J. Disparate Mutations Confer Therapeutic Gain of Hsp104 Function. *ACS Chem Biol*. 2015;10(12):2672-9. doi: 10.1021/acschembio.5b00765. PubMed PMID: 26441009; PubMed Central PMCID: PMC4684741.

34. Tariq A, Lin J, Noll MM, Torrente MP, Mack KL, Murillo OH, et al. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain. *FEMS Yeast Res*. 2018;18(5). Epub 2018/05/23. doi: 10.1093/femsyr/foy042. PubMed PMID: 29788207.

35. Sweeny EA, Tariq A, Gurpinar E, Go MS, Sochor MA, Kan ZY, et al. Structural and mechanistic insights into Hsp104 function revealed by synchrotron X-ray footprinting. *J Biol Chem*. 2020;295(6):1517-38. Epub 2019/12/29. doi: 10.1074/jbc.RA119.011577. PubMed PMID: 31882541; PubMed Central PMCID: PMC7008382.

36. Ryan JJ, Sprunger ML, Holthaus K, Shorter J, Jackrel ME. Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma. *J Biol Chem*. 2019;294(29):11286-96. Epub 2019/06/07. doi: 10.1074/jbc.RA119.009494. PubMed PMID: 31171724; PubMed Central PMCID: PMC6643043.

37. Tariq A, Lin J, Jackrel ME, Hesketh CD, Carman PJ, Mack KL, et al. Mining protein-disaggregase sequence space to safely counter TDP-43, FUS, and alpha-synuclein proteotoxicity. *Cell Rep*. 2019;28(8):2080-95.

38. Erives AJ, Fassler JS. Metabolic and chaperone gene loss marks the origin of animals: evidence for Hsp104 and Hsp78 chaperones sharing mitochondrial enzymes as clients. *PLoS One*. 2015;10(2):e0117192. Epub 2015/02/25. doi: 10.1371/journal.pone.0117192. PubMed PMID: 25710177; PubMed Central PMCID: PMC4339202.

39. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. *Science*. 2003;302(5651):1772-5. Epub 2003/12/06. doi: 10.1126/science.1090439. PubMed PMID: 14657500; PubMed Central PMCID: PMC1780172.

40. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. *Proc Natl Acad Sci U S A*. 2008;105(17):6439-

44. Epub 2008/04/25. doi: 10.1073/pnas.0802082105. PubMed PMID: 18434538; PubMed Central PMCID: PMCPMC2359814.
41. Ho CM, Beck JR, Lai M, Cui Y, Goldberg DE, Egea PF, et al. Malaria parasite translocon structure and mechanism of effector export. *Nature*. 2018;561(7721):70-5. Epub 2018/08/29. doi: 10.1038/s41586-018-0469-4. PubMed PMID: 30150771; PubMed Central PMCID: PMCPMC6555636.
42. Bullen HE, Charnaud SC, Kalanon M, Riglar DT, Dekiwadia C, Kangwanrangsan N, et al. Biosynthesis, localization, and macromolecular arrangement of the *Plasmodium falciparum* translocon of exported proteins (PTEX). *J Biol Chem*. 2012;287(11):7871-84. Epub 2012/01/19. doi: 10.1074/jbc.M111.328591. PubMed PMID: 22253438; PubMed Central PMCID: PMCPMC3318755.
43. de Koning-Ward TF, Gilson PR, Boddey JA, Rug M, Smith BJ, Papenfuss AT, et al. A newly discovered protein export machine in malaria parasites. *Nature*. 2009;459(7249):945-9. Epub 2009/06/19. doi: 10.1038/nature08104. PubMed PMID: 19536257; PubMed Central PMCID: PMCPMC2725363.
44. Cashikar AG, Duennwald M, Lindquist SL. A chaperone pathway in protein disaggregation. Hsp26 alters the nature of protein aggregates to facilitate reactivation by Hsp104. *J Biol Chem*. 2005;280(25):23869-75. Epub 2005/04/23. doi: 10.1074/jbc.M502854200. PubMed PMID: 15845535; PubMed Central PMCID: PMCPMC1391974.
45. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science*. 2006;314(5796):130-3. Epub 2006/10/07. doi: 10.1126/science.1134108. PubMed PMID: 17023659.
46. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. *Nature*. 1997;388(6645):839-40. Epub 1997/08/28. doi: 10.1038/42166. PubMed PMID: 9278044.
47. Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, et al. The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. *Proc Natl Acad Sci U S A*. 2008;105(1):145-50. Epub 2007/12/29. doi: 10.1073/pnas.0710685105. PubMed PMID: 18162536; PubMed Central PMCID: PMCPMC2224176.
48. Soper JH, Roy S, Stieber A, Lee E, Wilson RB, Trojanowski JQ, et al. Alpha-synuclein-induced aggregation of cytoplasmic vesicles in *Saccharomyces cerevisiae*. *Mol Biol Cell*. 2008;19(3):1093-103. Epub 2008/01/04. doi: 10.1091/mbc.E07-08-0827. PubMed PMID: 18172022; PubMed Central PMCID: PMCPMC2262993.

49. Zabrocki P, Pellens K, Vanhelmont T, Vandebroek T, Griffioen G, Wera S, et al. Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast. *FEBS J.* 2005;272(6):1386-400. Epub 2005/03/09. doi: 10.1111/j.1742-4658.2005.04571.x. PubMed PMID: 15752356.
50. Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, et al. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. *Nat Neurosci.* 2019;22(7):1099-109. Epub 2019/06/27. doi: 10.1038/s41593-019-0423-2. PubMed PMID: 31235907.
51. Oguchi Y, Kummer E, Seyffer F, Berynskyy M, Anstett B, Zahn R, et al. A tightly regulated molecular toggle controls AAA+ disaggregase. *Nat Struct Mol Biol.* 2012;19(12):1338-46. Epub 2012/11/20. doi: 10.1038/nsmb.2441. PubMed PMID: 23160353.
52. Rizo AN, Lin J, Gates SN, Tse E, Bart SM, Castellano LM, et al. Structural basis for substrate gripping and translocation by the ClpB AAA+ disaggregase. *Nat Commun.* 2019;10(1):2393. Epub 2019/06/05. doi: 10.1038/s41467-019-10150-y. PubMed PMID: 31160557; PubMed Central PMCID: PMC6546751.
53. Castellano LM, Bart SM, Holmes VM, Weissman D, Shorter J. Repurposing Hsp104 to Antagonize Seminal Amyloid and Counter HIV Infection. *Chem Biol.* 2015;22(8):1074-86. Epub 2015/08/11. doi: 10.1016/j.chembiol.2015.07.007. PubMed PMID: 26256479; PubMed Central PMCID: PMC4546571.
54. Avellaneda MJ, Franke KB, Sunderlikova V, Bukau B, Mogk A, Tans SJ. Processive extrusion of polypeptide loops by a Hsp100 disaggregase. *Nature.* 2020;578(7794):317-20. Epub 2020/01/31. doi: 10.1038/s41586-020-1964-y. PubMed PMID: 31996849.
55. Lee C, Franke KB, Kamal SM, Kim H, Lunsdorf H, Jager J, et al. Stand-alone ClpG disaggregase confers superior heat tolerance to bacteria. *Proc Natl Acad Sci U S A.* 2018;115(2):E273-e82. Epub 2017/12/22. doi: 10.1073/pnas.1712051115. PubMed PMID: 29263094; PubMed Central PMCID: PMC5777039.
56. Katikaridis P, Meins L, Kamal SM, Romling U, Mogk A. ClpG Provides Increased Heat Resistance by Acting as Superior Disaggregase. *Biomolecules.* 2019;9(12). Epub 2019/12/08. doi: 10.3390/biom9120815. PubMed PMID: 31810333.
57. Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. *J Biol Chem.* 2008;283(19):13302-9. Epub 2008/02/29. doi:

10.1074/jbc.M800342200. PubMed PMID: 18305110; PubMed Central PMCID: PMCPMC2442318.

58. Ramdzan YM, Wood R, Hatters DM. Pulse shape analysis (PulSA) to track protein translocation in cells by flow cytometry: applications for polyglutamine aggregation. *Methods Mol Biol.* 2013;1017:85-93. Epub 2013/05/31. doi: 10.1007/978-1-62703-438-8_6. PubMed PMID: 23719909.

59. Cao S, Gelwix CC, Caldwell KA, Caldwell GA. Torsin-mediated protection from cellular stress in the dopaminergic neurons of *Caenorhabditis elegans*. *J Neurosci.* 2005;25(15):3801-12. doi: 10.1523/JNEUROSCI.5157-04.2005. PubMed PMID: 15829632.

60. Torrente MP, Chuang E, Noll MM, Jackrel ME, Go MS, Shorter J. Mechanistic Insights into Hsp104 Potentiation. *J Biol Chem.* 2016;291(10):5101-15. Epub 2016/01/10. doi: 10.1074/jbc.M115.707976. PubMed PMID: 26747608; PubMed Central PMCID: PMCPMC4777845.

61. Sanchez Y, Lindquist SL. HSP104 required for induced thermotolerance. *Science.* 1990;248(4959):1112-5. Epub 1990/06/01. PubMed PMID: 2188365.

62. Queitsch C, Hong SW, Vierling E, Lindquist S. Heat shock protein 101 plays a crucial role in thermotolerance in *Arabidopsis*. *Plant Cell.* 2000;12(4):479-92. Epub 2000/04/13. doi: 10.1105/tpc.12.4.479. PubMed PMID: 10760238; PubMed Central PMCID: PMCPMC139847.

63. Mogk A, Tomoyasu T, Goloubinoff P, Rudiger S, Roder D, Langen H, et al. Identification of thermolabile *Escherichia coli* proteins: prevention and reversion of aggregation by DnaK and ClpB. *Embo j.* 1999;18(24):6934-49. Epub 1999/12/22. doi: 10.1093/emboj/18.24.6934. PubMed PMID: 10601016; PubMed Central PMCID: PMCPMC1171757.

64. Parsell DA, Kowal AS, Singer MA, Lindquist S. Protein disaggregation mediated by heat-shock protein Hsp104. *Nature.* 1994;372(6505):475-8. Epub 1994/12/01. doi: 10.1038/372475a0. PubMed PMID: 7984243.

65. Wallace EW, Kear-Scott JL, Pilipenko EV, Schwartz MH, Laskowski PR, Rojek AE, et al. Reversible, Specific, Active Aggregates of Endogenous Proteins Assemble upon Heat Stress. *Cell.* 2015;162(6):1286-98. Epub 2015/09/12. doi: 10.1016/j.cell.2015.08.041. PubMed PMID: 26359986; PubMed Central PMCID: PMCPMC4567705.

66. Parsell DA, Sanchez Y, Stitzel JD, Lindquist S. Hsp104 is a highly conserved protein with two essential nucleotide-binding sites. *Nature.* 1991;353(6341):270-3. Epub 1991/09/19. doi: 10.1038/353270a0. PubMed PMID: 1896074.

67. Tessarz P, Mogk A, Bukau B. Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation. *Mol Microbiol.* 2008;68(1):87-97. Epub 2008/03/04. doi: 10.1111/j.1365-2958.2008.06135.x. PubMed PMID: 18312264.
68. Miot M, Reidy M, Doyle SM, Hoskins JR, Johnston DM, Genest O, et al. Species-specific collaboration of heat shock proteins (Hsp) 70 and 100 in thermotolerance and protein disaggregation. *Proc Natl Acad Sci U S A.* 2011;108(17):6915-20. Epub 2011/04/09. doi: 10.1073/pnas.1102828108. PubMed PMID: 21474779; PubMed Central PMCID: PMC3084080.
69. Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. *Cell.* 2007;131(6):1059-71. Epub 2007/12/18. doi: 10.1016/j.cell.2007.10.014. PubMed PMID: 18083097.
70. Lum R, Niggemann M, Glover JR. Peptide and protein binding in the axial channel of Hsp104. Insights into the mechanism of protein unfolding. *J Biol Chem.* 2008;283(44):30139-50. Epub 2008/08/30. doi: 10.1074/jbc.M804849200. PubMed PMID: 18755692; PubMed Central PMCID: PMC2662077.
71. Lum R, Tkach JM, Vierling E, Glover JR. Evidence for an unfolding/threading mechanism for protein disaggregation by *Saccharomyces cerevisiae* Hsp104. *J Biol Chem.* 2004;279(28):29139-46. Epub 2004/05/07. doi: 10.1074/jbc.M403777200. PubMed PMID: 15128736.
72. Sweeny EA, Jackrel ME, Go MS, Sochor MA, Razzo BM, DeSantis ME, et al. The Hsp104 N-terminal domain enables disaggregase plasticity and potentiation. *Mol Cell.* 2015;57(5):836-49. doi: 10.1016/j.molcel.2014.12.021. PubMed PMID: 25620563; PubMed Central PMCID: PMC4623595.
73. Hattendorf DA, Lindquist SL. Analysis of the AAA sensor-2 motif in the C-terminal ATPase domain of Hsp104 with a site-specific fluorescent probe of nucleotide binding. *Proc Natl Acad Sci U S A.* 2002;99(5):2732-7. Epub 2002/02/28. doi: 10.1073/pnas.261693199. PubMed PMID: 11867765; PubMed Central PMCID: PMC122416.
74. Mogk A, Schlieker C, Strub C, Rist W, Weibezahn J, Bukau B. Roles of individual domains and conserved motifs of the AAA+ chaperone ClpB in oligomerization, ATP hydrolysis, and chaperone activity. *J Biol Chem.* 2003;278(20):17615-24. Epub 2003/03/08. doi: 10.1074/jbc.M209686200. PubMed PMID: 12624113.
75. Fitzsimmons WJ, Woods RJ, McCrone JT, Woodman A, Arnold JJ, Yennawar M, et al. A speed-fidelity trade-off determines the mutation rate and virulence of an RNA virus. *PLoS Biol.* 2018;16(6):e2006459. Epub 2018/06/29. doi: 10.1371/journal.pbio.2006459. PubMed PMID: 29953453; PubMed Central PMCID: PMC6040757.

76. Paaby AB, Rockman MV. Cryptic genetic variation: evolution's hidden substrate. *Nat Rev Genet.* 2014;15(4):247-58. Epub 2014/03/13. doi: 10.1038/nrg3688. PubMed PMID: 24614309; PubMed Central PMCID: PMC4737706.
77. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol.* 2011;7:539. Epub 2011/10/13. doi: 10.1038/msb.2011.75. PubMed PMID: 21988835; PubMed Central PMCID: PMC3261699.
78. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2--a multiple sequence alignment editor and analysis workbench. *Bioinformatics.* 2009;25(9):1189-91. Epub 2009/01/20. doi: 10.1093/bioinformatics/btp033. PubMed PMID: 19151095; PubMed Central PMCID: PMC2672624.
79. Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids Res.* 2019;47(W1):W636-w41. Epub 2019/04/13. doi: 10.1093/nar/gkz268. PubMed PMID: 30976793; PubMed Central PMCID: PMC6602479.
80. Kumar S, Stecher G, Suleski M, Hedges SB. TimeTree: A Resource for Timelines, Timetrees, and Divergence Times. *Mol Biol Evol.* 2017;34(7):1812-9. Epub 2017/04/08. doi: 10.1093/molbev/msx116. PubMed PMID: 28387841.
81. Schirmer EC, Homann OR, Kowal AS, Lindquist S. Dominant gain-of-function mutations in Hsp104p reveal crucial roles for the middle region. *Mol Biol Cell.* 2004;15(5):2061-72. Epub 2004/02/24. doi: 10.1091/mbc.e02-08-0502. PubMed PMID: 14978213; PubMed Central PMCID: PMC404004.
82. Gietz RD, Schiestl RH. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. *Nat Protoc.* 2007;2(1):31-4. Epub 2007/04/03. doi: 10.1038/nprot.2007.13. PubMed PMID: 17401334.
83. Brenner S. The genetics of *Caenorhabditis elegans*. *Genetics.* 1974;77:71-94.
84. Berkowitz LA, Knight AL, Caldwell GA, Caldwell KA. Generation of stable transgenic *C. elegans* using microinjection. *J Vis Exp.* 2008;(18). Epub 2008/12/11. doi: 10.3791/833. PubMed PMID: 19066505; PubMed Central PMCID: PMC3253564.
85. Hamamichi S, Rivas RN, Knight AL, Cao S, Caldwell KA, Caldwell GA. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. *Proc Natl Acad Sci U S A.* 2008;105:728-33.

86. Knight AL, Yan X, Hamamichi S, Aijuri RR, Mazzuli JR, Zhang MW, et al. The glycolytic enzyme GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models. *Cell Metab.* 2014;20(1):145-57.
87. DeSantis ME, Sweeny EA, Snead D, Leung EH, Go MS, Gupta K, et al. Conserved distal loop residues in the Hsp104 and ClpB middle domain contact nucleotide-binding domain 2 and enable Hsp70-dependent protein disaggregation. *J Biol Chem.* 2014;289(2):848-67. doi: 10.1074/jbc.M113.520759. PubMed PMID: 24280225; PubMed Central PMCID: PMC3887210.

Figure 1. Diverse Hsp104 homologs suppress TDP-43 toxicity in yeast
(A) Phylogenetic tree constructed using EMBL-EBI Simple Phylogeny tool from a multiple sequence alignment of the indicated Hsp104 homologs generated in Clustal Omega (see also Supplemental Information for alignments) showing evolutionary relationships between Hsp104 homologs studied in this paper. *C. thermophila* is in green, TDP-43-specific homologs are colored in shades of blue,

α Syn-specific homologs are colored in red, and non-rescuing homologs are colored in shades of gray.

(B) $\Delta hsp104$ yeast transformed with plasmids encoding galactose-inducible TDP-43 and the indicated galactose-inducible Hsp104 (either wild-type Hsp104 from *Saccharomyces cerevisiae*, the potentiated variant A503S, or the Hsp104 homolog from *Calcarisporiella thermophila* (Ct)) were serially diluted 5-fold and spotted onto glucose (expression off) or galactose (expression on).

(C) $\Delta hsp104$ yeast transformed with plasmids encoding galactose-inducible TDP-43 and the indicated galactose-inducible Hsp104 (either wild-type Hsp104 from *Saccharomyces cerevisiae*, the potentiated variant A503S, or homologs from *Galdieria sulphuraria* (Gs), *Monosiga brevicollis* (Mb), *Chlamydomonas reinhardtii* (Cr), *Populus euphratica* (Pe), and *Salpingoeca rosetta* (Sr)) were serially diluted 5-fold and spotted onto glucose (expression off) or galactose (expression on).

(D) Western blots confirm consistent expression of FLAG-tagged Hsp104s and proteotoxic protein substrates in yeast, and that neither Hsp104 expression nor TDP-43 expression induces upregulation of the endogenous heat shock protein Hsp26. The first lane are isogenic yeast that have not been grown in galactose to induce Hsp104 and TDP-43 expression but instead have been pretreated at 37 °C for 30 min to upregulate endogenous heat shock proteins. 3-phosphoglycerate kinase (PGK) is used as a loading control. Molecular weight markers are indicated (right).

(E) Representative images of yeast co-expressing TDP-43-GFPS11 (and separately GFPS1-10 to promote GFP reassembly) and the indicated Hsp104 homologs. Cells were stained with DAPI to visualize nuclei (blue). Scale bar, 2.5 μ m.

(F) Quantification of cells where TDP-43 displays nuclear localization. Values represent means $\pm$ SEM (n=3 trials with >200 cells counted per trial). One-way ANOVA with Dunnett's multiple comparisons test was used to compare $\Delta hsp104$ to all other conditions. ****, p<0.0001.

(G) Quantification of cells with no, single, or multiple TDP-43 foci. Values represent means $\pm$ SEM (n=3). Two-way ANOVA with Tukey's multiple comparisons test was used to compare the proportion of cells with either no or multiple TDP-43 foci between strains expressing different Hsp104 homologs and a control strain expressing SchHsp104. *, p<0.05; **, p<0.01; ***, p<0.001.

Figure 2. Hsp104 homologs from thermophilic fungi suppress α Syn toxicity in yeast

(A) Δ hsp104 yeast transformed with plasmids encoding galactose-inducible α Syn and the indicated galactose-inducible Hsp104 (either wild-type Hsp104 from *Saccharomyces cerevisiae*, the potentiated variant A503S, or the Hsp104 homolog from *Calcarisporiella thermophila* (Ct)) were serially diluted 5-fold and spotted onto glucose (expression off) or galactose (expression on).

(B) Δ hsp104 yeast transformed with plasmids encoding galactose-inducible α Syn and the indicated galactose-inducible Hsp104 (either wild-type Hsp104 from

Saccharomyces cerevisiae, the potentiated variant A503S, or homologs from *Calcarisporiella thermophila* (Ct), *Thielavia terrestris* (Tt), and *Thermomyces lanuginosus* (Tl)) were serially diluted 5-fold and spotted onto glucose (expression off) or galactose (expression on).

(C) Western blots confirm consistent expression of FLAG-tagged Hsp104s and proteotoxic protein substrates in yeast, and that neither Hsp104 expression nor α Syn expression induces upregulation of the endogenous heat shock protein Hsp26. The first lane are isogenic yeast that have not been grown in galactose to induce Hsp104 and α Syn expression but instead have been pretreated at 37 °C for 30 min to upregulate heat shock proteins. 3-phosphoglycerate kinase (PGK) is used as a loading control. Molecular weight markers are indicated (right).

(D-E) Fluorescence microscopy of cells coexpressing GFP-tagged α Syn and vector, ScHsp104^{WT}, ScHsp104^{A503S}, CtHsp104, TtHsp104, or TlHsp104. Scale bar, 2.5 μ m. α Syn localization was quantified as the number of cells with fluorescence at the membrane or cytoplasmic inclusions. Values are means $\pm$ SEM (n=3 trials with >200 cells counted per trial). One-way ANOVA with Dunnett's multiple comparisons test was used to compare $\Delta hsp104$ to all other conditions. ***, p<0.001; ****, p<0.0001.

Figure 3. Hsp104 homologs reduce TDP-43 aggregation in HEK293T cells.

(A) HEK293T cells were cotransfected with doxycycline-inducible constructs encoding mClover3-TDP-43 Δ NLS. Protein expression was induced with 1 μ g/ml doxycycline 6h post-transfection. At varying times, cells were sorted by FACS into populations lacking TDP-43 foci (P7) or cells with TDP-43 foci (P4). Representative fluorescent microscopy of sorted cells is shown at right. Scale bar, 500 μ m.

(B) At 24h post-transfection, cells were processed for Western blot to confirm Hsp104 expression and mClover3-TDP-43 Δ NLS expression.

(C) At 24h post-transfection, cells were analyzed by flow cytometry to quantify cells bearing TDP-43 aggregates (C, *left*). Cells were also analyzed by flow cytometry 48h post-transfection (C, *right*). Values are means $\pm$ SEM (n=3 independent transfections with 10,000 cells counted per trial). One-way ANOVA with Tukey's multiple comparisons test was used to compare no Hsp104 (top set of asterisks) and DPLA:DWB (bottom set of asterisks) to all other conditions, and to each other. ***, p<0.001; ****, p<0.0001.

Figure 4. Hsp104 homologs protect against α Syn toxicity and dopaminergic neurodegeneration in *C. elegans*.

(A) qRT-PCR for the expression of α Syn and various Hsp104 homologs in transgenic *C. elegans*. α Syn expression was normalized to transgenic worms overexpressing α Syn alone. Hsp104 expression was normalized to transgenic worms overexpressing both α Syn and CtHsp104. Values represent means $\pm$ SEM (N=100 worms per transgenic line, 3 independent transgenic lines examined for each genotype). The expression of either α Syn or Hsp104 homologs among all genotypes was not significantly different (one-way ANOVA, $p>0.05$).

(B) α Syn and the indicated Hsp104 homolog were coexpressed in the dopaminergic (DA) neurons of *C. elegans*. Hermaphrodite nematodes have six anterior DA neurons, which were scored at day 7 posthatching. Worms are considered WT if they have all six anterior DA neurons intact (see methods for more details). TtHsp104 and TlHsp104 significantly protect over α Syn alone, while CtHsp104 had no protective effect. Values represent means $\pm$ SEM (n=30 worms per genotype per replicate, 3 independent replicates). One-way ANOVA with Dunnett's multiple comparisons test was used to compare α Syn alone to all other conditions. *, $p<0.05$.

(C) Photomicrographs of the anterior region of *C. elegans* coexpressing GFP with α Syn. Worms expressing α Syn alone (top left) exhibit an age-dependent loss of DA neurons. Worms expressing α Syn plus either Ct (bottom left) Tt (top right) or Tl (bottom right) exhibit greater neuronal integrity. Arrows indicate degenerating or missing neurons. Arrowheads indicate normal neurons. Scale bar, 10 μ m.

Figure 5. Hsp104 homologs function in induced thermotolerance and are ATPase-driven disaggregases, but differences in disaggregase activity do not explain suppression of TDP-43 or αSyn toxicity

(A) WT or $\Delta hsp104$ yeast carrying a plasmid encoding the indicated Hsp104 homolog under the control of the native *HSP104* promoter were pre-treated at 37 °C for 30 min, treated at 50 °C for 0-60 min, and plated. Surviving colonies were quantified after 2d recovery. Values represent means $\pm$ SEM (n=3 independent transformations).

(B) Hsp104s ranked by thermotolerance performance after a 20 min heat shock at 50°C.

(C) Expression of Hsp104 homologs from the *HSP104* promoter was confirmed by Western blotting. Molecular weight markers are indicated (right).

(D) Survival after 20 min heat shock does not track with the evolutionary separation between a given species and *S. cerevisiae*.

(E) Thermotolerance activity of Hsp104 homologs that suppress TDP-43 or α Syn does not noticeably differ from Hsp104 homologs that do not suppress TDP-43 or α Syn toxicity.

(F) ATPase activity of the indicated Hsp104 homologs. Values represent means $\pm$ SEM (n=3).

(G) Luciferase aggregates (50 nM) were incubated with the indicated Hsp104 (0.167 μ M hexamer) with or without 0.167 μ M Ssa1, 0.073 μ M Ydj1, and 0.073 μ M Sis1 for 90 min at 25°C. Values represent means $\pm$ SEM (n=3).

(H) Luciferase aggregates were treated as in (B) but Ssa1, Ydj1, and Sis1 were replaced with Hsc70, Hdj1, and Hdj2. Values represent means $\pm$ SEM (n=3).

(I) TDP-43 (3 μ M) was incubated in the presence of the indicated Hsp104 (6 μ M) and 5 mM ATP, and turbidity was measured at 3h relative to TDP-43 aggregation reactions containing no Hsp104. Values represent means $\pm$ SEM (n=3).

(J) As in (I), except ATP was omitted and turbidity was measured at 2h.

Figure 6. Genetic variation within Hsp104 homologs enables their disaggregase-independent suppression of TDP-43 or α Syn toxicity.

(A) WebLogo sequence logos demonstrating high conservation of Walker A, tyrosine-bearing pore loops, and Walker B motifs in both NBD1 and NBD2 across all Hsp104 homologs.

(B) Spotting assay demonstrating that suppression of TDP-43 (*left*) and α Syn (*right*) toxicity by ScHsp104^{A503S} (A503S) is inhibited by mutations in Walker A (DWA), pore loop (DPLA), and Walker B (DWB) motifs.

(C-G) Spotting assays demonstrate that suppression of TDP-43 toxicity by GsHsp104 (C), MbHsp104, (D), CrHsp104 (E), PeHsp104 (F), and SrHsp104 (G) is resistant to multiple mutations that impair ATP-driven disaggregase activity.

(H-J) Spotting assays demonstrate that suppression of α Syn toxicity by CtHsp104 (H), TtHsp104 (I), and TlHsp104 (J) is resistant to multiple mutations that impair ATP-driven disaggregase activity.

Figure 7. Interactions between the NTD, NBD1, and MD support proteotoxicity suppression by Hsp104 homologs.

- (A) Color codes and domain boundaries and labels of Hsp104 homologs.
- (B) Spotting assay of $\Delta hsp104$ yeast coexpressing TDP-43 and the indicated chimeric Hsp104s between ScHsp104 and MbHsp104 illustrates that chimeras possessing the NTD, NBD1, and MD from MbHsp104 copy the TDP-43 toxicity suppression phenotype of MbHsp104.
- (C) Spotting assay of $\Delta hsp104$ yeast coexpressing TDP-43 and the indicated chimeric Hsp104 between ScHsp104 and CrHsp104 illustrates that chimeras possessing the NTD, NBD1, and MD from CrHsp104 copy the TDP-43 toxicity suppression phenotype of CrHsp104.
- (D) Spotting assay of $\Delta hsp104$ strains coexpressing α Syn and the indicated chimeric Hsp104 between ScHsp104 and TtHsp104 illustrates that no chimeras between ScHsp104 and TtHsp104 replicate the α Syn toxicity-suppressing phenotype of TtHsp104.
- (E) Spotting assay of $\Delta hsp104$ yeast coexpressing TDP-43 and the indicated chimeric Hsp104 between ScHsp104 and GsHsp104 illustrates that chimeras possessing the NTD, NBD1, and MD from GsHsp104 copy the TDP-43 toxicity suppression phenotype of GsHsp104.
- (F) Spotting assay of $\Delta hsp104$ yeast coexpressing TDP-43 and the indicated chimeric Hsp104 between ScHsp104 and PeHsp104 illustrates that chimeras possessing the NTD, NBD1, and MD from PeHsp104 copy the TDP-43 toxicity suppression phenotype of PeHsp104.
- (G) Spotting assay of $\Delta hsp104$ yeast coexpressing TDP-43 and the indicated chimeric Hsp104 between ScHsp104 and SrHsp104 illustrates that chimeras possessing the NTD, NBD1, and MD from SrHsp104 copy the TDP-43 toxicity suppression phenotype of SrHsp104.
- (H) Spotting assay of $\Delta hsp104$ strains coexpressing the indicated chimeric Hsp104 and α Syn illustrates that chimeras possessing the NTD and NBD1 from CtHsp104 copies the α Syn toxicity-suppressing phenotype of CtHsp104^{WT}.
- (I) Spotting assay of $\Delta hsp104$ strains coexpressing α Syn and the indicated chimeric Hsp104 between ScHsp104 and TIHsp104 illustrates that no chimeras between ScHsp104 and TIHsp104 replicate the α Syn toxicity-suppressing phenotype of TIHsp104.
- (J-K) Spotting assays of $\Delta hsp104$ strains coexpressing the indicated chimeric Hsp104 and α Syn illustrates that NBD2 from TtHsp104 (J) or TIHsp104 (K) is not sufficient to copy the α Syn toxicity-suppression phenotype of TtHsp104 or TIHsp104.
- (L) Spotting assay of $\Delta hsp104$ strains coexpressing TDP-43 and either full-length PeHsp104 or SrHsp104, or monomeric fragments derived from these homologs demonstrates that Hsp104-mediated toxicity suppression is an emergent property of hexameric Hsp104.

Supplemental Information

Therapeutic genetic variation revealed in diverse Hsp104 homologs

Zachary M. March, Katelyn Sweeney, Hanna Kim, Xiaohui Yan, Laura M. Castellano, Meredith E. Jackrel, Edward Chuang, Edward Gomes, Karolina Michalska, Robert Jedrzejczak, Andrzej Joachimiak, Kim A. Caldwell, Guy A. Caldwell, Ophir Shalem, and James Shorter

Table S1. Amino acid sequences of Hsp104 homologs.

Species	
<i>Galdieria sulphuraria</i>	MNLDNLTDKAQEAIQASHELALENGHSQTLPLHLAAALFTED HGLASSVATKAKADPVNVRRELQKAVIRLPSQDPPPTTVPPS QSFLKVIRDAQSLRKKQGDTHLAVDHLLIALCDDKDVIACFSS ADLTKHALEEAVKSVRGNRKVDSKAADSTYDALNQYAQDFV ALAEEGKLDPVIGRDDEIRRVIRVLCRRRKNNPVLIGDPGVGK TAIVEGLAQRIVRGDVPENLNCRLYALDMGALVAGAKYRGEF EERLKAVLREVKEGEGKIILFIDELHLVLGAGKSDGAMDAANL LKPMLARGELRCIGATTLEEYRKYVEKDAAFERRFQQVFVSE PSVPDTSILRGLKERYEVHHGVRILDSALVAAAKLSARYITN RFLPDKAIDLVDACANVRMQLDSQPEVIDTLEHRKLQLEIEI AALEKEKDEASRARLAAVKEELDNVNEKLRLPKARFESER GK MNELKDMMTKLDALKIKLADAERRRDTVQAADLRYAIP EIEE RIRSLKNEIDKEKETDAMETDEESGKLLSDVVGYEQIADVVS RWTGIPTTKLSQSDAERLLSLSASLHQRIIGQDEAVDAVAAV LRSRAGVSRPTQPLGSFLFLGPTGVGKTELAKALAAELFDDE KHVVRIDCSEYMEQHSVSRLIGAPPGYVG YEEGGQLTEAVL RRPYNVVLFDVEVEKAHRNVMNVLLQVLDDGRLTDNQGR TID FTNTVIILTSNLGAQFLMNIGSKGPAELSEGSDHEGTPVVSIP KEATIDNRTREAVMREVKLHFRPEFLNRLDDIVIFKPLALDEL RQIVRLQLDQVAKRLEERDITVSMNRAADYILREAYDPSFG ARPIRRYLEKHVATELSIRLIKGLLTNHSHVQVTRATEGSGLA FQVTPKKRSATDMGNGSVYNKQGIVEEPDEEDM
<i>Monosiga brevicollis</i>	MAINPNEFTDKVNKTLFEAQNFAIQEGHSQVEPAHVAVILFED PEGMAKR VVQRAGAALQP VQAALRSLLQRM PRQEPAPLEA SLSSDTRRLQSAAKLQKKNNEAHLAVDHLLGALVQDKQILA KLAESGLAKNHFEETLKR VKGTTTADSKSAEENYDALSKYGV DLVQQAADGKLDPV LGRDEEIRRVIQILARRIKSNPCLVGPPG VGKSAIVEGLAQRIMLGDVPETLKGKLISLDMGALIAGAKYRG EFEERLKAVLEEIKQSEGR IILFVDEVHNVLGAGKTEGSMDAA NLLKPLLARGELRMIGATTEDEYRKYVEKDSAFERRFQVVQV REPSVPDTSILRGLKERYEAHHGVRIADAALVAAAQLSHRYI QGRFLPDKAIDLIDEACANARVQLDSRPEEIDQLERRRLQLQ VEATALEKEKDQASKLRLKDVRKELANIEEQLQPLL MKFEME RGRVDEL RDLQEKLDSLRSKAQRAERQGD LATAADLKYYAI PDCERRIQQLTLEDEERSAQRSGMDEQEDAPMLSEEVGPE QITDIIARWTGIPVTKLNQSQRERLLALAERI KSRVIGQDHA VD AVAEAVLRSRAGLSRPSQPTGSFLFLGTTGVGKTELAKALAA ELFDDDKHIVRIDMSEYME SHA VSR LIGSPPGYVG YEQGGQL TEAVRRRPYNVVLFDVEVEKAHPQVLNVLLQVLDDGVLT DGQ GRHVDFTNTVIVLTSNIGAHDLLNADV VNGAIDPETEAKVRR QVQQHFRPEFLNRLDEVVMFKPLGQRDLR KICRNMVDLINQ RLVDRDIALLVSDDACDLVLDEAYNPAYGARPVRRYVEKHM VTEISRLVLSGELVNHSTVHIDTTKRPDGGRDLSYQVHHSKR PKISED SA
<i>Chlamydomonas reinhardtii</i>	MSFDTKKATEKVNNVLGEAINLAKEDKHAALTPTHLAVVLFE EPHGLAKVAATKVAGEEVWRS AIRVL RKRLTKLPKVD PAPES VSPGRELSKVL TAAAKLQKDRGDAFLGTD TLLTAVINAAEVS EALGEAGISKAQLETALSEVRQAAGGGPINSETADANFDALA

	KYGTDLTANAARADPVIGRDDEIRRVVRVLCRRRTKNNPVLIG EPGVGKTAIVEGLAQRIVKNDVPETLQGVRLISLDMGSLVAG AKYRGEFEERLKAVLNEVAQQQGVVLFIDELHLVLGAGKSG DGAMDAANLLKPMLARGELRCIGATTLEGEYREHIEKDAAFER RFQQVLVKEPSVPDTIAILRGIKDRYETHHGVHITDRALVAA ELSDRYITTRFLPDKAIDLVEACANMRVQLDSKPEQLDALE RQRQRLQVEAAALAKEKDALS KARAKEV GKELAALEEALRPL QMKYAEKARLEELRRLGQKRDEILVNIQIAEQHGNLARIADL RYGALPDVEDRIKQVRAAAPSDAMLSEEVGTEEIAVVVSRW TGIPVNRLLKQTERDKLLSLRSELQQRVVGQDAVAVAADAVL RSRAGLAARGRGSSFLFLGPTGVGKTELAKALQLLFDDEK MMIRIDMGEYMEKHSVSRLIGAPPGYVGHEQGGQLTEAVRR RPYSVVLFDVEVEKAHAEEVFNVLISILDDGRVTD SKGRTVNFA NTVILTSNLGAEALLHAAHDVLAHPGKAAAGQDPYKAARES VLAARRRFFRPEFLNRLDDIVVFEPLRPEQLVDIARLMGNELA ARLTNRNITLTFTPEALQFAVSHAYDPAYGARPLRRWMEQK VVTQLSRMVVGGDLPDNSNVEVGLAEGGRDFDYRVWPKPA AEAGGGNGSGAATEALLKKARMYSVEHPDEGEDSMDEGDD VGAMRD
<i>Populus euphratica</i>	MDPGKFTHTKNEALATAHELTVGAGHAQITPLHLAVALISDPS GIMRQAVANAGDGENTAQA AERVFNQVLKKLPSQSPPPDEV PPSTSLIKVIRRSQALQKSRGDSYLAVDQMILGLLEDSQIRDL FKEVGVSASTVKSEVEKLRGKEGKKVENASGDTNFQALKTY GRDLVEGAGKLDPVIGRDEEIRRVVRILSRRTKNNPVLIGEPG VGKTAVAEGLAQRIVRGDVPSNLADVRLIALDMGALVAGAKY RGEFEERLKAVLKEVEEAEGKVILFIDEIHLVLGAGRTEGSMD AANLFKPMLARGQLRCIGATTLEEYRKYVEKDAAFERRFQQ VYVAEPSVPDTISILRGLKEKEYEGHHGVRIQDRALVIAAQLSS RYITGRHLPDKAIDLVEACANVRVQLDSQPEEIDSLERKRM QLEVELHALEKEKDKASKARLAEVVKELDDLRLDKLQPLLKMY KKEKERIDEIRRLKQKREEILFSIQEAERRYDLARVADLRYGA LEEVEAAIARLEGSTTDENLMLTETVGPEHIAEVVSRWTGIPF TRLGQNEKERLIGLADRLHHRVVGQDQAVTAVAEAVLRSRA GLGRPQQPTGSFLFLGPTGVGKTELAKALAEQLFDDENLV RIDMSEYMEQHSVARLIGAPPGYVGHEEGGQLTEAVRRRPY SVVLFDVEVEKAHISVFNTLLQVLDGRLTDGQGRTVDFRNTV IIMTSNLGAEHLLSGLLGKCSMQVARDRVMEVRKQFRPELL NRLDEIVVFDPLSHDQLRKVARLQMKDVASRLAERGIALAVT DAALDYILAESYDPVYGARPIRRWLERKVVTLSRMLVREEID ENSTVYIDAGPDGQNLVYRVEKNGGLVNAATGQKTDVLIQIP KAPRDDAAQKVKKMKIQEIVDNDDEEMIE
<i>Salpingoeca rosetta</i>	MALNPNEWTEKVQEMYLEAKNVAINNKNAYMDPIHFAVALF EDEGGLPQRVVQKSGASLDAVEGAMRSLLKAIPQQDPAPVD VSTSHKALRFLQNAQKKQKKNDEAHLAIDHLLLALVQEKDILQ ALAGCGLAKDRFEEIVKKIKGTTTRANTKTAESTYDALGKYGV DLVQRAADGKLDPVIGRDEEIRRVIIQILARRTKNNPVLVGP TGKTAIVEGLAQRILNGDVPETLKARLVSLDMGALIAGAKYRG EFEERLKSVLDEVKQAEGSIILFVDEIHTVLGAGKTEGSMDAA NLLKPMLARGELRMIGATTLEDEYRKHVEKDAAFERRFQMVH VSEPSVPDTVSILRGLKERYEAHHGVRIQDAALVTAAQLADR YITQRFLPDKAIDLVEACAKTRVQLDSRP EEIDALERRKLQL

	EVEATALGKEKDKMSKQRLKEVKKQLADIEEQGLGPLKMKFE MERGRVDEMRELQEKLNLNRNKVQRAERAGDLSTAADLKY YAIPDCEKRLKQLIEEQEKRQQEQQSMVSDDEKPMLEEV GPDQVTEIVARWTGIPVNLKSQSQRERLLTLEEKIEQRVVGQ TAAVKAVCEAVLRSRAGLSRPNQPVGSFLFLGPTGVGKTEL AKALAMELFDDDKHIVRVDMSEYMESHVARLIGSPPGYVG YEEGGQLTEAVRRRPYNLILLDEVEKAHKDVLNVLLQLLDDGI LTDGMGRTVDFNTNTVVLTSTNIGAPILLSGKVDPETGDLNEN TRTQVMHEVQSYFRPEFLNRLDDVIMFKPLQKHALRTICRNM VEQINERLADRDLTLDCTDAACDVILLNSFHPQYGARPVRRYI EKQVVTAMSKMLSNQVPNGSRVTIDGDKQRQELTYSVQAA KRPRMMMDSTSEE
<i>Thielavia terrestris</i>	MEFTDRAKKALEDAMALAEQYSHSQLVPVHLAVALLDP LPDQSKDQQNAPPGTTSSLFRQVVERANGDPQLFDRA LKKSLVRLPSQEPPPEVSMAPSLNTVLRKAMELQKVQ KDTYIAVDHLITALSEDPSIQVALKEANIPKSKLVQDAVT AIRGTRRVDSRNADTEQENENLSKFTIDMTAMAREGKI DPVIGREEEIRRVIRILSRRTKNNPVLIGEPGVGKTTIVEG LAQRIVNADVDPNLAACKLLSLDV GALVAGSKYRGEFE ERMKGVLKEIQESKETIVLFVDEIHLLMGAGATGEGGM DAANLLKPMLARGQLHCIGATTGLEYRKYIEKDAAFERR FQQVLVKEPSIPETISILRGLKEKYEVHHGVTIADAAIVAA ANLAARYLTSRRLPDSAVDLIDEAAA AVRVA RESQPEIID SLERRLRQLKIEIHLSREKDDASKARLAQAKQDAQNVE EELRPLREKYERERQRGKDIQEAKLKLENLRVKAEDAS RMGDHGRAADLQYYAIP EQEQVIKRLEKEKAAADAALN ANGADVGGSMVTDVVGPEQINEIVARWTGIPVTRLKTS EKEKLLHMERALS KIVVGQKEAVQSVSNAILRQRGLS NPNQPPSFLFCGPGSGTGKTLTKALAEFLFDDAKAMIRF DMSEYQERHSLSRMIGAPPGYVGH DAGGQLTEALRRK PFSILLFDEVEKAAKEVLT VLLQLMDDGRITDGQGRVVD AKNCIVVMTSNLGAEYLSRPNGKDGQIDPTTKELVMNT LRNYFLPEFLNRISIVIFNRLTRREIRKIVDLRIAEIQRRL YDNDNRNVQIAVSEAAKDKLGAAGYSPAYGARPLQRLLE KEVLNRLAILILRGNIRDGEVAHVLDLVDGKVTVPNHPD SEGEDEEMMVDEDEALEEIPDSMDEDDIYSG
<i>Thermomyces lanuginosus</i>	MSSAQFTDRANKALLDSNQLAEQYSHTQILPVHLAVSLL NPPRDDERE GAEGASVPLFKQVVERAHGDPQLLERSL MKMLVRQPSQDPPPEHVSVSPALAKVIRSATELSKMQK DSFVAIDHLICALAQDSQIQRALADANIPNVKLIDNAVQQI RGTKRVDSKTADSEEDHENLKRFTVDMTALAREGKIDP VIGREEEIRRVIRILTRRTKNNPVLIGEPGVGKTTIVEGLA RRIVNADV PANLAHCKLLSLDV GSVL VAGSKYRGEFEER MKGVLKEIEESRDMVVL FVDEIHLLMGAGTSGEGGMDA ANLLKPMLARGQLHCIGATT LAEYRKYIEKDQAFERRFQ QVFVKEPSVSETISILRGLKEKYEVHHGVNILDAAIVASA ELAARYLTARRLPDSAVDLIDEAAA AVRVTRESEPEALD

	NLERRLRQLQIEIHALEREKDPASKSRLEAAKQEAANVT EELRPLREKYEQEKQRSKAIQDAKVKLDALKVKRDEAL RSGDTATAADLEYAIPETQSLIQKLEAERAKADAEERA RAHENGTTETLVPDAVGPDQINEIVARWTGIPVTRLKTSE KDRLLQMEKHLGKIVVGQKEAVQTVSNAIRLQSRGLAN PNAPPSFLFCGPGSGTGKTLTKALAEFLFDDPKAMVRF DMSEYQERHSLSRMIGAPPGYVGHDAAGGQLTEHLRRR PFSILLFDEVEKAAKEVLTVLLQLMDDGRITDGQGRVVD AKNCIVVMTSNLGAEYLSRPTGKNGRIEPQTRELMGA LRDYFLPEFLNRISIVIFNRLTKREIRQIVELRLDEVQRR LEANGRDVKIECADEVKDYLGAEAGYSPAYGARPLSRLE KEVLNKLAILLLRGNIRDGEVAHCVLKDGRVDVIPNHPS DEMEDDEDMIDPNEALEQVEDTSADMDLYE
<i>Saccharomyces cerevisiae</i>	MNDQTQFTERALTILTAQKLASDHQHPQLQPIHILAAFI ETPEDGSVPYQLNLIKGRYDYDLFKKVNRNLVRIPQ QQPAPAEITPSYALGKVLQDAKIQKQQKDSFIAQDHIL FALFNDSSIQQIFKEAQVDIEAIKQQAELRGNTRIDSRG ADTNTPLEYLSKYAIDMTEQARQGKLDPVIGREEEIRSTI RVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPTILQ GAKLFSLDLAALTAGAKYKGDFEERFKGVLKEIEESKTLI VLFIDEIHMLMGNGKDDAANILKPALSARGQLKVIGATTN NEYRSIVEKDGAFFERRFQKIEVAEPSVRQTVAILRGLQP KYEIHHGVRILDSALVTAAQLAKRYLPYRRLPDSALDLV DISCAGVAVARDSKPEELDSKERQLQLIQVEIKALERDE DADSTTKDRLKLARQKEASLQEELEPLRQRYNEEKHGH EELTQAKKKLDELENKALDAERRYDTATAADLRYFAIPD IKKQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAA RLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIAV SNAVRLSRGLANPRQPASFLFLGLSGSGKTELAKKVA GFLFNDEDMMIRVDCSELSEKYAVSKLLGTTAGYVGYD EGGFLTQNLQYKPYSVLLFDEVEKAHPDVLTVMLQMLD DGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKIQE STKNLVMGAVRQHFREPEFLNRISIVIFNKLRSKAIHKIV DIRLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDM GARPLNRLIQNEILNKLALRILKNEIKDKETVNVVLKKGK SRDENVPPEEAEECLEVLPNHEATIGADTLGDDDNEDSM EIDDDLD
<i>Dictyostelium discoideum</i>	MSFNPEEFTDKTNTILLRTQELAREKSNVQLAPIHLAVTL LNDEDNLAKSIFEKAGGDVPKIDAGFKRLLAKQPQNPV PPEISPNSLFLQVLRSAARHQKNNGDShLAVDHLILGLL DDRDLVSLGDAGATKEQVIQAVKEIRGNKKITSKTAEST YEALSKYGYDLVSQAQEGKLDPVIGRDEEIRRVRVLSR RTKNNPVLIGEPGVGKTAVVEGLAQRIVRGDIPDNLNAR VIALDMGALIAGAKYRGDFEERLKAVLKEVKDSNGGIILF IDEIHLVLGAGKTDGAMDAANLLKPMLARGELRCIGATT LDEYRQYVEKDPAFERRFQQVFVNEPTVNDTISILRGLK

	<p>ERYETHHGVRLTDNALVVAQQLSHRYITNRFLPDKAIDL VDEACANTRVQLNSQPEAIDNLERRRLQLEVESAALEK EEDDASKQRLKAVQEELNQIKDELQPLEAKYQKERSRV DKIRELRKKLEDIKVKLSDAERRYDTSAADYRYFVIPDL EKQIEVCDKERKENKKDAMVSEVVTPEQIADVVSRTWG IPVSKLSQTEKQRLLSLADHLHNRVVGQDEAVDAVADA VLRSKSGLARENQPLGSFLFLGPTGVGKTELAKALALEL FDDESHMVRIDMSEYMEQHSVSRIGAPPGYVGYDQG GQLTEAVRRRPYSVVLDFEVEKAHQVWNVLLQVLDE GRLTDGQGRTVDFSNVVIIMTSNLGSQYILGEQANKEG GNNSLSQACKDKVIDEVRKHFRPEFLNRLDDIIVFTPLS KENLHSITLQLRSVEKRLEDQNMSLKISNDALDSIINAAAY DPIFGGRPLKRYIEKNIVTELSKLILGGKLKENQGVVNE KDHLNFDIIDLKQQQQRPAASPTKKQKTIK</p>
ClpG _{GI} , from <i>Pseudomonas aeruginosa</i>	<p>MAQELCAICHERPAVARVSLVQNGQRRELALCELHYR QLMRQQRMRSPLSLFGGGSPFDEIFSGFGEQSPVTP VRAREPEAVDIAEYFSKQTTEYLQRAAQVAAEFQKREV DTEHLLYALADADVQAVLKQFGLSPADLKQYIEANAVR GASKGEASEDMTISPRVKSALQHAFALSRELGHSYVGP EHLGLAAVPDSFAGTLLKKYGLTEQALRQKAVKVVG KGAEDGRVDGPSNTPQLDKFSRDLTRLAREGKLDPVIG RSKEVETTIEVLARRKKNPVLIGEPGVGKTAIVEGLAQ RMVQGEVPEVLRDKRLVELNINAMVAGAKYRGEFEERL KQVMDELQAAQSEILFIDEVHTIVGAGQGGGEGGLDVA NVLKPAMARGEMNLIGATTLENYQKYIEKDAALERRFQ PVFVPEPTVEQTISILRGLRDKLEGHHKVTIRDEAFVAAA ELSDRYIGNRFLPDKAIDLIDQAAARVRIASTSRPAEIQE LEAELAQLKREQDYAASRKWYDEAKVFQKRIQERKEHL EQITERWQQQTQGSKTEEVVRVEDIAEISRLTGIPVTELT EEREKLLQMEERLHQRVIGQQEAITAVSDAVRLARAGL RQGSRIATFLFLGPTGVGKTELAKALAEVFGDEDAMI RIDMSEYMERHAVSRIGAPPGYVGYDEGGQLTERVR RRPYSVILLDEIEKAHADVNILLQVFDDGRLTDGKGRV VDFTNTIIATSNLGSELIMKNAQAGEFAQPPEKLKRELM TTLRGHFRPEFLNRLDEVIVFESLSKAQIEDIVRLQLERV KRAAHAQDIYLIHDDSLVGHLEAEAYQPEFGARELKRQI RQQLETRLATAMLKGEVKEGETVTFFYDAKDGVGYRK GAAPKPAARKKSGAGETPKGRATAARKPAKKGAAK GKADKPKAK</p>
ClpB, from <i>Escherichia coli</i>	<p>MRLDRLTNKFQLALADAQSLALGHDNQFIEPLHLMSALL NQEGGSVSPLLTSAGINAGQLRTDINQALNRLPQVEGT GGDVQPSQDLVRVLNLCDKLAQKRGDNFISSELFVLA LESRGTLADILKAAGATTANITQAIEQMRGGESVNDQGA EDQRQALKKYTIDLTERAEQGLDPVIGRDEEIRRTIQVL QRRTKNNPVLIGEPGVGKTAIVEGLAQRIINGEVPEGLK GRRVLALDMGALVAGAKYRGEFEERLKGVLNDLAKQE</p>

	<p>GNVILFIDELHTMVGAGKADGAMDAGNMLKPALARGE HCVGATTLDEYRQYIEKDAALERRFQKVFAEPSVEDTI AILRGLKERYELHHHVQITDPAIVAAATLSHRYIADRQLP DKAIDLIDEAASSIRMQIDSKPEELDRLDRRIQLKLEQQA LMKESDEASKRDLMLNEELSDKERQYSELEEEWKA KASLSGTQTIKAELEQAKIAIEQARRVGD LARMSELQYG KIPELEKQLEAATQLEGKTMRLLRNKVTD AEIAEVLARW TGIPVSRMMESEREKLLRMEQELHHRVIGQNEAVDAVS NAIRRSRAGLADPNRPIGSFLFLGPTGVGKTELCKALAN FMFDSDEAMVRIDMSEFMEKHSVSRLVGAPPGYVGYE EGGYLTEAVRRRPYSVILLDEVEKAHPDVFNILLQVLDD GRLTDGQGRTVDFRNTVVIMTSNLGSDLIQERFGELDY AHMKELVLGVVSHNFRPEFINRIDEVVVFHPLGEQHIASI AQIQLKRLYKRLEERGYEIHISDEALKLLSENGYDPVYG ARPLKRAIQQQIENPLAQQILSGELVPGKVIRLEV NEDRI VAVQ</p>
<i>Chaetomium thermophilum</i>	<p>MNSKMEFTDRAKKALEDAMALAEQYQHLQLQPVHLAV ALLDPTDPDSKDQSIAPGTTSTLFRQVVERAHGDAQAF DRALKKKLVRLPSQDPPPDQVSM SAGCSNVL RKANEL QKVQKDSYIAVDHLIAALAE DHAIQEALKEANIPKPKLIQ DAIQAIRGNKRVD SRNADTEQENENLSKFCIDMTAMAR EGKIDPVI GREEEIRR VIRILSRRTKNNPVLIGEPGVGKTT IVEGLAQ RIVNADV PDNLAACKLLSLDV GALVAGSKYRG EFEERMKGVLKEIQESKETIILFVDEI HLLMGAGSSGEG GMDAANLLKPMLARGQLHCIGATT LAEYRKYIEKDAAFE RRFQQVLVKEPSISETISILRGLKEKYEVHHGVNIADAAI VAAANLAARYLTSRRLPDSAVDLIDEAAA AVRVAESQ PEIIDSLERRLRQLKIEIHALSREKDEASKARLAQAKQDA QNVEEELRPLREKYERERQRGKAIQEAKMKLEALRVKA EDASRMGDHSRAADLQYYAIP EQEAIKRLEAEKAAADA ALNANGADVGGSMITDVVGPDQINEIVARWTGIPVTRLK TSEKEKLLHMEQALS KIVVGQKEAVQSVSNAIRLQRSGL SNPNQPPSFLFCGPSGTGKTLTKALAEFLDDPKSMIR FDMSEYQERHSLSRMIGAPPGYVGH DAGGQLTEALRR RPF SILLFDEVEKAAKEVLT VLLQLMDDGRITDGQGRVV DAKNCIVVM TSNLGAEYLSRANNGKDGKIDPTTRELVM NTRLRNYFLPEFLNRIS SVIFNRLTRREIRKIVDLRIAEIQK RLTDNDRNVIKVSEEAKDKLGAQGYSPVYGARPLQ RLL EKEVLNRLAILIRGQIREGEVAHV ELVDGKVQVLPNHP DSEPEDVDVMDSDDAVDEVAPDSMDEDIYND</p>
<i>Lachancea thermotolerans</i>	<p>MNDETQFTERALTILTAQKLAQDHQHAQLQPVHILGAF VETPEDGSIPYLQNLIEKARYDYDTFRRTVNKHVVRI PQ QNPAPAQVTPSYATGQVLQEAMKIQKQKDSFVAQDHI LFALFKDSTIQQIFKEAQVDVEAVKQQALELRGNQKIDS RGADTSSSLEYLSKYAIDMTEQARMGKLDPVIGREEEIR STIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPS</p>

	ILFGSKLFSLDLAALTAGAKYKGDYEERLKGVLKEVEES KTLIILFIDEIHMLMGNGKDDAANILKPALSRGHLKVIGAT TNNEYRSIVEKDGAFFERRFQKIDVQEPTTRQTVAILRGL QQKYEIHHGVRILDSALVTASQLAKRYLPYRRLPDSALD LVDISCAGVAVARDSKPEELDSKERALQLLQVEIKALER DEEADPTTKERLQQARQREASLQEELEPLRQRYNEER KGHEELTKAKKKLEELNKAADAERRYDTATAADLRYF AIPDLKNQIEVLENQVLEEEESRAGSGAMVQNVVDSDTIA ETAARLTGIPVNKLTESENEKLIHMERELSSEVVGQSEAI KAVSNAVRLSRGLSNPRQPASFLFLGLSGSGKTELAK RIAAFLFNDSDAMIRVDCSELSEKYSVSKLLGTTAGYVG YEEGGFLTNNQLQRRPYSVLLFDEVEKAHPDVLTVMLQM LDDGRLTSGQGKTIDCSNCIIIMTSNLGATFISSQSGSRI EESTKNLVMGAVKQHFPEFLNRISIVVFNLSPKAIH RIVDIRLKEIEDRFEENDKHYKLDLTPEAKNYLARNYS EDMGARPLNRLIQNEILNRMAMRILKGQIKDKETVRVVL KHENPDMEEPDQLDVLPHQSSDADMDVDNDWDED LDDSVTDATPLD
<i>Myceliophthora thermophila</i>	MNSKMEFTDRAKKALEDAMALAEQYAHSQLLPVHLAV ALLDPLPDPSRDQQNAAPGTTSTLFRQVIERAHGDPQQ FDRALKKTLVRLPSQDPPPDQVSMAPSFNTVLRKAMEL QKVQKDTYIAVDHLITALAEDHTIQTALKEANIPKPKLIQD AISAIRGTRVDSRNADAEENENLAKFTVDMTAMARE GKLDPVIGREEEIRRVIRILSRRTKNNPVLIGEPGVGKTT VVEGLAQRIVNADVDPDNLAACKLLSLDVGALVAGSKYR GEFEERMKSVLKEIEESKDMIVLFVDEIHLMLMGAGSSGE GGMDAANLLKPMLARGQLHCIGATTAEYRKYIEKDAA FERRFQQVIVKEPSIPETISILRGLKEKYEVHHGVNIADG AIVAAANLAARYLTSRRLPDSAVDLIDEAAAARVARES QPEIIDSLERRRLRQLKIEIHLSREKDEASKARLAQAKQD AQNVEEELRPLREKYERERQRGKDIQEARLKLENLRVK AEDASRMGDHSRAADLQYYAIPQEQQIIRLEKEKAAAD AALNESGPDGTGGAMVTDVVGPDQINEIVARWTGIPVTR LKTSEKERLLHMEQALSKIVVGQKEAVQSVSNAIRLQRS GLANPNQPPSFLFCGPGSGTGKTLTKALAEFLFDDPKA MIRFDMSEYQERHSLSRMIGAPPGYVGHDAAGGQLTEA LRRKPF SILLFDEVEKAAKEVLT VLLQLMDDGRITDGGQ RIVDAKNCIVVMTSNLGAEYLSRPNGKDGKVDPTTKEL VMNALRNYFLPEFLNRISIVIFNRLTRREIRKIVDLRIAEI QKRLQDNDRNVTIRVSDAAKDKLGAAGYSPVYGARPL QRLLEKEVLNRMAILLRGSIRDGEVANVDLVDGKVTVIP NHPDSEGEDEDEMMVDEDEALDEVAPDSMDEDIYD
<i>Scytalidium thermophilum</i>	MNSKMEFTDRAKKALEDAMVLAEQYAHSQLVPVHLAIS LLDPLPDPSKDDQNNQAPGTTSSLFQVVERANGDPQA FDRALKRTLVRPLPSQDPPPEQVSMSPSFNKVLRQAMEL QKVQKDTYIAVDHLISALSEDNTIQAALKEANIPKPKLIQE

	<p>AISTIRGTRRVDSRSADTESENEENLAKFTIDMTAQAREG KIDPVIREEEEIRRVIRILSRRTKNNPVLIGEPGVGKTTVV EGLAQRIVNADVDPNLANCKLLSLDVGLVAGSKYRGE FEERMKGVLKEIQESKDTIILFVDEIHLLMGAGASGEGG MDAANLLKPMLARGQLHCIGATTAEYRKYIEKDAAFER RFQQVLVKEPTIPETISILRGLKEKEYEVHHGVTIADAAIVA AANLAARYLTQRRLPDSAVDLIDEAAAARVAVRESQPEI IDSLERRLRQLKIEIHLSREKDEASKARLAQAKQDAQN VEEELRPLREKYERERQRGKAIQEAKLKLENLRVKAEE ASRMGDHSRAADLQYYAIPQEQQIIRLEREKAAADAAL NESGADVGGSMITDVVGPDPQINEIVARWTGIPVTRLRTS EKEKLLHMEKHLAKIVVGQKEAVQSVSNAILRQRSGLA NPNQPPSFLFCGPGSGTGKTLTKALAEFLFDDPKSMIRF DMSEYQERHSLSRMIGAPPGYVGHDAAGGQLTEALRRK PFSILLFDEVEKAAKEVLTVLLQLMDDGRITDGGGRIVD AKNCIVVMTSNLGAEYLARPSGKDGKIDPTTKELVMNAL RNYFLPEFLNRISIVIFNRLTRREIRKIVDLRIAEIQKRLR DNDNRVTIIVSDAAKDKLGAAGYSPAYGARPLQRLLKE VLNRLAILILRGNIIRDGEVARVDVVDGKVTVLPNHEDEM SDEEMLVDEEDAVEEVAPDSMDEDIYD</p>
<i>Thermoascus aurantiacus</i>	<p>MNGTQFTDRANKALLDSNNLAEQYAHSQILPLHLAISLL TPPQDEMEKQPAGHPSHEGAAAPLFRQVVERAHGDP QLLERNLMKMLVRQPSQDPPPERVAVSPALAKVIRQAT ELSKTQKDSYVAIDHLILAVVQDSQIQRALADANIPNVKLI DSAVQQIRGNKRVDSTADAEAGDNENLKKFTIDMTAMA REGKIDPVIREEEEIRRVIRILSRRTKNNPVLIGEPGVGK TTVVEGLARRIVNADV PANLAQCRLLSLDVGSLVAGSK YRGEFEERMKGVLKEIEDSKDMIVLFVDEIHLLMGAGSS GEGGMDAANLLKPMLARGQLHCIGATTLEGEYRKYIEKD QAFERRFQQVLVKEPTVNETISILRGLKEKEYEVHHGVNI LDAAIVAAANLAARYLTARRLPDSAVDLIDEAAAARVVT RESEPEALDNLERKLRQLQIEIHALEREQDPASKQRLEA AKQEAANVTEELRPLREKYESEKKRSKDIQDAKIKLDSL KVKRDEAERSGDTQTAADLEYAIPETKALIERLEADRA RADAERARQGEAGETLLADAVGPDQINEIVARWTGIP VTRLKTTEKDKLLNMEKHLHRIVVGQKEAVTSVSNAILR QRSGLSNPNSPPSFLFCGPGSGTGKTLTKALAEFLFDD PKAMIRFDMSEYQERHSLSRMIGAPPGYVGHDAAGGQL TENLRRRPFSILLFDEVEKAAKEVLTVLLQLMDDGRITD GQGRIVDARNCIVVMTSNLGAEYLSRPTTKDGKIEPQT RELVMGALRDYFLPEFLNRISIIIFNRLTKREIRKIVELRL SEVQRRLEQNDRNVKIECTEEVKDYLG DAGYSPAYGA RPLSRLIEREVLNRLAVLILRGAIIRDGEVARVVMREGRV EVLPNHIEPMEDEEMLDEEEALAEIEENAGGDMDLYE</p>
<i>Arabidopsis thaliana</i>	<p>MNPEKFTHKTNETIATAHELAVNAGHAQFTPLHLAGALI SDPTGIFPQAISSAGGENAAQSAERVINQALKKLPSQSP</p>

	<p>PPDDIPASSSLIKVIRRAQAAQKSRGDTHLAVDQLIMGLL EDSQIRDLLNEVGVATARVKSEVEKLRGKEGKKVESAS GDTNFQALKTYGRDLVEQAGKLDPVIGRDEEIRRVRIL SRRTKNNPVLIGEPGVGKTAVVEGLAQIRIVKGDVPNSL TDVRLISLDMGALVAGAKYRGEFEERLKSVLKEVEDAE GKVILFIDEIHLVLGAGKTEGSM DAANLFKPMLARGQLR CIGATTLEEYRKYVEKDAAFERRFQQVYVAEPSVPTIS ILRGLKEKYEGHHGVRIQDRALINAAQLSARYITGRHLP DKAIDLVD EACANVRVQLDSQPEEIDNLERKRMQLEIEL HALEREKDKASKARLIEVRKELDDL RDKLQPLTMKYRK EKERIDEIRRLKQKREELMFSLQEAERRYDLARAADLRY GAIQEVESAIAQLEGTSSEENVMLTENVGPEHIAEVVSR WTGIPVTRLGQNEKERLIGLADRLHKRVVGQNQAVNAV SEAILRSRAGLGRAQQPTGSFLFLGPTGVGKTELAKAL AEQLFDDENLLVRIDMSEYMEQHSVSR LIGAPPGYVGH EEGGQLTEAVRRRPYCVILFDEVEKAHVAVFNTLLQVL DDGRLTDGQGRTVDFRNSVIIMTSNLGA EHLLAGLTGK VTMEVARDCVMREVRKHFRPELLNRLDEIVVFDPLSHD QLRKVARLQMKDVAVRLAERGVALAVTDAALDYILAES YDPVYGARPIRRWMEKKVTEL SKMVVREEIDENSTVY IDAGAGDLVYRVESGGLVDASTGKKSDVLIHIANGPKRS DAAQAVKKMRIEEEIEDDDNEEMIED</p>
<i>Calcarisporiella thermophila</i>	<p>MSSMQFTDKATETLNAAAKYAAENSHVQLHP SHVAVV MLDEENSLFRSILEKAGGDVVS IERGFKKIMVRQPSQDP PPTEMGHSP ELAKLLHYAHEHMKKQRDL YIAQDHLILAL ADLP SMAQVLKEGGVT KKSLEN AVTHVRGNRRVESKS AEEAYEALSKYCIDLTELAASGKLD PVIGRDEIISRVIRVL SRRTKNNPCLVGEPGVGKTAIAEGLANRIVKGDIPSSLQ KKVYSLDIGSLLAGAKYRGEFEERLKAVLKE LKEAQAI FIDEIHTVLGAGKSEGAIDANLLKPMLARGE LRCIGATT LTEYRQYVEKDPAFERRFQLVMVEEPSVTDTISILRGLK ERYETHHGVRIADAAIVAAAQLAARYITQRFMPDKAIDLI DEACANTRVQLDSQPEAIDKLERRHLQLEVEATALEKE KDAASKQRLQEVRAEMARIQEELRPLKMKYESEKGRDL EIRNLSQRLDELKAKAEDAERRYDLARAADIRYYAIPDL EKRLAQLQAEKSQADAERADGLLAEVVGPDQIMEVVSR WTGIPVSNLQRSEKEKLLHMEEYMKQHVVGGQDEAIKAI CDAIRLSRTGLQNRNRPLASFLFLGPTGCGKTL CVKELA AFLFNDPGAIVRIDMSEYMEKHAVSRLVGAPPGYIGHD EGGQLTEAVRRRPYTVVLFDEMEKAHKDVSNLLLQILD DGHCTDSKGRRVDFKNTIIVMTSNLGADLFELDEGDKV SQATKNAVLATARRHFANEFINRIDELIVFNRLTPSNIRKI VDVRLKEVQERLDEKQITLDVDDKAKDLLAQGGFDPVY GARPLNRLIQHALLTQLSRLLLDGGVRPGEIAKVTV DQE GEIIVIRNHGIESPAPWADEDMVEDEDMEI</p>

<i>Plasmodium falciparum</i>	MAPDNKQEQGKYLNRTINILNAGKNIKSYGHNKLKPIHI LSALAKSDYGSTLFKENNVNAANLKEYIDIALEQTRAGA PLDNKSKIVNSAEVKETLALAEAAANKYKSPKVDVEHLL SGLSNDELVN EIFNEVYLTDEAIKAILKRKFEKTKKDKDG KTGTLYIEQFGSNMNEKVRNGKLQGIYGRDEEIRAIIESL LRYNKNPVLVGNPGTGKTTIVEGLVYRIEKGDVPKELQ GYTVISLNFRTSGTSYRGEFETRMKNIIKELKNKKNKII LFVDEIHLLLGAGKAEGGTDAANLLKPVL SKGEIKLIGAT TIAEYRKFIESC SAFERRFEKILVEPPSVDMTVKILRSLKS KYENFYGINITDKALVAAAKISDRFIKDRYLPDKAIDLLNK ACSFLQVQLSGKPRIIDVTERDIERLSYEISTLEKDVVDKV SKKKYNKLIKEFEEKKEQLKKYEEYVITGERLKRKKEIE KKLNDLKELTQNYVYSNKEPPIELQNSLKEAQQKYLELY KETVAYVEAKTHNAMNVDAVYQEHVSYIYLRDSGMPLG SLSFESSKGALKLYNSLSKSIIGNEDIKSLSDAVVKAATG MKDPEKPIGTFLFLGPTGVGKTELAKTLAIELFNSKDNLI RVNMSEFTEAHSVSKITGSPPGYVGFSDSGQLTEAVRE KPHSVVLFDELEKAHADVFVLLQILGDGYINDNHRRI DFSNTIIIMTSNLGAELFKKKLFFDADNSGTPEYKRVME DVRLSLIKKCKKVFKPEFVNRIKIGVFEPLNKKNLHKIV ALRFKKLEKRLEEKNIQVSVSEKAIDYIIDQSYDPELGAR PTLIFIESVIMTKFAIMYLKKELVDDMDVFVDYNSKAKNL VINLSKT
------------------------------	--

Table S2. Amino acid sequences of Hsp104 chimeras.

Chimera Name	Sequence
GSSS	MNLDNLTDKAQEAIQASHELALENGHSQLTPLHLAAALFTEDHGL ASSVATKAKADPVNVRRELQKAVIRLPSQDPPPTTVPPSQSFLKVI RDAQSLRKKQGDTHLAVDHLLIALCDDKDVIACFSSADLTKHALEE AVKSVRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLDPMVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSLDLAALTAGAKYKGDFFERFKGVLKEIEESKTLIVLFID EIHMLMGNGKDDAANILKPALSRLGQKLVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEELDSKERQLQ LIQVEIKALERDEDEDADSTTKDRLKLARQKEASLQEELEPLRQRYNE EKHGHEELTQAKKKLDELENKALDAERRYDTATAADLRYFAIPDIK KQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAARLTGIPVKK LSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRGLANPR QPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKY AVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFDEVEKAHPDV LTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKI QESTKNLVMGAVRQHFREPEFLNRISIVIFNKLRSKAIHKIVDIRLKE IEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRLIQNEI LNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAECEVL PN HEATIGADTLGDDDNEDSMEIDDDLD
GGSS	MNLDNLTDKAQEAIQASHELALENGHSQLTPLHLAAALFTEDHGL ASSVATKAKADPVNVRRELQKAVIRLPSQDPPPTTVPPSQSFLKVI RDAQSLRKKQGDTHLAVDHLLIALCDDKDVIACFSSADLTKHALEE AVKSVRGNRKVDSKAADSTYDALNQYAQDFVALAE EGKLDPVIGR DDEIRRVIRVLCRRRKNNPV LIGDPGVGKTAIVEGLAQ RIVRGDVP ENLNCRLYALDMGALVAGAKYRGEFEERLKAVLREVKEGEGKIILF IDELHLVLGAGKSDGAMDAANLLKPMLARGELRCIGATTLEEYRKY VEKDAAFERRFQQVFVSEPSVPDTSILRGLKERYEVHHGVRILD SALVAAAKLSARYITNRFLPDKAIDLVEACANVRMQLDSKPEELD SKERQLQLIQVEIKALERDEDEDADSTTKDRLKLARQKEASLQEELEP LRQRYNEEKHGHEELTQAKKKLDELENKALDAERRYDTATAADLR YFAIPDIKKQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAARL TGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSR GLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCS ELSEKYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFDEVE KAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFIN SQQGSKIQUESTKNLVMGAVRQHFREPEFLNRISIVIFNKLRSKAIHK IVDIRLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPL NRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAE CLEVL PNHEATIGADTLGDDDNEDSMEIDDDLD
GGGS	MNLDNLTDKAQEAIQASHELALENGHSQLTPLHLAAALFTEDHGL ASSVATKAKADPVNVRRELQKAVIRLPSQDPPPTTVPPSQSFLKVI

	<p>RDAQSLRKKQGDTHLAVDHLLIALCDDKDVIACFSSADLTKHALEE AVKSVRGNRKVDSKAADSTYDALNQYAQDFVALAEEGKLDPVIGR DDEIRRVIRVLCRRRKNNPVLIGDPGVGKTAIVEGLAQRIVRGDVP ENLNCRLYALDMGALVAGAKYRGEFEERLKAVLREVKEGEGKIILF IDELHLVLGAGKSDGAMDAANLLKPMLARGELRCIGATTLEEYRKY VEKDAAFERRFQQVFVSEPSVPDTSILRGLKERYEVHHGVRILD SALVAAAKLSARYITNRFLPDKAIDLVEACANVRMQLDSQPEVID TLEHRKLQLEIEIAALEKEKDEASRARLA AVKEELDNVNEKLRPLKA RFESERGMNELKDMMTKLDALKIKLADAERRRDTVQAADLRYYA IPEIEERIRSLKNEIDKEKETDAMETDEESGKLLSDVVGYEQIADV SRLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIAVSNVRL SRSGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRV DCSELSEKYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFD EVEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAE FINSQQGSKIQUESTKNLVMGAVRQHFRPEFLNRISIVIFNKLSRKA IHKIVDIRLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGA RPLNRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD</p>
SSGS	<p>MNDQTQFTERALTILTLAQKLASDHQHPQLQPIHILAAFIETPEDGS VPYLQNLIEKGRYDYDLFKKVVNRNLVRIPQQQPAPAEITPSYALG KVLQDAAKIQKQKQDSFIAQDHILFALFNDSSIQQIFKEAQVDIEAIK QQAELRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLDPVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIVLFD EIHMLMGNGKDDAANILKPALSRLGQLKVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSQPEVIDTLEHRKLQ LEIEIAALEKEKDEASRARLA AVKEELDNVNEKLRPLKARFESERGM NELKDMMTKLDALKIKLADAERRRDTVQAADLRYYA IPEIEERI RSLKNEIDKEKETDAMETDEESGKLLSDVVGYEQIADVVSRLTGIP VKKLSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLA NPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELS EKYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFD EVEKAH PDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQ GSKIQUESTKNLVMGAVRQHFRPEFLNRISIVIFNKLSRKAIHKIVDI RLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRL IQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLE VLPNHEATIGADTLGDDDNEDSMEIDDDLD</p>
GSGS	<p>MNLDNLTDKAQEA IQASHELALENGHSQLTPLHLAAALFTEDHGL ASSVATKAKADPVNVRRELQKAVIRLPSQDPPPTTVPPSQSFLKVI RDAQSLRKKQGDTHLAVDHLLIALCDDKDVIACFSSADLTKHALEE AVKSVRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLDPVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIVLFD EIHMLMGNGKDDAANILKPALSRLGQLKVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAAQ</p>

	LAKRYLPYRRLPDSALDLVDISCAGVAVARDSQPEVIDTLEHRKLQ LEIEIAALEKEKDEASRARLA AVKEELDNVNEKLRPLKARFESERG KMNELKDMMTKLDALKIKLADAERRRDTVQAADLRYAIP EIEERI RSLKNEIDKEKETDAMETDEESGKLLSDVVGYE QIADVVSRLTGIP VKKLSESENEKLIHMERDLSSEVVGQMDA KAVSNAVRLSRSGLA NPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELS EKYAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDEVEKAH PDVLTVM LQMLDDGRITSGQGKTIDCSNCIVIMTSNLGA EFINSQQ GSKIQUESTKNLVMGAVRQHFRPEFLNR ISSIVIFNKLSRKAIHKIVDI RLKEIEERFEQNDKH YKLNLTQEAKD FLAKYGYSDDMGARPLNRL IQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLE VLPNHEATIGADTLGDDDNEDSMEIDDDLD
MSSS	MAINPNEFTDKVNKTLFEAQNF AIQEGHSQVEPAHVAVILFEDPEG MAKR VVQRAGAALQPVQAALRSLLQRM PRQEPAPLEASLSSDTR RLLQSAAKLQKKNN EAH LAVDHLLGALVQDKQILAKLAESGLAKN HFEETLKR VKRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQ GK LDPVIGREEEIRSTIRVLARRIKSNPCLIGEPGIGKTA IIEGVAQRIIDD DVPTILQGAKLFSLDLAALTAGAKYKGD FEERFKGVLKEIEESKTLI VLFIDEIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVE KDGA FERRFQKIEVAEPSVRQTVAILRGLQPKY EIIHHGVRILDSAL VTAAQLAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEELDSK ERQLQLIQVEIKALERDEDADSTTKDRLKLARQKEASLQEELEPLR QRYNEEKHGHEELTQAKKKLDELENKALDAERRYDTATAADLRYF AIPDIKKQIEKLEDQVAEEERRAGANS MIQNVVDSDTISETAARLTG IPVKKLSESENEKLIHMERDLSSEVVGQMDA KAVSNAVRLSRSGL ANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSEL SEKYAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDEVEKA HPDVLTVM LQMLDDGRITSGQGKTIDCSNCIVIMTSNLGA EFINSQ QGSKIQUESTKNLVMGAVRQHFRPEFLNR ISSIVIFNKLSRKAIHKIV DIRLKEIEERFEQNDKH YKLNLTQEAKD FLAKYGYSDDMGARPLN RLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEEC LEVLPNHEATIGADTLGDDDNEDSMEIDDDLD
MMSS	MAINPNEFTDKVNKTLFEAQNF AIQEGHSQVEPAHVAVILFEDPEG MAKR VVQRAGAALQPVQAALRSLLQRM PRQEPAPLEASLSSDTR RLLQSAAKLQKKNN EAH LAVDHLLGALVQDKQILAKLAESGLAKN HFEETLKR VKGTTTADSKSAEENYDALSKYGV DLVQQAADGKLDP VLGRDEEIRRVIQILARRIKSNPCLVGP PGVGKSAIVEGLAQ RIMLG DVPETLKGKLISLDMGALIAGAKYRG EFEEERLKAVLEEIKQSEGRIL FVDEVHNVLGAGKTEGSMDAANLLKPLLARGELRMIGATTEDEYR KYVEKDSAFERRFQVVQVREPSVPD TVSILRGLKERYEAHHGVRI ADAALVAAAQLSHRYIQGRFLPDKAIDLIDEACANARVQLDSKPEE LDSKERQLQLIQVEIKALERDEDADSTTKDRLKLARQKEASLQEEL EPLRQRYNEEKHGHEELTQAKKKLDELENKALDAERRYDTATAAD LRYFAIPDIKKQIEKLEDQVAEEERRAGANS MIQNVVDSDTISETAA RLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDA KAVSNAVRLS RSGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVD

	CSEELSEKYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFDE VEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEF INSQQGSKIQUESTKNLVMGAVRQHFRPEFLNRISIVIFNKLRSKAI HKIVDIRLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGAR PLNRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVPEEA EECLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD
MMMS	MAINPNEFTDKVNKTLFEAQNFQEGHSQVEPAHVAVILFEDPEG MAKRVVQRAGAALQPVAALRSLLQRMQRQEPAPLEASLSSDTR RLLQSAAKLQKKNNEAHLAVDHLLGALVQDKQILAKLAESGLAKN HFEETLKRVKGTTTADSKSAEENYDALSKYGVDLVQQAADGKLDP VLGRDEEIRRVIQILARRIKSNPCLVGPPGVGKSAIVEGLAQRIMLG DVPETLKGKLISLDMGALIAGAKYRGEFEERLKAIVLEEIKQSEGRIL FVDEVHNVLGAGKTEGSMMDAANLLKPLLARGELRMIGATTEDEYR KYVEKDSAFERRFQVVQVREPSVPDTSILRGLKERYEAHHGVRI ADAALVAAAQLSHRYIQGRFLPDKAIDLIDEACANARVQLDSRPEEI DQLERRRLQLQVEATALEKEKDQASKRLRLKDVRELKELANIEEQQLP LLMKFEMERGRVDELRLDLQEKLDLSRKAQRAERQGDALATAADL KYAIPDCERRIQQLTLEDEERSAQRSGMDEQEDAPMLSEEVGP EQITDIARLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIAVS NAVRLSRGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDED MMIRVDCSEELSEKYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYS VLLFDEVEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTS NLGAEFINSQQGSKIQUESTKNLVMGAVRQHFRPEFLNRISIVIFNK LSRKAIHKIVDIRLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSD DMGARPLNRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDEN VPEEAEECLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD
SSMS	MNDQTQFTERALTILTLAQKLASDHQHPQLQPIHILAAFIETPEDGS VPYLQNLIEKGRYDYDLFKKVVNRNLVRIPQQQPAPAEITPSYALG KVLQDAAKIQKQKQDSFIAQDHILFALFNDSSIQQIFKEAQVDIEAIK QQALELRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLDPVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSDLAALTAGAKYKGDFFERFKGVLKEIEESKTLIVLFID EIHMLMGNGKDDAANILKPALSRLGQKLVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYIEHHGVRILDSALVTAAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEEIDQLERRRLQ LQVEATALEKEKDQASKRLRLKDVRELKELANIEEQQLPLLMKFEMER GRVDELRLDLQEKLDLSRKAQRAERQGDALATAADLKYYAIPDCER RIQQLTLEDEERSAQRSGMDEQEDAPMLSEEVGPEQITDIARLTG IPVKKLSESENEKLIHMERDLSSEVVGQMDAIAVSNAVRLSRGL ANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSEL SEKYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFDEVEKA HPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQ QGSKIQUESTKNLVMGAVRQHFRPEFLNRISIVIFNKLRSKAIHKIV DIRLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLN RLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVPEEAEEC LEVLPNHEATIGADTLGDDDNEDSMEIDDDLD

MSMS	<p> MAINPNEFTDKVNKTLFEAQNFAIQEGHSQVEPAHVAVILFEDPEG MAKRVVQRAGAALQPVQAALRSLLQRMPRQEPAPLEASLSSDTR RLLQSAAKLQKKNNEAHLAVDHLLGALVQDKQILAKLAESGLAKN HFEETLKRVRKRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQ GK LDPVIGREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDD DVPTILQGAKLFSDLAALTAGAKYKGD FEERFKGVLKEIEESKTLI VLFIDEIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVE KDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSAL VTAAQLAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEEIDQLE RRRLQLQVEATALEKEKDQASKRLRKDVRKELANIEEQQLQPLL MK FEMERGRVDELRLDQEKLDSLRSKAQRAERQGD LATAADLKYYAI PDCERRIQQLTLEDEERSAQRSGMDEQEDAPMLSEEVGPEQITDI IARLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIKAVSNAVRL SRSGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRV DCSEELSEKYAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFD EVEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAE FINSQQGSKIQUESTKNLVMGAVRQHFRPEFLNR ISSIVIFNKL SRKA IHKIVDIRLKEIEERFEQNDKHYKLNL TQEAKDFLAKYGYSDDMGA RPLNRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVPEE AECELEVLPNHEATIGADTLGDDDNEDSMEIDDDLD </p>
CSSS	<p> MSFDTKKATEKVNNVLGEAINLAKEDKHAALTPTHLAVVLFEEPHG LAKVAATKVAGEEVWRSAIRVLRKRLTKLPKVPAPESVSPGREL SKVL TAAAKLQKDRGDAFLGTD TLLTAVINAAEVSEALGEAGISKA QLETALSEVRQARGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQ GKLDPVIGREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQR II DDDVPTILQGAKLFSDLAALTAGAKYKGD FEERFKGVLKEIEESK TLIVLFIDEIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSI VEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDS ALVTAAQLAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEELDS KERQLQLIQVEIKALERDEDADSTTKDRLKLARQKEASLQEELEPL RQRYNEEKHGHHEELTQAKKKLDELENKALDAERRYDTATAADLR YFAIPDIKKQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAARL TGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIKAVSNAVRLSRS GLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCS ELSEKYAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDEVE KAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFIN SQQGSKIQUESTKNLVMGAVRQHFRPEFLNR ISSIVIFNKL SRKAIHK IVDIRLKEIEERFEQNDKHYKLNL TQEAKDFLAKYGYSDDMGARPL NRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVPEEAE CLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD </p>
CCSS	<p> MSFDTKKATEKVNNVLGEAINLAKEDKHAALTPTHLAVVLFEEPHG LAKVAATKVAGEEVWRSAIRVLRKRLTKLPKVPAPESVSPGREL SKVL TAAAKLQKDRGDAFLGTD TLLTAVINAAEVSEALGEAGISKA QLETALSEVRQAAGGGPINSETADANFDALAKYGTDLTANAARAD PVIGRDDEIRRVVRVLCRRTKNNPV LIGEPGVGKTAIVEGLAQ RIVK NDVPETLQGVRLISLDMGSLVAGAKYRGFEFEERLKA VLNEVAQQQ </p>

	GKVVLFIDELHLVLGAGKSGDGAMDAANLLKPMLARGE LRCIGAT TLGEYREHIEKDAAFERRFQQVLVKEPSVPDTIAILRGIKDRYETHH GVHITDRALVVAEELSDRYITRFLPDKAIDLVD EACANMRVQLDS KPEELDSKERQLQLIQVEIKALERDEDEDADSTTKDRLKLARQKEASL QEELEPLRQRYNEEKHGHEELTQAKKKLDELENKALDAERRYDTA TAADLRYFAIPDIKKQIEKLEDQVAEEERRAGANSMIQNVVDSDTIS ETAARLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIAVSN VRLSRGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDED MIRVDCSELSEKYAVSKLLGTTAGYVGYDEGGFLTNQLQYKPYSV LLFDEVEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSN LGAEFINSQQGSKIQUESTKNLVMGAVRQHFRPEFLNRIS SIVIFNKL SRKAIHKIVDIRLKEIEERFEQNDKHYKLNLTQEAKD FLAKYGYSD MGARPLNRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDEN VPEEAEECLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD
CCCS	MSFDTKKATEKVNNVLGEAINLAKEDKHAALTPTHLAVVLFE EPHG LAKVAATKVAGEEVWRSAIRVLRKRLTKLPKVDPAPE SVSPGREL SKVLTA AAKLQKDRGDAFLGTDLLTAVINAAEVSEALGEAGISKA QLETALSEVRQAAGGGPINSETADANFDALAKYGTDLTANAARAD PVIGRDDEIRRVVRVLCRRTKNNPVLIGEPGVGKTAIVEGLAQRIVK NDVPETLQGVRLISLDMGSLVAGAKYRGEFEERLKA VLNVAQQQ GKVVLFIDELHLVLGAGKSGDGAMDAANLLKPMLARGE LRCIGAT TLGEYREHIEKDAAFERRFQQVLVKEPSVPDTIAILRGIKDRYETHH GVHITDRALVVAEELSDRYITRFLPDKAIDLVD EACANMRVQLDS KPEQLDALERQRQRLQVEAAALAKEKDALSKARAKEV GKELAAL E EALRPLQMKYAEKARLEELRRLGQKRDEILVNIQIAEQHG NLARI ADLRYGALPDVEDRIKQVRAAAPSDAMLSEEVGT EEIAVVVSRLT GIPVKKLSESENEKLIHMERDLSSEVVGQMDAIAVSN VRLSRSG LANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSE LSEKYAVSKLLGTTAGYVGYDEGGFLTNQLQYKPYSVLLFDEVEK AHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGA EFINS QQGSKIQUESTKNLVMGAVRQHFRPEFLNRIS SIVIFNKL SRKAIHKI VDIRLKEIEERFEQNDKHYKLNLTQEAKD FLAKYGYSDDMGARPL NRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDEN VPEEAEE CLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD
SSCS	MNDQTQFTERALTILTLAQKLASDHQHPQLQPIHILAAFIETPEDGS VPYLQNLIEKGRYDYDLFKKVNRNLVRIPQQQPAPAEITPSYALG KVLQDAAKIQKQKQDSFIAQDHILFALFNDSSIQQIFKEAQVDIEAIK QQALELRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLD PVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSLDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIVLFID EIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEQLDALERQRQ RLQVEAAALAKEKDALSKARAKEV GKELAAL EALRPLQMKYAE KARLEELRRLGQKRDEILVNIQIAEQHG NLARIADLRYGALPDVED

	RIKQVRAAAPSDAMLSEEVGTEEIAVVVSRLTGIPVKKLSESENEK LIHMERDLSSEVVGQMDAIAVSNVRLSRSGLANPRQPASFLFL GLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKYAVSKLLGT TAGYVGYDEGGFLTQNLQYKPYSVLLFDEVEKAHPDVLTVMLQM LDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKIQUESTKNL VMGAVRQHFRPEFLNRISIVIFNKL SRKAIHKIVDIRLKEIEERFEQ NDKHYNLNTQEAKDFLAKYGYSDDMGARPLNRLIQNEILNKLALR ILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPNHEATIGA DTLGDDDNEDSMEIDDDLD
CSCS	MSFDTKKATEKVNNVLGEAINLAKEDKHAALTPTHLAVVLFEEPHG LAKVAATKVAGEEVWRSAIRVLRKRLTKLPKVPAPESVSPGREL SKVLTAAAKLQKDRGDAFLGTDLTLLTAVINAAEVSEALGEAGISKA QLETALSEVRQARGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQ GKLDPVIGREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRRI DDDVPTILQGAKLFSDLAALTAGAKYKGDFEERFKGVLKEIEESK TLIVLFIDEIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSI VEKDGAFFRRFQKIEVAEPSVRQTVAILRGLQPKYIEHHGVRILDS ALVTAAQLAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEQLD ALERQRQRLQVEAAALAKEKDALS KARAKEVKGELAALEEALRPL QMKYAEKARLEELRRLGQKRDEILVNIQIAEQHGNLARIADLRYG ALPDVEDRIKQVRAAAPSDAMLSEEVGTEEIAVVVSRLTGIPVKKL SESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLANPRQ PASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKYA VSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFDEVEKAHPDVL TVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKI QUESTKNLVMGAVRQHFRPEFLNRISIVIFNKL SRKAIHKIVDIRLKE IEERFEQNDKHYNLNTQEAKDFLAKYGYSDDMGARPLNRLIQNEI LNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPN HEATIGADTLGDDDNEDSMEIDDDLD
PSSS	MDPGKFTHTKNEALATAHELTVGAGHAQITPLHLAVALISDPGIM RQAVANAGDGENTAQA AERVFNQVLKKLPSQSPPPDEVPPSTSLI KVIRRSQALQKSRGDSYLAVDQMILGLLEDSQIRDLFKEVGVAST VKSEVEKLRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLD PVIGREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRRIIDD VPTILQGAKLFSDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIV LFIDEIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVEK DGAFERRFQKIEVAEPSVRQTVAILRGLQPKYIEHHGVRILDSALVT AAQLAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEELDSKER QLQLIQVEIKALERDEDEDADSTTKDRLKLARQKEASLQEELEPLRQR YNEEKHGHEELTQAKKKLDELENKALDAERRYDTATAADLRYFAI PDIKKQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAARLTGIP VKKLSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRGLA NPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELS EKYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFDEVEKAH PDVLTVMMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQ GSKIQUESTKNLVMGAVRQHFRPEFLNRISIVIFNKL SRKAIHKIVDI

	RLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRL IQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEEAECCLE VLPNHEATIGADTLGDDDNEDSMEIDDDLD
PPSS	MDPGKFTHKTNEALATAHELTVGAGHAQITPLHLAVALISDPSGIM RQAVANAGDGENTAQA AERVFNQVLKKLPSQSPPPDEVPPSTSLI KVIRRSQALQKSRGDSYLAVDQMILGLLEDSQIRDLFKEVGVASST VKSEVEKLRGKEGKKVENASGDTNFQALKTYGRDLVEGAGKLDP VIGRDEEIRRVRILSRRTKNNPVLIGEPGVGKTAVAEGLAQRIVR GDVPSNLADVRLIALDMGALVAGAKYRGFEERLKA VLKEVEEAE GKVILFIDEIHLVLGAGRTEGSMDAANLFKPMLARGQLRCIGATTLE EYRKYVEKDAAFERRFQQVYVAEPSVPDTISILRGLKEKYE GHHG VRIQDRALVIAAQLSSRYITGRHLPDKAIDLVEACANVRVQLDSK PEELDSKERQLQLIQVEIKALERDEDEDADSTTKDRLKLARQKEASLQ EELEPLRQRYNEEKHGHEELTQAKKKLDELENKALDAERRYDTAT AADLRYFAIPDIKKQIEKLEDQVAEEERRAGANSMIQNVVDSDTISE TAARLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIAVSNV RLSRSGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMI RVDCSELSEKYAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLL FDEVEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLG AEFINSQQGSKIQUESTKNLVMGAVRQHFRPEFLNRIS SIVIFNKLRSR KAHKIVDIRLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDM GARPLNRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAECCLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD
PPPS	MDPGKFTHKTNEALATAHELTVGAGHAQITPLHLAVALISDPSGIM RQAVANAGDGENTAQA AERVFNQVLKKLPSQSPPPDEVPPSTSLI KVIRRSQALQKSRGDSYLAVDQMILGLLEDSQIRDLFKEVGVASST VKSEVEKLRGKEGKKVENASGDTNFQALKTYGRDLVEGAGKLDP VIGRDEEIRRVRILSRRTKNNPVLIGEPGVGKTAVAEGLAQRIVR GDVPSNLADVRLIALDMGALVAGAKYRGFEERLKA VLKEVEEAE GKVILFIDEIHLVLGAGRTEGSMDAANLFKPMLARGQLRCIGATTLE EYRKYVEKDAAFERRFQQVYVAEPSVPDTISILRGLKEKYE GHHG VRIQDRALVIAAQLSSRYITGRHLPDKAIDLVEACANVRVQLDSQ PEEIDSLERKRMQLEVELHALEKEKDKASKARLAEVVKELDDL RD KLQPLL MKYKKEKERIDEIRRLKQKREEILFSIQEAERRYDLARVAD LRYGALEEVEAAIARLEGSTTDENLMLTETVGPEHIAEVVSRLTGIP VKKLSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLA NPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELS EKYAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDEVEKAH PDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGA EFINSQQ GSKIQUESTKNLVMGAVRQHFRPEFLNRIS SIVIFNKLRSRKAIHKIVDI RLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRL IQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEEAECCLE VLPNHEATIGADTLGDDDNEDSMEIDDDLD
SSPS	MNDQTQFTERALTILTLAQKLASDHQHPQLQPIHILAAFIETPEDGS VPYLQNLIEKGRYDYDLFKKVVRNRLVRIPQQQPAPAEITPSYALG KVLQDAAKIQKQQKDSFIAQDHILFALFNDSSIQQIFKEAQVDIEAIK

	<p> QQALELRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLDPVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIVLFID EIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSQPPEIDSLEKRM QLEVELHALEKEKDKASKARLAEVVKELDDLRLDKLQPLLMKYKKE KERIDEIRRLKQKREEILFSIQEAERRYDLARVADLRYGALEEEVEAA IARLEGSTTDENLMLTETVGPEHIAEVVSRLTGIPVKKLSESENEKL IHMERDLSSEVVGQMDAIKAVSNAVRLSRSGLANPRQPASFLFLG LSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKYAVSKLLGTT AGYVGYDEGGFLTQNLQYKPYSVLLFDEVEKAHPDVLTVMLQML DDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKIQUESTKNLV MGAVRQHFRRPEFLNRISIVIFNKLRSKAIHKIVDIRLKEIEERFEQN DKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRLIQNEILNKLALRI LKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPNHEATIGAD TLGDDDDNEDSMEIDDDLD </p>
PSPS	<p> MDPGKFTHTKNEALATAHELTVGAGHAQITPLHLAVALISDPGIM RQAVANAGDGENTAQAARVFNQVLKKLPSQSPPPDEVPPSTSLI KVIRRSQALQKSRGDSYLAVDQMILGLLEDSQIRDLFKEVGVAST VKSEVEKLRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLD PVIGREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDD VPTILQGAKLFSDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIV LFIDEIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVEK DGAFERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVT AAQLAKRYLPYRRLPDSALDLVDISCAGVAVARDSQPPEIDSLEKRM RMQLEVELHALEKEKDKASKARLAEVVKELDDLRLDKLQPLLMKYK KEKERIDEIRRLKQKREEILFSIQEAERRYDLARVADLRYGALEEEVE AAIARLEGSTTDENLMLTETVGPEHIAEVVSRLTGIPVKKLSESENE KLIHMERDLSSEVVGQMDAIKAVSNAVRLSRSGLANPRQPASFLF LGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKYAVSKLLG TTAGYVGYDEGGFLTQNLQYKPYSVLLFDEVEKAHPDVLTVMLQ MLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKIQUESTK NLVMGAVRQHFRRPEFLNRISIVIFNKLRSKAIHKIVDIRLKEIEERF EQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRLIQNEILNKL ALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPNHEATI GADTLGDDDDNEDSMEIDDDLD </p>
RSSS	<p> MALNPNEWTEKVQEMYLEAKNVAINNKNAYMDPIHFAVALFEDEG GLPQRVVQKSGASLDAVEGAMRSLLKAIPQQDPAPVDVSTSHKAL RFLQNAQKKQKKNDEAHLAIDHLLLALVQEKDILQALAGCGLAKDR FEEIVKKIRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLDP VIGREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDV PTLILQGAKLFSDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIVLF IDEIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVEKD GAFERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTA AQLAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEELDSKERQ </p>

	LQLIQVEIKALERDEDEDADSTTKDRLKLARQKEASLQEELEPLRQRY NEEKHGHEELTQAKKKLDELENKALDAERRYDTATAADLRYFAIP DIKKQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAARLTGIPV KKLSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLAN PRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSE KYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFDEVEKAHP DVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQG SKIQUESTKNLVMGAVRQHFRRPEFLNRISIVIFNKLRSKAIHKIVDIR LKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRLI QNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEV LPNHEATIGADTLGDDDNEDSMEIDDDLD
RRSS	MALNPNEWTEKVQEMYLEAKNVAINNKNAYMDPIHFAVALFEDEG GLPQRVVQKSGASLDAVEGAMRSLLKAIPQQDPAPVDVSTSHKAL RFLQNAQKKQKKNDEAHLAIDHLLLALVQEKDILQALAGCGLAKDR FEEIVKKIKGTTRANTKTAESTYDALGKYGVDLVQRAADGKLDPVI GRDEEIRRVIQILARRTKNNPVLVGPPGTGKTAIVEGLAQRILNGDV PETLKARLVSLDMGALIAGAKYRGFEERLKS SVLDEVKQAEGSIILF VDEIHTVLGAGKTEGSM DAANLLKPMLARGELRMIGATTLD EYRK HVEKDAAFERRFQMVHVSEPSVPD TVSILRGLKERYEAHHGVRIQ DAALVTAAQLADRYITQRFLPDKAIDL VDEACAKTRVQLDSKPEEL DSKERQLQLIQVEIKALERDEDEDADSTTKDRLKLARQKEASLQEELE PLRQRYNEEKHGHEELTQAKKKLDELENKALDAERRYDTATAADL RYFAIPDIKKQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAAR LTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSR SGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDC SELSEKYAVSKLLGTTAGYVGYDEGGFLTQNLQYKPYSVLLFDEV EKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFI NSQQGSKIQUESTKNLVMGAVRQHFRRPEFLNRISIVIFNKLRSKAIH KIVDIRLKEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARP LNRLIQNEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEA ECLEVL PNHEATIGADTLGDDDNEDSMEIDDDLD
RRRS	MALNPNEWTEKVQEMYLEAKNVAINNKNAYMDPIHFAVALFEDEG GLPQRVVQKSGASLDAVEGAMRSLLKAIPQQDPAPVDVSTSHKAL RFLQNAQKKQKKNDEAHLAIDHLLLALVQEKDILQALAGCGLAKDR FEEIVKKIKGTTRANTKTAESTYDALGKYGVDLVQRAADGKLDPVI GRDEEIRRVIQILARRTKNNPVLVGPPGTGKTAIVEGLAQRILNGDV PETLKARLVSLDMGALIAGAKYRGFEERLKS SVLDEVKQAEGSIILF VDEIHTVLGAGKTEGSM DAANLLKPMLARGELRMIGATTLD EYRK HVEKDAAFERRFQMVHVSEPSVPD TVSILRGLKERYEAHHGVRIQ DAALVTAAQLADRYITQRFLPDKAIDL VDEACAKTRVQLDSRPEEI DALERRKLQLEVEATALGKEKDKMSKQRLKEVKKQLADIEEQLGP LKMKFEMERGRVDEMRELQEKLDNLRNKVQRAERAGDLSTAADL KYAIPDCEKRLKQLIEEQEKRQQEQQSMDVSD EDKPMLSEEVG PDQVTEIVARLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIA AVSNVRLSRSGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFN DEDMMIRVDCSELSEKYAVSKLLGTTAGYVGYDEGGFLTQNLQY

	KPYSVLLFDEVEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIV IMTSNLGAEFINSQQGSKIQUESTKNLVMGAVRQHFRPEFLNRIS SIVIFNKL SRKAIHKIVDIRLKEIEERFEQNDKHYKLNLTQEAKD FLAKY GYSDDMGARPLNRLIQNEILNKLALRILKNEIKDKETV NVVLKKGKSRDENVP EEAEECLEVLPNHEATIGADTLGDDDNED SMEIDDDLD
SSRS	MNDQTQFTERALTILTLAQKLASDHQHPQLQPIHILAAFIETPEDGS VPYLQNLIEKGRYDYDLFKKVVNRNLVRIPQQQPAPAEITPSYALG KVLQDAAKIQKQQKDSFIAQDHILFALFNDSSIQQIFKEAQVDIEAIK QQAELRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLDPVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSDLAALTAGAKYKGD FEERFKGVLKEIEESKTLIVLFI D EIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSRPEEIDALERRKLQ LEVEATALGKEKDKMSKQRLKEVKKQLADIEEQLGPLKMKFEMER GRVDEMRELQEKL DNLNRNKVQRAERAGDLSTAADLKYYAIPDCE KRLKQLIEEQEKRRQQEQQSM DVSD EDPMLSEEVGPDQVTEIVA RLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIKAVSNAVRLS RSGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVD CSELSEKYAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDE VEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEF INSQQGSKIQUESTKNLVMGAVRQHFRPEFLNRIS SIVIFNKL SRKAI HKIVDIRLKEIEERFEQNDKHYKLNLTQEAKD FLAKY GYSDDMGAR PLNRLIQNEILNKLALRILKNEIKDKETV NVVLKKGKSRDENVP EEA EECLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD
RSRS	MALNPNEWTEKVQEMYLEAKNVAINNKNAYMDPIHFAVALFEDEG GLPQRVVQKSGASLDAVEGAMRSLLKAIPQQDPAPVDVSTSHKAL RFLQNAQKKQKKNDEAHLAIDHLLLALVQEKDILQALAGCGLAKDR FEEIVKKIRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLDP VIGREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDV PTILQGAKLFSDLAALTAGAKYKGD FEERFKGVLKEIEESKTLIVLF IDEIHMLMGNGKDDAANILKPALSRGQLKVIGATTNNEYRSIVEKD GAFERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTA AQLAKRYLPYRRLPDSALDLVDISCAGVAVARDSRPEEIDALERRK LQLEVEATALGKEKDKMSKQRLKEVKKQLADIEEQLGPLKMKFEM ERGRVDEMRELQEKL DNLNRNKVQRAERAGDLSTAADLKYYAIPD CEKRLKQLIEEQEKRRQQEQQSM DVSD EDPMLSEEVGPDQVTEI VARLTGIPVKKLSESENEKLIHMERDLSSEVVGQMDAIKAVSNAVR LSRSGLANPRQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIR VDCSELSEKYAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLF DEVEKAHPDVLTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGA EFINSQQGSKIQUESTKNLVMGAVRQHFRPEFLNRIS SIVIFNKL SRK AIHKIVDIRLKEIEERFEQNDKHYKLNLTQEAKD FLAKY GYSDDMG ARPLNRLIQNEILNKLALRILKNEIKDKETV NVVLKKGKSRDENVP E EAEECLEVLPNHEATIGADTLGDDDNEDSMEIDDDLD

CaSSS	MSSMQFTDKATETLNAAAKYAAENSHVQLHP SHVAVV MLDEENS LFRSILEKAGGDVVSIERGFKKIMVRQPSQDPPPTMGHSP ELAKL LHYAHEHMKKQRDL YIAQDHLILALADLP SMAQVLKEGGVTKKSLE NAVTHVRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGK LDPVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSLDLAALTAGAKYKGD FEERFKGVLKEIEESKTLIVLFID EIHMLMGNGKDDAANILKPALS RGLKQVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSKPEELDSKERQLQ LIQVEIKALERDEDEDADSTTKDRLKLARQKEASLQEELEPLRQRYNE EKHGHEELTQAKKKLDELENKALDAERRYDTATAADLRYFAIPDIK KQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAARLTGIPVKK LSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLANPR QPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKY AVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDEVEKAHPDV LTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKI QESTKNLVMGAVRQHF RPEFLNRISIVIFNKLSRKAIHKIVDIRLKE IEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRLIQNEI LNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPN HEATIGADTLGDDDNEDSMEIDDDLD
CaCaSS	MSSMQFTDKATETLNAAAKYAAENSHVQLHP SHVAVV MLDEENS LFRSILEKAGGDVVSIERGFKKIMVRQPSQDPPPTMGHSP ELAKL LHYAHEHMKKQRDL YIAQDHLILALADLP SMAQVLKEGGVTKKSLE NAVTHVRGNRRVESKSAEEAYEALSKYCIDLTELAASGKLDPVIGR DEIISRVIRVLSRRTKNNPCLVGEPGVGKTAIAEGLANRIVKGDIPS SLQKKVYSLDIGSLLAGAKYRGEFEERLKAVLKELKEAQAIVFIDEI HTVLGAGKSEGAIDAANLLKPMLARGE LRCIGATTLTEYRQYVEKD PAFERRFQLVMVEEPSVTD TISILRGLKERYETHHGVRIADAAIVAA AQLAARYITQRFMPDKAIDLIDEACANTRVQLDSKPEELDSKERQL QLIQVEIKALERDEDEDADSTTKDRLKLARQKEASLQEELEPLRQRYN EEKHGHEELTQAKKKLDELENKALDAERRYDTATAADLRYFAIPDI KKQIEKLEDQVAEEERRAGANSMIQNVVDSDTISETAARLTGIPVK KLSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLANP RQPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEK YAVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDEVEKAHPD VLTVMQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGS KIQESTKNLVMGAVRQHF RPEFLNRISIVIFNKLSRKAIHKIVDIRL KEIEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRLIQ NEILNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPN HEATIGADTLGDDDNEDSMEIDDDLD
CaCaCaS	MSSMQFTDKATETLNAAAKYAAENSHVQLHP SHVAVV MLDEENS LFRSILEKAGGDVVSIERGFKKIMVRQPSQDPPPTMGHSP ELAKL LHYAHEHMKKQRDL YIAQDHLILALADLP SMAQVLKEGGVTKKSLE NAVTHVRGNRRVESKSAEEAYEALSKYCIDLTELAASGKLDPVIGR DEIISRVIRVLSRRTKNNPCLVGEPGVGKTAIAEGLANRIVKGDIPS SLQKKVYSLDIGSLLAGAKYRGEFEERLKAVLKELKEAQAIVFIDEI

	HTVLGAGKSEGAIDAANLLKPMLARGE LRCIGATTLTEYRQYVEKD PAFERRFQLVMVEEPSVTDITISILRGLKERYETHHGVRIADAAIVAA AQLAARYITQRFMPDKAIDLIDEACANTRVQLDSQPEAIDKLERRH LQLEVEATALEKEKDAASKQRLQEVRAEMARIQEELRPLKMKYES EKGRLEIRNLSQRLDELKAKAEDAERRYDLARAADIRYYAIPDLE KRLAQLQAEKSQADAERADGLLAEVVGPDQIMEVVSRLTGIPVKK LSESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLANPR QPASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKY AVSKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDEVEKAHPDV LTVMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKI QESTKNLVMGAVRQHFRPEFLNRISIVIFNKLSRKAIHKIVDIRLKE IEERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRILQNEI LNKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPN HEATIGADTLGDDDNEDSMEIDDDLD
SSCaS	MNDQTQFTERALTILTLAQKLASDHQHPQLQPIHILAAFIETPEDGS VPYLQNLIEKGRYDYDLFKKVNRNLVRIPQQQPAPAEITPSYALG KVLQDAAKIQKQKDSFIAQDHILFALFNDSSIQQIFKEAQVDIEAIK QQALELRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLD PVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSLDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIVLFID EIHMLMGNGKDDAANILKPALS R GQLKVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSQPEAIDKLERRHLQ LEVEATALEKEKDAASKQRLQEVRAEMARIQEELRPLKMKYESEK GRLEIRNLSQRLDELKAKAEDAERRYDLARAADIRYYAIPDLEKR LAQLQAEKSQADAERADGLLAEVVGPDQIMEVVSRLTGIPVKKLS ESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLANPRQP ASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKYAV SKLLGTTAGYVGYDEGGFLT NQLQYKPYSVLLFDEVEKAHPDVL T VMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKIQ ESTKNLVMGAVRQHFRPEFLNRISIVIFNKLSRKAIHKIVDIRLKEIE ERFEQNDKHYKLNLTQEAKDFLAKYGYSDDMGARPLNRILQNEIL NKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPNH EATIGADTLGDDDNEDSMEIDDDLD
CaSCaS	MSSMQFTDKATETLNAAKYAAENSHVQLHP SHVAVVMLDEENS LFRSILEKAGGDVVSIERGFKKIMVRQPSQDPPPTMGHSP ELAKL LHYAHEHMKKQRDLIAQDHLILALADLP SMAQVLKEGGVTKKSLE NAVTHVRGNTRIDSRGADTNTPLEYLSKYAIDMTEQARQGKLD PVI GREEEIRSTIRVLARRIKSNPCLIGEPGIGKTAIEGVAQRIIDDDVPT ILQGAKLFSLDLAALTAGAKYKGDFEERFKGVLKEIEESKTLIVLFID EIHMLMGNGKDDAANILKPALS R GQLKVIGATTNNEYRSIVEKDGA FERRFQKIEVAEPSVRQTVAILRGLQPKYEIHHGVRILDSALVTAAQ LAKRYLPYRRLPDSALDLVDISCAGVAVARDSQPEAIDKLERRHLQ LEVEATALEKEKDAASKQRLQEVRAEMARIQEELRPLKMKYESEK GRLEIRNLSQRLDELKAKAEDAERRYDLARAADIRYYAIPDLEKR LAQLQAEKSQADAERADGLLAEVVGPDQIMEVVSRLTGIPVKKLS

	ESENEKLIHMERDLSSEVVGQMDAIAVSNVRLSRSGLANPRQP ASFLFLGLSGSGKTELAKKVAGFLFNDEDMMIRVDCSELSEKYAV SKLLGTTAGYVG YDEGGFLT NQLQYKPYSVLLFDEVEKAHPDVL T VMLQMLDDGRITSGQGKTIDCSNCIVIMTSNLGAEFINSQQGSKI Q ESTKNLVMGAVRQHFRPEFLNRISIVIFNKLSRKAIHKIVDIRLKEIE ERFEQNDKH YKLNL TQEAKD FLAKYGYSDDMGARPLNR LIQNEIL NKLALRILKNEIKDKETVNVVLKKGKSRDENVP EEAEECLEVLPNH EATIGADTLGDDDNEDSMEIDDDLD
--	--

Table S3. Pairwise sequence identity between Hsp104 homologs.

		Total aa	Identical aa	% Identity	Similar aa
	<i>S.cerevisiae</i>	908			
<i>S.cerevisiae</i>	<i>P.falciparum</i>	881	319	34	316
<i>S.cerevisiae</i>	<i>L.thermotolerans</i>	907	761	84	105
<i>S.cerevisiae</i>	<i>Ch.thermophilum</i>	926	467	50	265
<i>S.cerevisiae</i>	<i>S.thermophilum</i>	924	463	49	265
<i>S.cerevisiae</i>	<i>M.thermophila</i>	925	459	49	274
<i>S.cerevisiae</i>	<i>T.terrestris</i>	923	463	49	262
<i>S.cerevisiae</i>	<i>T.lanuginosus</i>	922	454	48	294
<i>S.cerevisiae</i>	<i>T.aurantiacus</i>	926	458	49	291
<i>S.cerevisiae</i>	<i>C.thermophila</i>	882	418	46	292
<i>S.cerevisiae</i>	<i>C.reinhardtii</i>	925	383	40	298
<i>S.cerevisiae</i>	<i>P.euphratica</i>	914	391	42	298
<i>S.cerevisiae</i>	<i>A.thaliana</i>	911	394	42	294
<i>S.cerevisiae</i>	<i>M.brevicollis</i>	889	387	42	303
<i>S.cerevisiae</i>	<i>S.rosetta</i>	892	381	41	316
<i>S.cerevisiae</i>	<i>G.sulphuraria</i>	922	386	41	332
<i>S.cerevisiae</i>	<i>D.discoideum</i>	886	401	43	299
<i>P.falciparum</i>	<i>L.thermotolerans</i>		302	32	337
<i>P.falciparum</i>	<i>Ch.thermophilum</i>		317	33	331
<i>P.falciparum</i>	<i>S.thermophilum</i>		316	34	328
<i>P.falciparum</i>	<i>M.thermophila</i>		322	34	321
<i>P.falciparum</i>	<i>T.terrestris</i>		319	34	323
<i>P.falciparum</i>	<i>T.lanuginosus</i>		304	32	326
<i>P.falciparum</i>	<i>T.aurantiacus</i>		307	32	324
<i>P.falciparum</i>	<i>C.thermophila</i>		306	33	330
<i>P.falciparum</i>	<i>C.reinhardtii</i>		318	34	321
<i>P.falciparum</i>	<i>P.euphratica</i>		326	35	334
<i>P.falciparum</i>	<i>A.thaliana</i>		329	35	327
<i>P.falciparum</i>	<i>M.brevicollis</i>		321	35	332
<i>P.falciparum</i>	<i>S.rosetta</i>		316	35	337
<i>P.falciparum</i>	<i>G.sulphuraria</i>		341	36	324
<i>P.falciparum</i>	<i>D.discoideum</i>		328	36	343
<i>L.thermotolerans</i>	<i>Ch.thermophilum</i>		469	50	269
<i>L.thermotolerans</i>	<i>S.thermophilum</i>		459	49	279
<i>L.thermotolerans</i>	<i>M.thermophila</i>		465	50	273
<i>L.thermotolerans</i>	<i>T.terrestris</i>		459	49	272

<i>L.thermotolerans</i>	<i>T.lanuginosus</i>		448	48	300
<i>L.thermotolerans</i>	<i>T.aurantiacus</i>		450	48	298
<i>L.thermotolerans</i>	<i>C.thermophila</i>		411	45	298
<i>L.thermotolerans</i>	<i>C.reinhardtii</i>		367	39	315
<i>L.thermotolerans</i>	<i>P.euphratica</i>		390	42	310
<i>L.thermotolerans</i>	<i>A.thaliana</i>		391	42	302
<i>L.thermotolerans</i>	<i>M.brevicollis</i>		387	42	309
<i>L.thermotolerans</i>	<i>S.rosetta</i>		381	41	312
<i>L.thermotolerans</i>	<i>G.sulphuraria</i>		405	43	314
<i>L.thermotolerans</i>	<i>D.discoideum</i>		410	44	295
<i>Ch.thermophilum</i>	<i>S.thermophilum</i>		831	90	61
<i>Ch.thermophilum</i>	<i>M.thermophila</i>		841	91	54
<i>Ch.thermophilum</i>	<i>T.terrestris</i>		834	90	51
<i>Ch.thermophilum</i>	<i>T.lanuginosus</i>		697	75	147
<i>Ch.thermophilum</i>	<i>T.aurantiacus</i>		692	74	142
<i>Ch.thermophilum</i>	<i>C.thermophila</i>		486	52	258
<i>Ch.thermophilum</i>	<i>C.reinhardtii</i>		420	43	283
<i>Ch.thermophilum</i>	<i>P.euphratica</i>		452	48	271
<i>Ch.thermophilum</i>	<i>A.thaliana</i>		449	47	278
<i>Ch.thermophilum</i>	<i>M.brevicollis</i>		438	47	278
<i>Ch.thermophilum</i>	<i>S.rosetta</i>		430	46	280
<i>Ch.thermophilum</i>	<i>G.sulphuraria</i>		460	48	276
<i>Ch.thermophilum</i>	<i>D.discoideum</i>		446	47	278
<i>S.thermophilum</i>	<i>M.thermophila</i>		850	92	63
<i>S.thermophilum</i>	<i>T.terrestris</i>		840	91	60
<i>S.thermophilum</i>	<i>T.lanuginosus</i>		697	75	147
<i>S.thermophilum</i>	<i>T.aurantiacus</i>		703	76	132
<i>S.thermophilum</i>	<i>C.thermophila</i>		483	52	252
<i>S.thermophilum</i>	<i>C.reinhardtii</i>		424	44	281
<i>S.thermophilum</i>	<i>P.euphratica</i>		445	47	288
<i>S.thermophilum</i>	<i>A.thaliana</i>		458	48	273
<i>S.thermophilum</i>	<i>M.brevicollis</i>		440	48	276
<i>S.thermophilum</i>	<i>S.rosetta</i>		431	46	278
<i>S.thermophilum</i>	<i>G.sulphuraria</i>		463	49	278
<i>S.thermophilum</i>	<i>D.discoideum</i>		447	48	284
<i>M.thermophila</i>	<i>T.terrestris</i>		848	91	58
<i>M.thermophila</i>	<i>T.lanuginosus</i>		701	76	145
<i>M.thermophila</i>	<i>T.aurantiacus</i>		693	75	146
<i>M.thermophila</i>	<i>C.thermophila</i>		485	52	254

<i>M.thermophila</i>	<i>C.reinhardtii</i>		423	44	286
<i>M.thermophila</i>	<i>P.euphratica</i>		445	47	271
<i>M.thermophila</i>	<i>A.thaliana</i>		458	48	268
<i>M.thermophila</i>	<i>M.brevicollis</i>		439	47	280
<i>M.thermophila</i>	<i>S.rosetta</i>		432	46	275
<i>M.thermophila</i>	<i>G.sulphuraria</i>		457	48	282
<i>M.thermophila</i>	<i>D.discoideum</i>		451	48	281
<i>T.terrestris</i>	<i>T.lanuginosus</i>		698	75	143
<i>T.terrestris</i>	<i>T.aurantiacus</i>		695	75	141
<i>T.terrestris</i>	<i>C.thermophila</i>		483	52	251
<i>T.terrestris</i>	<i>C.reinhardtii</i>		427	45	280
<i>T.terrestris</i>	<i>P.euphratica</i>		447	47	277
<i>T.terrestris</i>	<i>A.thaliana</i>		454	48	274
<i>T.terrestris</i>	<i>M.brevicollis</i>		443	48	271
<i>T.terrestris</i>	<i>S.rosetta</i>		427	46	280
<i>T.terrestris</i>	<i>G.sulphuraria</i>		458	48	284
<i>T.terrestris</i>	<i>D.discoideum</i>		444	47	279
<i>T.lanuginosus</i>	<i>T.aurantiacus</i>		794	85	101
<i>T.lanuginosus</i>	<i>C.thermophila</i>		482	52	256
<i>T.lanuginosus</i>	<i>C.reinhardtii</i>		418	43	276
<i>T.lanuginosus</i>	<i>P.euphratica</i>		437	46	275
<i>T.lanuginosus</i>	<i>A.thaliana</i>		447	47	265
<i>T.lanuginosus</i>	<i>M.brevicollis</i>		437	47	277
<i>T.lanuginosus</i>	<i>S.rosetta</i>		420	25	290
<i>T.lanuginosus</i>	<i>G.sulphuraria</i>		460	49	281
<i>T.lanuginosus</i>	<i>D.discoideum</i>		444	48	292
<i>T.aurantiacus</i>	<i>C.thermophila</i>		475	51	261
<i>T.aurantiacus</i>	<i>C.reinhardtii</i>		424	44	271
<i>T.aurantiacus</i>	<i>P.euphratica</i>		444	47	270
<i>T.aurantiacus</i>	<i>A.thaliana</i>		446	47	267
<i>T.aurantiacus</i>	<i>M.brevicollis</i>		419	45	293
<i>T.aurantiacus</i>	<i>S.rosetta</i>		417	45	293
<i>T.aurantiacus</i>	<i>G.sulphuraria</i>		456	48	281
<i>T.aurantiacus</i>	<i>D.discoideum</i>		439	47	300
<i>C.thermophila</i>	<i>C.reinhardtii</i>		454	49	257
<i>C.thermophila</i>	<i>P.euphratica</i>		463	50	257
<i>C.thermophila</i>	<i>A.thaliana</i>		464	50	253
<i>C.thermophila</i>	<i>M.brevicollis</i>		468	52	258
<i>C.thermophila</i>	<i>S.rosetta</i>		467	52	259

<i>C.thermophila</i>	<i>G.sulphuraria</i>		479	52	264
<i>C.thermophila</i>	<i>D.discoideum</i>		494	55	263
<i>C.reinhardtii</i>	<i>P.euphratica</i>		526	56	236
<i>C.reinhardtii</i>	<i>A.thaliana</i>		523	56	242
<i>C.reinhardtii</i>	<i>M.brevicollis</i>		487	52	248
<i>C.reinhardtii</i>	<i>S.rosetta</i>		480	51	245
<i>C.reinhardtii</i>	<i>G.sulphuraria</i>		503	53	236
<i>C.reinhardtii</i>	<i>D.discoideum</i>		491	53	248
<i>P.euphratica</i>	<i>A.thaliana</i>		791	86	97
<i>P.euphratica</i>	<i>M.brevicollis</i>		500	54	252
<i>P.euphratica</i>	<i>S.rosetta</i>		487	52	261
<i>P.euphratica</i>	<i>G.sulphuraria</i>		526	55	242
<i>P.euphratica</i>	<i>D.discoideum</i>		525	57	235
<i>A.thaliana</i>	<i>M.brevicollis</i>		507	54	236
<i>A.thaliana</i>	<i>S.rosetta</i>		500	54	255
<i>A.thaliana</i>	<i>G.sulphuraria</i>		527	56	242
<i>A.thaliana</i>	<i>D.discoideum</i>		527	57	231
<i>M.brevicollis</i>	<i>S.rosetta</i>		634	71	176
<i>M.brevicollis</i>	<i>G.sulphuraria</i>		528	57	225
<i>M.brevicollis</i>	<i>D.discoideum</i>		512	57	255
<i>S.rosetta</i>	<i>G.sulphuraria</i>		517	56	240
<i>S.rosetta</i>	<i>D.discoideum</i>		499	56	282
<i>G.sulphuraria</i>	<i>D.discoideum</i>		538	58	240

Figure S1. Alignment of all Hsp104 homologs investigated in this study (related to Figures 1 and 2).

Amino acid sequences of Hsp104 homologs were aligned using Clustal Omega, and the multiple sequence alignment was visualized with JalView. Positions in the alignment are colored by Clustal X convention: conserved hydrophobic positions (A,I,L,M,F,W,V,C) are blue; conserved basic residues (K,R) are red; acidic residues (E,D) are magenta; polar residues (N,Q,S,T) are green; aromatic residues (H,Y) are cyan; conserved cysteines are pink; glycines are orange, prolines are yellow. Structural elements of Hsp104 are indicated. *C. thermophila* and ClpG are in green, TDP-43-specific homologs are colored in shades of blue, α Syn-specific homologs are colored in red, and non-rescuing homologs are colored in shades of gray.

Figure S2. Hsp104 homologs do not typically induce temperature-dependent toxicity (related to Figures 1 and 2).

Spotting assay showing that yeast strains expressing the indicated Hsp104 homolog do not show a temperature-dependent growth defect. None of the Hsp104 homologs were toxic at 30°C or 37°C with the exception of PfHsp104, which was toxic at both temperatures. PfHsp104 was even more toxic than the potentiated Hsp104 variant, Hsp104^{A503V}, at 37°C. Unlike PfHsp104, Hsp104^{A503V} was not toxic at 30°C.

Figure S3. Suppression of TDP-43 or α Syn toxicity by select Hsp104 homologs is a substrate-specific effect (related to Figures 1 and 2)

(A) Spotting assay showing that MbHsp104, SrHsp104, CrHsp104, PeHsp104, and GsHsp104, which all suppress TDP-43 toxicity, do not suppress α Syn nor FUS toxicity. SchHsp104^{A503S} is included as a positive control and empty vector and SchHsp104^{WT} are included as negative controls

(B) Spotting assay showing that TtHsp104 and TIHsp104 do not suppress TDP-43 nor FUS toxicity

(C) Spotting assay showing that other Hsp104s investigated in this study do not suppress toxicity of TDP-43 (left), α Syn (middle), or FUS (right).

Figure S5. Alignment comparing ScHsp104 to Hsp104 homologs that rescue α Syn toxicity (related to Figure 2).

Amino acid sequences of the indicated Hsp104 homologs were aligned using Clustal Omega, and the multiple sequence alignment was visualized with JalView. Amino acids are colored according to Clustal X convention, and structural elements of Hsp104 are indicated.

Figure S6. Alignment comparing Hsp104 homologs that rescue TDP-43 toxicity to those that rescue α Syn toxicity (related to Figures 1 and 2).

(A) Amino acid sequences of the indicated Hsp104 homologs were aligned using Clustal Omega, and the multiple sequence alignment was visualized with JalView. Amino acids are colored according to Clustal X convention, and structural elements of Hsp104 are indicated. TDP-43-specific Hsp104 homologs are boxed in blue and alpha-synuclein-specific homologs are boxed in red.

(B) Bar chart comparing average pairwise sequence identities between Hsp104 homologs with different toxicity suppression phenotypes.

Figure S7. ClpB does not suppress TDP-43, FUS, or αSyn toxicity whereas ClpG_{GI} robustly suppresses αSyn toxicity and confers thermotolerance to Δhsp104 yeast (related to Figures 1 and 2).

(A) Spotting assay demonstrating that neither ClpB nor hyperactive ClpB variants suppress TDP-43, FUS, or αSyn toxicity. Dashed line indicates splicing of FUS plate.

(B) Spotting assay demonstrating slight suppression of TDP-43 and FUS toxicity, and robust suppression of αSyn toxicity by ClpG_{GI}.

(C) Western blots show consistent expression of FLAG-tagged ClpB, ClpB variants, and ClpG in yeast. These Hsp104s also do not affect TDP-43, FUS, or α Syn levels in yeast.

(D) Neither ClpB nor ClpG_{GI} cause temperature-dependent toxicity when expressed in yeast.

(E) $\Delta hsp104$ yeast carrying a plasmid encoding empty vector or the indicated Hsp104 homolog were pre-treated at 37 °C for 30 min, treated at 50 °C for 0-60 min, and plated. Surviving colonies were quantified after 2d recovery. Values represent means $\pm$ SEM (n=3 independent transformations).

Figure S8. Hsp104 homologs remodel SEVI fibers (related to Figure 5).

(A) SEVI fibrils (20 μ M monomer) were incubated with buffer (untreated) or the indicated Hsp104 homolog (3 μ M) for 0-24 h. Fibril integrity was assessed by ThT fluorescence. Values represent means $\pm$ SEM (n=3).

(B) Representative EM images of SEVI fibrils incubated with buffer (untreated) or the indicated Hsp104 homolog (3 μ M) for 3 h. Scale bar is indicated (bottom right of gallery).

Figure S9. Hsp104 homologs do not affect MBP-TEV-TDP43 cleavage by TEV protease (related to Figure 5).

Western blot of MBP-TEV-TDP43 incubated either alone, or in combination with TEV protease, Hsp104s, and ATP, as indicated above lanes. Molecular weight markers are indicated (right).

(I) Survival of yeast expressing GsHsp104, MbHsp104, CrHsp104, PeHsp104, SrHsp104, CtHsp104, TtHsp104, TIHsp104, or the indicated chimera was assessed following 20 min heat shock at 50 °C. Values represent means $\pm$ SEM (n=3 independent transformations). Top dashed line indicates average survival of strains expressing wild-type Hsp104s, while bottom dashed line indicates average survival of *Δ hsp104* cells.

Figure S11. Chimeric Hsp104s and proteotoxic substrates are consistently expressed in yeast (related to Figure 7).

(A) Color code of Hsp104 homologs, and schematic of Hsp104 domain organization.

(B-K) Western blots show that chimeras between ScHsp104 and GsHsp104 (B), MbHsp104 (C), CrHsp104 (D), PeHsp104 (E), SrHsp104 (F), CtHsp104 (G), TtHsp104 (H,J) and TIHsp104 (I,K) are expressed consistently and at a level comparable to wild-type protein. TDP-43 (B-F) and α Syn (G-I) are expressed consistently in all strains. Molecular weight markers are indicated at right of each panel.

(L) Western blot showing expression of PeHsp104, SrHsp104, or fragments derived from these homologs in TDP-43-expressing yeast strains. Molecular weight markers are indicated at the right of the panel.

Figure S12. Characterization of Hsp104 chimera specificity (related to Figure 7).

(A) Spotting assay of $\Delta hsp104$ strains coexpressing α Syn and the indicated chimeras between ScHsp104 and GsHsp104 shows that none of these chimeras suppress α Syn toxicity.

(B) Spotting assay of $\Delta hsp104$ strains coexpressing α Syn and the indicated chimeras between ScHsp104 and MbHsp104 shows that none of these chimeras suppress α Syn toxicity.

(C) Spotting assay of $\Delta hsp104$ strains coexpressing α Syn and the indicated chimeras between ScHsp104 and CrHsp104 shows that none of these chimeras suppress α Syn toxicity.

- (D)** Spotting assay of *Δhsp104* strains coexpressing α Syn and the indicated chimeras between ScHsp104 and PeHsp104 shows that a chimera possessing the NTD and NBD1 from PeHsp104 suppresses α Syn toxicity.
- (E)** Spotting assay of *Δhsp104* strains coexpressing α Syn and the indicated chimeras between ScHsp104 and SrHsp104 shows that none of these chimeras suppress α Syn toxicity.
- (F)** Spotting assay of *Δhsp104* strains coexpressing TDP-43 and the indicated chimeras between ScHsp104 and CtHsp104 shows that none of these chimeras suppress TDP-43 toxicity.
- (G)** Spotting assay of *Δhsp104* strains coexpressing TDP-43 and the indicated chimeras between ScHsp104 and TtHsp104 shows that none of these chimeras suppress TDP-43 toxicity.
- (H)** Spotting assay of *Δhsp104* strains coexpressing TDP-43 and the indicated chimeras between ScHsp104 and TIHsp104 shows that none of these chimeras suppress TDP-43 toxicity.

Figure S13. Characterization of chimera intrinsic toxicity (related to Figure 7).

Strains expressing chimeras between ScHsp104 and GsHsp104 (A), MbHsp104 (B), CrHsp104 (C), PeHsp104 (D), SrHsp104 (E), CtHsp104 (F), TtHsp104 (G), and TtHsp104 (H) were spotted onto glucose and galactose media, and incubated at 37 °C for 2-3 days to observe growth. In several cases (panels A, C, D, E, and F) chimeras possessing non-cognate NTD:NBD1 units displayed toxicity.

Figure S14. Thermotolerance activity of Hsp104 chimeras (related to Figure 7).

Survival of yeast expressing GsHsp104, MbHsp104, CrHsp104, PeHsp104, SrHsp104, CtHsp104, TtHsp104, TlHsp104, or a chimera between one of these (as indicated by color in bar chart) and ScHsp104 was assessed following 20 min heat shock at 50 °C. Values are relative to wild-type ScHsp104 (single black bar at left) and represent means $\pm$ SEM (n=3 independent transformations). Illustrations on x-axis indicate chimera composition. Gray indicates portions of the chimera from ScHsp104 and white indicates variable regions from other homologs